<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">nid</journal-id><journal-title-group><journal-title xml:lang="ru">Нефрология и диализ</journal-title><trans-title-group xml:lang="en"><trans-title>Nephrology and Dialysis</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1680-4422</issn><issn pub-type="epub">2618-9801</issn><publisher><publisher-name>Российское диализное общество</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.28996/2618-9801-2019-2-105-190</article-id><article-id custom-type="elpub" pub-id-type="custom">nid-262</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КЛИНИЧЕСКИЕ РЕКОМЕНДАЦИИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CLINICAL GUIDELINES</subject></subj-group></article-categories><title-group><article-title>Клинические практические рекомендации KDIGO 2018 по профилактике, диагностике, оценке и лечению гепатита С при хронической болезни почек</article-title><trans-title-group xml:lang="en"><trans-title>KDIGO 2018 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Статья</surname><given-names>Редакционная</given-names></name><name name-style="western" xml:lang="en"><surname>Article</surname><given-names>Editorial</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email></contrib></contrib-group><pub-date pub-type="collection"><year>2019</year></pub-date><pub-date pub-type="epub"><day>05</day><month>08</month><year>2024</year></pub-date><volume>21</volume><issue>2</issue><fpage>105</fpage><lpage>190</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Статья Р., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Статья Р.</copyright-holder><copyright-holder xml:lang="en">Article E.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://journal.nephro.ru/jour/article/view/262">https://journal.nephro.ru/jour/article/view/262</self-uri><abstract><p>Kidney International Supplements (2018) 8, 91-165 © 2018 KDIGO Перевод с английского Е.С. Камышовой и Е.В. Захаровой под общей редакцией Е.В. Захаровой Перевод выполнен по инициативе Российского Диализного Общества и одобрен KDIGO Translation to Russian by E.S. Kamyshova and E.V. Zakharova, ed. E.V. Zakharova Translation was initiated by Russian Dialysis Society and approved by KDIGO Все права принадлежат KDIGO Воспроизведение возможно только с разрешения РДО и KDIGO Предисловие к переводу на русский язык Клинических практических рекомендаций KDIGO 2018 по профилактике, диагностике, оценке и лечению гепатита С при хронической болезни почек Глубокоуважаемые коллеги! В этом номере журнала Нефрология и Диализ мы продолжаем серию публикаций переводов на русский язык Клинических Практических Рекомендаций KDIGO и предлагаем вашему вниманию перевод Рекомендаций по профилактике, диагностике, оценке и лечению гепатита С при хронической болезни почек. Как и предыдущие переводы, опубликованные в журнале Нефрология и Диализ, данный перевод осуществлен по инициативе Российского Диализного Общества с разрешения KDIGO. Руководство РДО и редколлегия журнала Нефрология и Диализ надеются, что публикуемый материал будет полезен вам в вашей работе. На сайте журнала Нефрология и Диализ и на сайте KDIGO вы можете также найти осуществленные по инициативе РДО переводы на русский язык Клинических Практических Рекомендаций KDIGO по МКН-ХБП, ОПП, Анемии у больных с ХБП, Гломерулонефритам, Ведению дислипидемии у пациентов с ХБП и Диагностике и Лечению Хронической Болезни Почек. Мы планируем и в дальнейшем знакомить вас с материалами KDIGO, с новостями от KDIGO вы можете ознакомиться на специальной страничке в конце каждого выпуска нашего журнала. С наилучшими пожеланиям от имени KDIGO и РДО, заместитель главного редактора журнала «Нефрология и Диализ» Е.В. Захарова Клинические практические рекомендации KDIGO 2018 по профилактике, диагностике, обследованию и лечению гепатита С при хронической болезни почек представляют собой полностью обновленный вариант предыдущих рекомендаций, опубликованных в 2008 г. Данное руководство предназначено для оказания помощи в практическим врачам при лечении пациентов, инфицированных вирусом гепатита С (ВГС) и страдающих хронической болезнью почек (ХБП), включая и пациентов, получающих лечение хроническим диализом и реципиентов почечного трансплантата. Основные специфические вопросы, освещаемые в новых рекомендациях, включают выявление и оценку ВГС у пациентов с ХБП, лечение ВГС-инфекции у пациентов с ХБП, лечение инфицированных ВГС пациентов до и после трансплантации почки, профилактику передачи ВГС в отделениях гемодиализа, а также диагностику и лечение заболеваний почек, ассоциированных с ВГС. Разработка данных рекомендаций проводилась в строгом соответствии с процессом рассмотрения и оценки доказательств. Подходы к лечению и положения рекомендаций основаны на систематическом обзоре соответствующих исследований, а оценка качества доказательств и силы рекомендаций проводилась в соответствии с системой оценки, разработки и изучения рекомендаций GRADE (Grading of Recommendations Assessment, Development and Evaluation). Обсуждаются случаи ограничения доказательности результатов, а также представлены рекомендации по будущим исследованиям.</p></abstract><trans-abstract xml:lang="en"><p>Kidney International Supplements (2018) 8, 91-165 © 2018 KDIGO</p></trans-abstract><kwd-group xml:lang="ru"><kwd>хроническая болезнь почек</kwd><kwd>криоглобулинемия</kwd><kwd>диализ</kwd><kwd>препараты прямого противовирусного действия</kwd><kwd>гломерулярные заболевания</kwd><kwd>гемодиализ</kwd><kwd>вирус гепатита С</kwd><kwd>контроль над инфекциями</kwd><kwd>рекомендации</kwd><kwd>KDIGO</kwd><kwd>трансплантация почки</kwd><kwd>печеночные пробы</kwd><kwd>внутрибольничная передача инфекции</kwd><kwd>скрининг</kwd><kwd>систематический обзор</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Wirtz VJ, Hogerzeil HV, Gray AL, et al. Essential medicines for universal health coverage. Lancet. 2017;389:403-476.</mixed-citation><mixed-citation xml:lang="en">Wirtz VJ, Hogerzeil HV, Gray AL, et al. Essential medicines for universal health coverage. Lancet. 2017;389:403-476.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">The Lancet Gastroenterology Hepatology. Access to HCV treatments: hurdles not barriers. Lancet Gastroenterol Hepatol. 2017;2:1.</mixed-citation><mixed-citation xml:lang="en">The Lancet Gastroenterology Hepatology. Access to HCV treatments: hurdles not barriers. Lancet Gastroenterol Hepatol. 2017;2:1.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Reau N, Kwo PY, Rhee S, et al. Glecaprevir/pibrentasvir treatment in liver or kidney transplant patients with hepatitis C virus infection [e-pub ahead of print]. Hepatology. https://doi.org/10.1002/hep.30046. Accessed July 25, 2018.</mixed-citation><mixed-citation xml:lang="en">Reau N, Kwo PY, Rhee S, et al. Glecaprevir/pibrentasvir treatment in liver or kidney transplant patients with hepatitis C virus infection [e-pub ahead of print]. Hepatology. https://doi.org/10.1002/hep.30046. Accessed July 25, 2018.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">World Health Organization. Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection. July 2018. Available at: http://www.who.int/hepatitis/publications/hepatitis-cguidelines- 2018/en/. Accessed July 27, 2018.</mixed-citation><mixed-citation xml:lang="en">World Health Organization. Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection. July 2018. Available at: http://www.who.int/hepatitis/publications/hepatitis-cguidelines- 2018/en/. Accessed July 27, 2018.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Bergman S, Accortt N, Turner A, et al. Hepatitis C infection is acquired pre- ESRD. Am J Kidney Dis. 2005;45:684-689.</mixed-citation><mixed-citation xml:lang="en">Bergman S, Accortt N, Turner A, et al. Hepatitis C infection is acquired pre- ESRD. Am J Kidney Dis. 2005;45:684-689.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Iwasa Y, Otsubo S, Sugi O, et al. Patterns in the prevalence of hepatitis C virus infection at the start of hemodialysis in Japan. Clin Exp Nephrol. 2008;12:53-57.</mixed-citation><mixed-citation xml:lang="en">Iwasa Y, Otsubo S, Sugi O, et al. Patterns in the prevalence of hepatitis C virus infection at the start of hemodialysis in Japan. Clin Exp Nephrol. 2008;12:53-57.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Fabrizi F, Verdesca S, Messa P, et al. Hepatitis C virus infection increases the risk of developing chronic kidney disease: a systematic review and metaanalysis. Dig Dis Sci. 2015;60:3801-3813.</mixed-citation><mixed-citation xml:lang="en">Fabrizi F, Verdesca S, Messa P, et al. Hepatitis C virus infection increases the risk of developing chronic kidney disease: a systematic review and metaanalysis. Dig Dis Sci. 2015;60:3801-3813.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Crook ED, Penumalee S, Gavini B, et al. Hepatitis C is a predictor of poorer renal survival in diabetic patients. Diabetes Care. 2005;28:2187-2191.</mixed-citation><mixed-citation xml:lang="en">Crook ED, Penumalee S, Gavini B, et al. Hepatitis C is a predictor of poorer renal survival in diabetic patients. Diabetes Care. 2005;28:2187-2191.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Noureddine LA, Usman SA, Yu Z, et al. Hepatitis C increases the risk of progression of chronic kidney disease in patients with glomerulonephritis. Am J Nephrol. 2010;32:311-316.</mixed-citation><mixed-citation xml:lang="en">Noureddine LA, Usman SA, Yu Z, et al. Hepatitis C increases the risk of progression of chronic kidney disease in patients with glomerulonephritis. Am J Nephrol. 2010;32:311-316.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Wyatt CM, Malvestutto C, Coca SG, et al. The impact of hepatitis C virus coinfection on HIV-related kidney disease: a systematic review and metaanalysis. AIDS. 2008;22:1799-1807.</mixed-citation><mixed-citation xml:lang="en">Wyatt CM, Malvestutto C, Coca SG, et al. The impact of hepatitis C virus coinfection on HIV-related kidney disease: a systematic review and metaanalysis. AIDS. 2008;22:1799-1807.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Easterbrook PJ. Who to test and how to test for chronic hepatitis C infection - 2016 WHO testing guidance for low- and middle-income countries. J Hepatol. 2016;65:S46-S66.</mixed-citation><mixed-citation xml:lang="en">Easterbrook PJ. Who to test and how to test for chronic hepatitis C infection - 2016 WHO testing guidance for low- and middle-income countries. J Hepatol. 2016;65:S46-S66.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Kamili S, Drobeniuc J, Araujo AC, et al. Laboratory diagnostics for hepatitis C virus infection. Clin Infect Dis. 2012;55 Suppl 1:S43-S48.</mixed-citation><mixed-citation xml:lang="en">Kamili S, Drobeniuc J, Araujo AC, et al. Laboratory diagnostics for hepatitis C virus infection. Clin Infect Dis. 2012;55 Suppl 1:S43-S48.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Cresswell FV, Fisher M, Hughes DJ, et al. Hepatitis C core antigen testing: a reliable, quick, and potentially cost-effective alternative to hepatitis C polymerase chain reaction in diagnosing acute hepatitis C virus infection. Clin Infect Dis. 2015;60:263-266.</mixed-citation><mixed-citation xml:lang="en">Cresswell FV, Fisher M, Hughes DJ, et al. Hepatitis C core antigen testing: a reliable, quick, and potentially cost-effective alternative to hepatitis C polymerase chain reaction in diagnosing acute hepatitis C virus infection. Clin Infect Dis. 2015;60:263-266.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Hu KQ, Cui W. A highly specific and sensitive hepatitis C virus antigen enzyme immunoassay for One-step diagnosis of viremic hepatitis C virus infection. Hepatology. 2016;64:415-424.</mixed-citation><mixed-citation xml:lang="en">Hu KQ, Cui W. A highly specific and sensitive hepatitis C virus antigen enzyme immunoassay for One-step diagnosis of viremic hepatitis C virus infection. Hepatology. 2016;64:415-424.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Miedouge M, Saune K, Kamar N, et al. Analytical evaluation of HCV core antigen and interest for HCV screening in haemodialysis patients. J Clin Virol. 2010;48:18-21.</mixed-citation><mixed-citation xml:lang="en">Miedouge M, Saune K, Kamar N, et al. Analytical evaluation of HCV core antigen and interest for HCV screening in haemodialysis patients. J Clin Virol. 2010;48:18-21.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Fissell RB, Bragg-Gresham JL, Woods JD, et al. Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. Kidney Int. 2004;65:2335-2342.</mixed-citation><mixed-citation xml:lang="en">Fissell RB, Bragg-Gresham JL, Woods JD, et al. Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. Kidney Int. 2004;65:2335-2342.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Saune K, Kamar N, Miedouge M, et al. Decreased prevalence and incidence of HCV markers in haemodialysis units: a multicentric French survey. Nephrol Dial Transplant. 2011;26:2309-2316.</mixed-citation><mixed-citation xml:lang="en">Saune K, Kamar N, Miedouge M, et al. Decreased prevalence and incidence of HCV markers in haemodialysis units: a multicentric French survey. Nephrol Dial Transplant. 2011;26:2309-2316.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Hmaied F, Ben Mamou M, Saune-Sandres K, et al. Hepatitis C virus infection among dialysis patients in Tunisia: incidence and molecular evidence for nosocomial transmission. J Med Virol. 2006;78:185-191.</mixed-citation><mixed-citation xml:lang="en">Hmaied F, Ben Mamou M, Saune-Sandres K, et al. Hepatitis C virus infection among dialysis patients in Tunisia: incidence and molecular evidence for nosocomial transmission. J Med Virol. 2006;78:185-191.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Izopet J, Sandres-Saune K, Kamar N, et al. Incidence of HCV infection in French hemodialysis units: a prospective study. J Med Virol. 2005;77:70-76.</mixed-citation><mixed-citation xml:lang="en">Izopet J, Sandres-Saune K, Kamar N, et al. Incidence of HCV infection in French hemodialysis units: a prospective study. J Med Virol. 2005;77:70-76.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Mbaeyi C, Thompson ND. Hepatitis C virus screening and management of seroconversions in hemodialysis facilities. Semin Dial. 2013;26:439-446.</mixed-citation><mixed-citation xml:lang="en">Mbaeyi C, Thompson ND. Hepatitis C virus screening and management of seroconversions in hemodialysis facilities. Semin Dial. 2013;26:439-446.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Nguyen DB, Gutowski J, Ghiselli M, et al. A large outbreak of hepatitis C virus infections in a hemodialysis clinic. Infect Control Hosp Epidemiol. 2016;37:125-133.</mixed-citation><mixed-citation xml:lang="en">Nguyen DB, Gutowski J, Ghiselli M, et al. A large outbreak of hepatitis C virus infections in a hemodialysis clinic. Infect Control Hosp Epidemiol. 2016;37:125-133.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Savey A, Simon F, Izopet J, et al. A large nosocomial outbreak of hepatitis C virus infections at a hemodialysis center. Infect Control Hosp Epidemiol. 2005;26:752-760.</mixed-citation><mixed-citation xml:lang="en">Savey A, Simon F, Izopet J, et al. A large nosocomial outbreak of hepatitis C virus infections at a hemodialysis center. Infect Control Hosp Epidemiol. 2005;26:752-760.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Recommendations for preventing transmission of infections among chronic hemodialysis patients. MMWR Recomm Rep. 2001;50:1-43.</mixed-citation><mixed-citation xml:lang="en">Recommendations for preventing transmission of infections among chronic hemodialysis patients. MMWR Recomm Rep. 2001;50:1-43.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Moyer VA. Screening for hepatitis C virus infection in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2013;159:349-357.</mixed-citation><mixed-citation xml:lang="en">Moyer VA. Screening for hepatitis C virus infection in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2013;159:349-357.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Barril G, Bartolome J, Sanz P, et al. Effect of hemodialysis schedules and membranes on hepatocyte growth factor and hepatitis C virus RNA levels. J Med Virol. 2010;82:763-767.</mixed-citation><mixed-citation xml:lang="en">Barril G, Bartolome J, Sanz P, et al. Effect of hemodialysis schedules and membranes on hepatocyte growth factor and hepatitis C virus RNA levels. J Med Virol. 2010;82:763-767.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Midgard H, Weir A, Palmateer N, et al. HCV epidemiology in high-risk groups and the risk of reinfection. J Hepatol. 2016;65:S33-S45.</mixed-citation><mixed-citation xml:lang="en">Midgard H, Weir A, Palmateer N, et al. HCV epidemiology in high-risk groups and the risk of reinfection. J Hepatol. 2016;65:S33-S45.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Centers for Disease Control and Prevention. Hepatitis C, Acute 2016: Case Definition. Available at: https://wwwn.cdc.gov/nndss/conditions/hepatitisc-acute/case-definition/2016/. Accessed July 27, 2018.</mixed-citation><mixed-citation xml:lang="en">Centers for Disease Control and Prevention. Hepatitis C, Acute 2016: Case Definition. Available at: https://wwwn.cdc.gov/nndss/conditions/hepatitisc-acute/case-definition/2016/. Accessed July 27, 2018.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Centers for Disease Control and Prevention Health Alert Network. CDC urging dialysis providers and facilities to assess and improve infection control practices to stop hepatitis C transmission in patients undergoing hemodialysis. Available at: https://emergency.cdc.gov/han/han00386.asp. Accessed July 27, 2018.</mixed-citation><mixed-citation xml:lang="en">Centers for Disease Control and Prevention Health Alert Network. CDC urging dialysis providers and facilities to assess and improve infection control practices to stop hepatitis C transmission in patients undergoing hemodialysis. Available at: https://emergency.cdc.gov/han/han00386.asp. Accessed July 27, 2018.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Allander T, Medin C, Jacobson SH, et al. Hepatitis C transmission in a hemodialysis unit: molecular evidence for spread of virus among patients not sharing equipment. J Med Virol. 1994;43:415-419.</mixed-citation><mixed-citation xml:lang="en">Allander T, Medin C, Jacobson SH, et al. Hepatitis C transmission in a hemodialysis unit: molecular evidence for spread of virus among patients not sharing equipment. J Med Virol. 1994;43:415-419.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Hmaied F, Ben Mamou M, Dubois M, et al. Determining the source of nosocomial transmission in hemodialysis units in Tunisia by sequencing NS5B and E2 sequences of HCV. J Med Virol. 2007;79:1089-1094.</mixed-citation><mixed-citation xml:lang="en">Hmaied F, Ben Mamou M, Dubois M, et al. Determining the source of nosocomial transmission in hemodialysis units in Tunisia by sequencing NS5B and E2 sequences of HCV. J Med Virol. 2007;79:1089-1094.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Izopet J, Pasquier C, Sandres K, et al. Molecular evidence for nosocomial transmission of hepatitis C virus in a French hemodialysis unit. J Med Virol. 1999;58:139-144.</mixed-citation><mixed-citation xml:lang="en">Izopet J, Pasquier C, Sandres K, et al. Molecular evidence for nosocomial transmission of hepatitis C virus in a French hemodialysis unit. J Med Virol. 1999;58:139-144.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Kokubo S, Horii T, Yonekawa O, et al. A phylogenetic-tree analysis elucidating nosocomial transmission of hepatitis C virus in a haemodialysis unit. J Viral Hepat. 2002;9:450-454.</mixed-citation><mixed-citation xml:lang="en">Kokubo S, Horii T, Yonekawa O, et al. A phylogenetic-tree analysis elucidating nosocomial transmission of hepatitis C virus in a haemodialysis unit. J Viral Hepat. 2002;9:450-454.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Saab S, Martin P, Brezina M, et al. Serum alanine aminotransferase in hepatitis C screening of patients on hemodialysis. Am J Kidney Dis. 2001;37:308-315.</mixed-citation><mixed-citation xml:lang="en">Saab S, Martin P, Brezina M, et al. Serum alanine aminotransferase in hepatitis C screening of patients on hemodialysis. Am J Kidney Dis. 2001;37:308-315.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int Suppl. 2008:S1-S99.</mixed-citation><mixed-citation xml:lang="en">KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int Suppl. 2008:S1-S99.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Liu CH, Liang CC, Huang KW, et al. Transient elastography to assess hepatic fibrosis in hemodialysis chronic hepatitis C patients. Clin J Am Soc Nephrol. 2011;6:1057-1065.</mixed-citation><mixed-citation xml:lang="en">Liu CH, Liang CC, Huang KW, et al. Transient elastography to assess hepatic fibrosis in hemodialysis chronic hepatitis C patients. Clin J Am Soc Nephrol. 2011;6:1057-1065.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Jadoul M, Horsmans Y. Impact of liver fibrosis staging in hepatitis C virus (HCV) patients with kidney failure. Nephrol Dial Transplant. 2014;29:1108-1110.</mixed-citation><mixed-citation xml:lang="en">Jadoul M, Horsmans Y. Impact of liver fibrosis staging in hepatitis C virus (HCV) patients with kidney failure. Nephrol Dial Transplant. 2014;29:1108-1110.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009;9 Suppl 3:S1-S155.</mixed-citation><mixed-citation xml:lang="en">KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009;9 Suppl 3:S1-S155.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Serpaggi J, Carnot F, Nalpas B, et al. Direct and indirect evidence for the reversibility of cirrhosis. Hum Pathol. 2006;37:1519-1526.</mixed-citation><mixed-citation xml:lang="en">Serpaggi J, Carnot F, Nalpas B, et al. Direct and indirect evidence for the reversibility of cirrhosis. Hum Pathol. 2006;37:1519-1526.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol. 2012;57:167-185.</mixed-citation><mixed-citation xml:lang="en">EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol. 2012;57:167-185.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Garcia-Tsao G, Abraldes JG, Berzigotti A, et al. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology. 2017;65:310-335.</mixed-citation><mixed-citation xml:lang="en">Garcia-Tsao G, Abraldes JG, Berzigotti A, et al. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology. 2017;65:310-335.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">de Franchis R. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. J Hepatol. 2015;63:743-752.</mixed-citation><mixed-citation xml:lang="en">de Franchis R. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. J Hepatol. 2015;63:743-752.</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2018. J Hepatol. 2018;69:461-511.</mixed-citation><mixed-citation xml:lang="en">European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2018. J Hepatol. 2018;69:461-511.</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Zampino R, Marrone A, Restivo L, et al. Chronic HCV infection and inflammation: clinical impact on hepatic and extra-hepatic manifestations. World J Hepatol. 2013;5:528-540.</mixed-citation><mixed-citation xml:lang="en">Zampino R, Marrone A, Restivo L, et al. Chronic HCV infection and inflammation: clinical impact on hepatic and extra-hepatic manifestations. World J Hepatol. 2013;5:528-540.</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Cacoub P, Comarmond C, Domont F, et al. Extrahepatic manifestations of chronic hepatitis C virus infection. Ther Adv Infect Dis. 2016;3:3-14.</mixed-citation><mixed-citation xml:lang="en">Cacoub P, Comarmond C, Domont F, et al. Extrahepatic manifestations of chronic hepatitis C virus infection. Ther Adv Infect Dis. 2016;3:3-14.</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Goodkin D, Bieber B, Jadoul M, et al. Mortality, hospitalization, and quality of life among patients with hepatitis C infection on hemodialysis. Clin J Am Soc Nephrol. 2017;12:287-297.</mixed-citation><mixed-citation xml:lang="en">Goodkin D, Bieber B, Jadoul M, et al. Mortality, hospitalization, and quality of life among patients with hepatitis C infection on hemodialysis. Clin J Am Soc Nephrol. 2017;12:287-297.</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Lucas GM, Ross MJ, Stock PG, et al. Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2014;59:e96-e138.</mixed-citation><mixed-citation xml:lang="en">Lucas GM, Ross MJ, Stock PG, et al. Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2014;59:e96-e138.</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Asrani SK, Buchanan P, Pinsky B, et al. Lack of association between hepatitis C infection and chronic kidney disease. Clin Gastroenterol Hepatol. 2010;8:79-84.</mixed-citation><mixed-citation xml:lang="en">Asrani SK, Buchanan P, Pinsky B, et al. Lack of association between hepatitis C infection and chronic kidney disease. Clin Gastroenterol Hepatol. 2010;8:79-84.</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Butt AA, Wang X, Fried LF. HCV infection and the incidence of CKD. Am J Kidney Dis. 2011;57:396-402.</mixed-citation><mixed-citation xml:lang="en">Butt AA, Wang X, Fried LF. HCV infection and the incidence of CKD. Am J Kidney Dis. 2011;57:396-402.</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Chen YC, Lin HY, Li CY, et al. A nationwide cohort study suggests that hepatitis C virus infection is associated with increased risk of chronic kidney disease. Kidney Int. 2014;85:1200-1207.</mixed-citation><mixed-citation xml:lang="en">Chen YC, Lin HY, Li CY, et al. A nationwide cohort study suggests that hepatitis C virus infection is associated with increased risk of chronic kidney disease. Kidney Int. 2014;85:1200-1207.</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">Hofmann JN, Torner A, Chow WH, et al. Risk of kidney cancer and chronic kidney disease in relation to hepatitis C virus infection: a nationwide register-based cohort study in Sweden. Eur J Cancer Prev. 2011;20:326-330.</mixed-citation><mixed-citation xml:lang="en">Hofmann JN, Torner A, Chow WH, et al. Risk of kidney cancer and chronic kidney disease in relation to hepatitis C virus infection: a nationwide register-based cohort study in Sweden. Eur J Cancer Prev. 2011;20:326-330.</mixed-citation></citation-alternatives></ref><ref id="cit51"><label>51</label><citation-alternatives><mixed-citation xml:lang="ru">Lee JJ, Lin MY, Chang JS, et al. Hepatitis C virus infection increases risk of developing end-stage renal disease using competing risk analysis. PLoS One. 2014;9:e100790.</mixed-citation><mixed-citation xml:lang="en">Lee JJ, Lin MY, Chang JS, et al. Hepatitis C virus infection increases risk of developing end-stage renal disease using competing risk analysis. PLoS One. 2014;9:e100790.</mixed-citation></citation-alternatives></ref><ref id="cit52"><label>52</label><citation-alternatives><mixed-citation xml:lang="ru">Moe SM, Pampalone AJ, Ofner S, et al. Association of hepatitis C virus infection with prevalence and development of kidney disease. Am J Kidney Dis. 2008;51:885-892.</mixed-citation><mixed-citation xml:lang="en">Moe SM, Pampalone AJ, Ofner S, et al. Association of hepatitis C virus infection with prevalence and development of kidney disease. Am J Kidney Dis. 2008;51:885-892.</mixed-citation></citation-alternatives></ref><ref id="cit53"><label>53</label><citation-alternatives><mixed-citation xml:lang="ru">Molnar MZ, Alhourani HM, Wall BM, et al. Association of hepatitis C viral infection with incidence and progression of chronic kidney disease in a large cohort of US veterans. Hepatology. 2015;61:1495-1502.</mixed-citation><mixed-citation xml:lang="en">Molnar MZ, Alhourani HM, Wall BM, et al. Association of hepatitis C viral infection with incidence and progression of chronic kidney disease in a large cohort of US veterans. Hepatology. 2015;61:1495-1502.</mixed-citation></citation-alternatives></ref><ref id="cit54"><label>54</label><citation-alternatives><mixed-citation xml:lang="ru">Su FH, Su CT, Chang SN, et al. Association of hepatitis C virus infection with risk of ESRD: a population-based study. Am J Kidney Dis. 2012;60:553-560.</mixed-citation><mixed-citation xml:lang="en">Su FH, Su CT, Chang SN, et al. Association of hepatitis C virus infection with risk of ESRD: a population-based study. Am J Kidney Dis. 2012;60:553-560.</mixed-citation></citation-alternatives></ref><ref id="cit55"><label>55</label><citation-alternatives><mixed-citation xml:lang="ru">Tsui JI, Vittinghoff E, Shlipak MG, et al. Association of hepatitis C seropositivity with increased risk for developing end-stage renal disease. Arch Intern Med. 2007;167:1271-1276.</mixed-citation><mixed-citation xml:lang="en">Tsui JI, Vittinghoff E, Shlipak MG, et al. Association of hepatitis C seropositivity with increased risk for developing end-stage renal disease. Arch Intern Med. 2007;167:1271-1276.</mixed-citation></citation-alternatives></ref><ref id="cit56"><label>56</label><citation-alternatives><mixed-citation xml:lang="ru">Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl. 2013;3:1-150.</mixed-citation><mixed-citation xml:lang="en">Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl. 2013;3:1-150.</mixed-citation></citation-alternatives></ref><ref id="cit57"><label>57</label><citation-alternatives><mixed-citation xml:lang="ru">Dalrymple LS, Koepsell T, Sampson J, et al. Hepatitis C virus infection and the prevalence of renal insufficiency. Clin J Am Soc Nephrol. 2007;2:715-721.</mixed-citation><mixed-citation xml:lang="en">Dalrymple LS, Koepsell T, Sampson J, et al. Hepatitis C virus infection and the prevalence of renal insufficiency. Clin J Am Soc Nephrol. 2007;2:715-721.</mixed-citation></citation-alternatives></ref><ref id="cit58"><label>58</label><citation-alternatives><mixed-citation xml:lang="ru">Lucas GM, Jing Y, Sulkowski M, et al. Hepatitis C viremia and the risk of chronic kidney disease in HIV-infected individuals. J Infect Dis. 2013;208:1240-1249.</mixed-citation><mixed-citation xml:lang="en">Lucas GM, Jing Y, Sulkowski M, et al. Hepatitis C viremia and the risk of chronic kidney disease in HIV-infected individuals. J Infect Dis. 2013;208:1240-1249.</mixed-citation></citation-alternatives></ref><ref id="cit59"><label>59</label><citation-alternatives><mixed-citation xml:lang="ru">Park H, Chen C, Wang W, et al. Chronic hepatitis C virus (HCV) increases the risk of chronic kidney disease (CKD) while effective HCV treatment decreases the incidence of CKD [e-pub ahead of print]. Hepatology. https://doi.org/10.1002/hep.29505.</mixed-citation><mixed-citation xml:lang="en">Park H, Chen C, Wang W, et al. Chronic hepatitis C virus (HCV) increases the risk of chronic kidney disease (CKD) while effective HCV treatment decreases the incidence of CKD [e-pub ahead of print]. Hepatology. https://doi.org/10.1002/hep.29505.</mixed-citation></citation-alternatives></ref><ref id="cit60"><label>60</label><citation-alternatives><mixed-citation xml:lang="ru">Soma J, Saito T, Taguma Y, et al. High prevalence and adverse effect of hepatitis C virus infection in type II diabetic-related nephropathy. J Am Soc Nephrol. 2000;11:690-699.</mixed-citation><mixed-citation xml:lang="en">Soma J, Saito T, Taguma Y, et al. High prevalence and adverse effect of hepatitis C virus infection in type II diabetic-related nephropathy. J Am Soc Nephrol. 2000;11:690-699.</mixed-citation></citation-alternatives></ref><ref id="cit61"><label>61</label><citation-alternatives><mixed-citation xml:lang="ru">Ble M, Aguilera V, Rubin A, et al. Improved renal function in liver transplant recipients treated for hepatitis C virus with a sustained virological response and mild chronic kidney disease. Liver Transpl. 2014;20:25-34.</mixed-citation><mixed-citation xml:lang="en">Ble M, Aguilera V, Rubin A, et al. Improved renal function in liver transplant recipients treated for hepatitis C virus with a sustained virological response and mild chronic kidney disease. Liver Transpl. 2014;20:25-34.</mixed-citation></citation-alternatives></ref><ref id="cit62"><label>62</label><citation-alternatives><mixed-citation xml:lang="ru">Norton BL, Park L, McGrath LJ, et al. Health care utilization in HIVinfected patients: assessing the burden of hepatitis C virus coinfection. AIDS Patient Care STDS. 2012;26:541-545.</mixed-citation><mixed-citation xml:lang="en">Norton BL, Park L, McGrath LJ, et al. Health care utilization in HIVinfected patients: assessing the burden of hepatitis C virus coinfection. AIDS Patient Care STDS. 2012;26:541-545.</mixed-citation></citation-alternatives></ref><ref id="cit63"><label>63</label><citation-alternatives><mixed-citation xml:lang="ru">Fabrizi F, Dixit V, Martin P, et al. Hepatitis C virus increases the risk of kidney disease among HIV-positive patients: Systematic review and metaanalysis. J Med Virol. 2016;88:487-497.</mixed-citation><mixed-citation xml:lang="en">Fabrizi F, Dixit V, Martin P, et al. Hepatitis C virus increases the risk of kidney disease among HIV-positive patients: Systematic review and metaanalysis. J Med Virol. 2016;88:487-497.</mixed-citation></citation-alternatives></ref><ref id="cit64"><label>64</label><citation-alternatives><mixed-citation xml:lang="ru">Satapathy SK, Lingisetty CS, Williams S. Higher prevalence of chronic kidney disease and shorter renal survival in patients with chronic hepatitis C virus infection. Hepatol Int. 2012;6:369-378.</mixed-citation><mixed-citation xml:lang="en">Satapathy SK, Lingisetty CS, Williams S. Higher prevalence of chronic kidney disease and shorter renal survival in patients with chronic hepatitis C virus infection. Hepatol Int. 2012;6:369-378.</mixed-citation></citation-alternatives></ref><ref id="cit65"><label>65</label><citation-alternatives><mixed-citation xml:lang="ru">Liangpunsakul S, Chalasani N. Relationship between hepatitis C and microalbuminuria: results from the NHANES III. Kidney Int. 2005;67:285-290.</mixed-citation><mixed-citation xml:lang="en">Liangpunsakul S, Chalasani N. Relationship between hepatitis C and microalbuminuria: results from the NHANES III. Kidney Int. 2005;67:285-290.</mixed-citation></citation-alternatives></ref><ref id="cit66"><label>66</label><citation-alternatives><mixed-citation xml:lang="ru">Tsui JI, Vittinghoff E, Shlipak MG, et al. Relationship between hepatitis C and chronic kidney disease: results from the Third National Health and Nutrition Examination Survey. J Am Soc Nephrol. 2006;17:1168-1174.</mixed-citation><mixed-citation xml:lang="en">Tsui JI, Vittinghoff E, Shlipak MG, et al. Relationship between hepatitis C and chronic kidney disease: results from the Third National Health and Nutrition Examination Survey. J Am Soc Nephrol. 2006;17:1168-1174.</mixed-citation></citation-alternatives></ref><ref id="cit67"><label>67</label><citation-alternatives><mixed-citation xml:lang="ru">Petta S, Adinolfi LE, Fracanzani AL, et al. Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis. J Hepatol. 2018;69:18-24.</mixed-citation><mixed-citation xml:lang="en">Petta S, Adinolfi LE, Fracanzani AL, et al. Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis. J Hepatol. 2018;69:18-24.</mixed-citation></citation-alternatives></ref><ref id="cit68"><label>68</label><citation-alternatives><mixed-citation xml:lang="ru">Rogal SS, Yan P, Rimland D, et al. Incidence and Progression of Chronic Kidney Disease After Hepatitis C Seroconversion: Results from ERCHIVES. Dig Dis Sci. 2016;61:930-936.</mixed-citation><mixed-citation xml:lang="en">Rogal SS, Yan P, Rimland D, et al. Incidence and Progression of Chronic Kidney Disease After Hepatitis C Seroconversion: Results from ERCHIVES. Dig Dis Sci. 2016;61:930-936.</mixed-citation></citation-alternatives></ref><ref id="cit69"><label>69</label><citation-alternatives><mixed-citation xml:lang="ru">Tsui J, Vittinghoff E, Anastos K, et al. Hepatitis C seropositivity and kidney function decline among women with HIV: data from the Women’s Interagency HIV Study. Am J Kidney Dis. 2009;54:43-50.</mixed-citation><mixed-citation xml:lang="en">Tsui J, Vittinghoff E, Anastos K, et al. Hepatitis C seropositivity and kidney function decline among women with HIV: data from the Women’s Interagency HIV Study. Am J Kidney Dis. 2009;54:43-50.</mixed-citation></citation-alternatives></ref><ref id="cit70"><label>70</label><citation-alternatives><mixed-citation xml:lang="ru">Hsu CS, Kao JH, Chao YC, et al. Interferon-based therapy reduces risk of stroke in chronic hepatitis C patients: a population-based cohort study in Taiwan. Aliment Pharmacol Ther. 2013;38:415-423.</mixed-citation><mixed-citation xml:lang="en">Hsu CS, Kao JH, Chao YC, et al. Interferon-based therapy reduces risk of stroke in chronic hepatitis C patients: a population-based cohort study in Taiwan. Aliment Pharmacol Ther. 2013;38:415-423.</mixed-citation></citation-alternatives></ref><ref id="cit71"><label>71</label><citation-alternatives><mixed-citation xml:lang="ru">van der Meer AJ, Berenguer M. Reversion of disease manifestations after HCV eradication. J Hepatol. 2016;65:S95-S108.</mixed-citation><mixed-citation xml:lang="en">van der Meer AJ, Berenguer M. Reversion of disease manifestations after HCV eradication. J Hepatol. 2016;65:S95-S108.</mixed-citation></citation-alternatives></ref><ref id="cit72"><label>72</label><citation-alternatives><mixed-citation xml:lang="ru">Berenguer J, Rodriguez E, Miralles P, et al. Sustained virological response to interferon plus ribavirin reduces non-liver-related mortality in patients coinfected with HIVand Hepatitis C virus. Clin Infect Dis. 2012;55:728-736.</mixed-citation><mixed-citation xml:lang="en">Berenguer J, Rodriguez E, Miralles P, et al. Sustained virological response to interferon plus ribavirin reduces non-liver-related mortality in patients coinfected with HIVand Hepatitis C virus. Clin Infect Dis. 2012;55:728-736.</mixed-citation></citation-alternatives></ref><ref id="cit73"><label>73</label><citation-alternatives><mixed-citation xml:lang="ru">Arase Y, Suzuki F, Kawamura Y, et al. Development rate of chronic kidney disease in hepatitis C virus patients with advanced fibrosis after interferon therapy. Hepatol Res. 2011;41:946-954.</mixed-citation><mixed-citation xml:lang="en">Arase Y, Suzuki F, Kawamura Y, et al. Development rate of chronic kidney disease in hepatitis C virus patients with advanced fibrosis after interferon therapy. Hepatol Res. 2011;41:946-954.</mixed-citation></citation-alternatives></ref><ref id="cit74"><label>74</label><citation-alternatives><mixed-citation xml:lang="ru">Chen YC, Hwang SJ, Li CY, et al. A Taiwanese nationwide cohort study shows interferon-based therapy for chronic hepatitis C reduces the risk of chronic kidney disease. Medicine (Baltimore). 2015;94:e1334.</mixed-citation><mixed-citation xml:lang="en">Chen YC, Hwang SJ, Li CY, et al. A Taiwanese nationwide cohort study shows interferon-based therapy for chronic hepatitis C reduces the risk of chronic kidney disease. Medicine (Baltimore). 2015;94:e1334.</mixed-citation></citation-alternatives></ref><ref id="cit75"><label>75</label><citation-alternatives><mixed-citation xml:lang="ru">Hsu YC, Ho HJ, Huang YT, et al. Association between antiviral treatment and extrahepatic outcomes in patients with hepatitis C virus infection. Gut. 2015;64:495-503.</mixed-citation><mixed-citation xml:lang="en">Hsu YC, Ho HJ, Huang YT, et al. Association between antiviral treatment and extrahepatic outcomes in patients with hepatitis C virus infection. Gut. 2015;64:495-503.</mixed-citation></citation-alternatives></ref><ref id="cit76"><label>76</label><citation-alternatives><mixed-citation xml:lang="ru">Hsu YC, Lin JT, Ho HJ, et al. Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients. Hepatology. 2014;59:1293-1302.</mixed-citation><mixed-citation xml:lang="en">Hsu YC, Lin JT, Ho HJ, et al. Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients. Hepatology. 2014;59:1293-1302.</mixed-citation></citation-alternatives></ref><ref id="cit77"><label>77</label><citation-alternatives><mixed-citation xml:lang="ru">Leone S, Prosperi M, Costarelli S, et al. Incidence and predictors of cardiovascular disease, chronic kidney disease, and diabetes in HIV/HCVcoinfected patients who achieved sustained virological response. Eur J Clin Microbiol Infect Dis. 2016;35:1511-1520.</mixed-citation><mixed-citation xml:lang="en">Leone S, Prosperi M, Costarelli S, et al. Incidence and predictors of cardiovascular disease, chronic kidney disease, and diabetes in HIV/HCVcoinfected patients who achieved sustained virological response. Eur J Clin Microbiol Infect Dis. 2016;35:1511-1520.</mixed-citation></citation-alternatives></ref><ref id="cit78"><label>78</label><citation-alternatives><mixed-citation xml:lang="ru">Feng B, Eknoyan G, Guo ZS, et al. Effect of interferon-alpha-based antiviral therapy on hepatitis C virus-associated glomerulonephritis: a meta-analysis. Nephrol Dial Transplant. 2012;27:640-646.</mixed-citation><mixed-citation xml:lang="en">Feng B, Eknoyan G, Guo ZS, et al. Effect of interferon-alpha-based antiviral therapy on hepatitis C virus-associated glomerulonephritis: a meta-analysis. Nephrol Dial Transplant. 2012;27:640-646.</mixed-citation></citation-alternatives></ref><ref id="cit79"><label>79</label><citation-alternatives><mixed-citation xml:lang="ru">Reiss G, Keeffe EB. Review article: hepatitis vaccination in patients with chronic liver disease. Aliment Pharmacol Ther. 2004;19:715-727.</mixed-citation><mixed-citation xml:lang="en">Reiss G, Keeffe EB. Review article: hepatitis vaccination in patients with chronic liver disease. Aliment Pharmacol Ther. 2004;19:715-727.</mixed-citation></citation-alternatives></ref><ref id="cit80"><label>80</label><citation-alternatives><mixed-citation xml:lang="ru">Tung J, Carlisle E, Smieja M, et al. A randomized clinical trial of immunization with combined hepatitis A and B versus hepatitis B alone for hepatitis B seroprotection in hemodialysis patients. Am J Kidney Dis. 2010;56:713-719.</mixed-citation><mixed-citation xml:lang="en">Tung J, Carlisle E, Smieja M, et al. A randomized clinical trial of immunization with combined hepatitis A and B versus hepatitis B alone for hepatitis B seroprotection in hemodialysis patients. Am J Kidney Dis. 2010;56:713-719.</mixed-citation></citation-alternatives></ref><ref id="cit81"><label>81</label><citation-alternatives><mixed-citation xml:lang="ru">Fabrizi F, Martin P, Messa P. Novel perspectives on the hepatitis B virus vaccine in the chronic kidney disease population. Int J Artif Organs. 2015;38:625-631.</mixed-citation><mixed-citation xml:lang="en">Fabrizi F, Martin P, Messa P. Novel perspectives on the hepatitis B virus vaccine in the chronic kidney disease population. Int J Artif Organs. 2015;38:625-631.</mixed-citation></citation-alternatives></ref><ref id="cit82"><label>82</label><citation-alternatives><mixed-citation xml:lang="ru">Inker LA, Schmid CH, Tighiouart H, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med. 2012;367:20-29.</mixed-citation><mixed-citation xml:lang="en">Inker LA, Schmid CH, Tighiouart H, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med. 2012;367:20-29.</mixed-citation></citation-alternatives></ref><ref id="cit83"><label>83</label><citation-alternatives><mixed-citation xml:lang="ru">Simmons B, Saleem J, Hill A, et al. Risk of late relapse or reinfection with hepatitis C virus after achieving a sustained virological response: a systematic review and meta-analysis. Clin Infect Dis. 2016;62:683-694.</mixed-citation><mixed-citation xml:lang="en">Simmons B, Saleem J, Hill A, et al. Risk of late relapse or reinfection with hepatitis C virus after achieving a sustained virological response: a systematic review and meta-analysis. Clin Infect Dis. 2016;62:683-694.</mixed-citation></citation-alternatives></ref><ref id="cit84"><label>84</label><citation-alternatives><mixed-citation xml:lang="ru">Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Chronic hepatitis C virus infection: developing direct-acting antiviral drugs for treatment. Guidance for industry. 2017. Available at: https://www.fda.gov/downloads/drugs/ guidancecomplianceregulatoryinformation/guidances/ucm225333.pdf. Accessed March 23, 2018.</mixed-citation><mixed-citation xml:lang="en">Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Chronic hepatitis C virus infection: developing direct-acting antiviral drugs for treatment. Guidance for industry. 2017. Available at: https://www.fda.gov/downloads/drugs/ guidancecomplianceregulatoryinformation/guidances/ucm225333.pdf. Accessed March 23, 2018.</mixed-citation></citation-alternatives></ref><ref id="cit85"><label>85</label><citation-alternatives><mixed-citation xml:lang="ru">Simmons B, Saleem J, Heath K, et al. Long-term treatment outcomes of patients infected with hepatitis C virus: a systematic review and metaanalysis of the survival benefit of achieving a sustained virological response. Clin Infect Dis. 2015;61:730-740.</mixed-citation><mixed-citation xml:lang="en">Simmons B, Saleem J, Heath K, et al. Long-term treatment outcomes of patients infected with hepatitis C virus: a systematic review and metaanalysis of the survival benefit of achieving a sustained virological response. Clin Infect Dis. 2015;61:730-740.</mixed-citation></citation-alternatives></ref><ref id="cit86"><label>86</label><citation-alternatives><mixed-citation xml:lang="ru">Falade-Nwulia O, Suarez-Cuervo C, Nelson DR, et al. Oral direct-acting agent therapy for hepatitis C virus infection: a systematic review. Ann Intern Med. 2017;166:637-648.</mixed-citation><mixed-citation xml:lang="en">Falade-Nwulia O, Suarez-Cuervo C, Nelson DR, et al. Oral direct-acting agent therapy for hepatitis C virus infection: a systematic review. Ann Intern Med. 2017;166:637-648.</mixed-citation></citation-alternatives></ref><ref id="cit87"><label>87</label><citation-alternatives><mixed-citation xml:lang="ru">AASLD-IDSA. Recommendations for testing, managing, and treating hepatitis C. Available at: http://www.hcvguidelines.org. Accessed June 12, 2018.</mixed-citation><mixed-citation xml:lang="en">AASLD-IDSA. Recommendations for testing, managing, and treating hepatitis C. Available at: http://www.hcvguidelines.org. Accessed June 12, 2018.</mixed-citation></citation-alternatives></ref><ref id="cit88"><label>88</label><citation-alternatives><mixed-citation xml:lang="ru">Gamal N, Andreone P. Grazoprevir/elbasvir fixed-dose combination for hepatitis C. Drugs Today (Barc). 2016;52:377-385.</mixed-citation><mixed-citation xml:lang="en">Gamal N, Andreone P. Grazoprevir/elbasvir fixed-dose combination for hepatitis C. Drugs Today (Barc). 2016;52:377-385.</mixed-citation></citation-alternatives></ref><ref id="cit89"><label>89</label><citation-alternatives><mixed-citation xml:lang="ru">Reddy KR, Roth D, Bruchfeld A, et al. Elbasvir/grazoprevir does not worsen renal function in patients with hepatitis C virus infection and pre-existing renal disease. Hepatol Res. 2017;47:1340-1345.</mixed-citation><mixed-citation xml:lang="en">Reddy KR, Roth D, Bruchfeld A, et al. Elbasvir/grazoprevir does not worsen renal function in patients with hepatitis C virus infection and pre-existing renal disease. Hepatol Res. 2017;47:1340-1345.</mixed-citation></citation-alternatives></ref><ref id="cit90"><label>90</label><citation-alternatives><mixed-citation xml:lang="ru">Roth D, Nelson DR, Bruchfeld A, et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the CSURFER study): a combination phase 3 study. Lancet. 2015;386:1537-1545.</mixed-citation><mixed-citation xml:lang="en">Roth D, Nelson DR, Bruchfeld A, et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the CSURFER study): a combination phase 3 study. Lancet. 2015;386:1537-1545.</mixed-citation></citation-alternatives></ref><ref id="cit91"><label>91</label><citation-alternatives><mixed-citation xml:lang="ru">Bruchfeld A, Roth D, Martin P, et al. Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4-5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial. Lancet Gastroenterol Hepatol. 2017;2:585-594.</mixed-citation><mixed-citation xml:lang="en">Bruchfeld A, Roth D, Martin P, et al. Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4-5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial. Lancet Gastroenterol Hepatol. 2017;2:585-594.</mixed-citation></citation-alternatives></ref><ref id="cit92"><label>92</label><citation-alternatives><mixed-citation xml:lang="ru">Alric L, Ollivier-Hourmand I, Berard E, et al. Grazoprevir plus elbasvir in HCV genotype-1 or -4 infected patients with stage 4/5 severe chronic kidney disease is safe and effective. Kidney Int. 2018;94:206-213.</mixed-citation><mixed-citation xml:lang="en">Alric L, Ollivier-Hourmand I, Berard E, et al. Grazoprevir plus elbasvir in HCV genotype-1 or -4 infected patients with stage 4/5 severe chronic kidney disease is safe and effective. Kidney Int. 2018;94:206-213.</mixed-citation></citation-alternatives></ref><ref id="cit93"><label>93</label><citation-alternatives><mixed-citation xml:lang="ru">Munoz-Gomez R, Rincon D, Ahumada A, et al. Therapy with ombitasvir/ paritaprevir/ritonavir plus dasabuvir is effective and safe for the treatment of genotype 1 and 4 hepatitis C virus infection (HCV) in patients with severe renal impairment: a multicenter experience. J Viral Hepat. 2017;24:464-471.</mixed-citation><mixed-citation xml:lang="en">Munoz-Gomez R, Rincon D, Ahumada A, et al. Therapy with ombitasvir/ paritaprevir/ritonavir plus dasabuvir is effective and safe for the treatment of genotype 1 and 4 hepatitis C virus infection (HCV) in patients with severe renal impairment: a multicenter experience. J Viral Hepat. 2017;24:464-471.</mixed-citation></citation-alternatives></ref><ref id="cit94"><label>94</label><citation-alternatives><mixed-citation xml:lang="ru">Pockros PJ, Reddy KR, Mantry PS, et al. Efficacy of direct-acting antiviral combination for patients with hepatitis C virus genotype 1 infection and severe renal impairment or end-stage renal disease. Gastroenterology. 2016;150:1590-1598.</mixed-citation><mixed-citation xml:lang="en">Pockros PJ, Reddy KR, Mantry PS, et al. Efficacy of direct-acting antiviral combination for patients with hepatitis C virus genotype 1 infection and severe renal impairment or end-stage renal disease. Gastroenterology. 2016;150:1590-1598.</mixed-citation></citation-alternatives></ref><ref id="cit95"><label>95</label><citation-alternatives><mixed-citation xml:lang="ru">Sarrazin C. The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. J Hepatol. 2016;64:486-504.</mixed-citation><mixed-citation xml:lang="en">Sarrazin C. The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. J Hepatol. 2016;64:486-504.</mixed-citation></citation-alternatives></ref><ref id="cit96"><label>96</label><citation-alternatives><mixed-citation xml:lang="ru">Jacobson IM, Asante-Appiah E, Wong P, et al. Prevalence and impact of baseline NSA resistance associated variants (RAVs) on the efficacy of elbasvir/grazoprevir (EBR/GZR) against GT1a infection [Abstract LB-22]. In: 66th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), November 13-17, 2015. San Francisco, CA; 2015.</mixed-citation><mixed-citation xml:lang="en">Jacobson IM, Asante-Appiah E, Wong P, et al. Prevalence and impact of baseline NSA resistance associated variants (RAVs) on the efficacy of elbasvir/grazoprevir (EBR/GZR) against GT1a infection [Abstract LB-22]. In: 66th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), November 13-17, 2015. San Francisco, CA; 2015.</mixed-citation></citation-alternatives></ref><ref id="cit97"><label>97</label><citation-alternatives><mixed-citation xml:lang="ru">Gane EJ, Solà R, Cohen E, et al. RUBY-II: Efficacy and Safety of a Ribavirinfree Ombitasvir/Paritaprevir/Ritonavir _ Dasabuvir Regimen in Patients with Severe Renal Impairment or End-Stage Renal Disease and HCV Genotypes 1a or 4 Infection. Hepatology. 2016;64(Suppl 1):470A.</mixed-citation><mixed-citation xml:lang="en">Gane EJ, Solà R, Cohen E, et al. RUBY-II: Efficacy and Safety of a Ribavirinfree Ombitasvir/Paritaprevir/Ritonavir _ Dasabuvir Regimen in Patients with Severe Renal Impairment or End-Stage Renal Disease and HCV Genotypes 1a or 4 Infection. Hepatology. 2016;64(Suppl 1):470A.</mixed-citation></citation-alternatives></ref><ref id="cit98"><label>98</label><citation-alternatives><mixed-citation xml:lang="ru">Gane E, Lawitz E, Pugatch D, et al. Glecaprevir and pibrentasvir in patients with HCVand severe renal impairment. N Engl J Med. 2017;377:1448-1455.</mixed-citation><mixed-citation xml:lang="en">Gane E, Lawitz E, Pugatch D, et al. Glecaprevir and pibrentasvir in patients with HCVand severe renal impairment. N Engl J Med. 2017;377:1448-1455.</mixed-citation></citation-alternatives></ref><ref id="cit99"><label>99</label><citation-alternatives><mixed-citation xml:lang="ru">Kirby BJ, Symonds WT, Kearney BP, et al. Pharmacokinetic, pharmacodynamic, and drug-interaction profile of the hepatitis C virus NS5B polymerase inhibitor sofosbuvir. Clin Pharmacokinet. 2015;54:677-690. 1</mixed-citation><mixed-citation xml:lang="en">Kirby BJ, Symonds WT, Kearney BP, et al. Pharmacokinetic, pharmacodynamic, and drug-interaction profile of the hepatitis C virus NS5B polymerase inhibitor sofosbuvir. Clin Pharmacokinet. 2015;54:677-690. 1</mixed-citation></citation-alternatives></ref><ref id="cit100"><label>100</label><citation-alternatives><mixed-citation xml:lang="ru">Gane EJ, Robson RA, Bonacini, et al. Safety, anti-viral efficacy and pharmacokinetics (PK) of sofosbuvir (SOF) in patients with severe renal impairment. [Abstract 966]. Hepatology. 2014;60:667A.</mixed-citation><mixed-citation xml:lang="en">Gane EJ, Robson RA, Bonacini, et al. Safety, anti-viral efficacy and pharmacokinetics (PK) of sofosbuvir (SOF) in patients with severe renal impairment. [Abstract 966]. Hepatology. 2014;60:667A.</mixed-citation></citation-alternatives></ref><ref id="cit101"><label>101</label><citation-alternatives><mixed-citation xml:lang="ru">Czul F, Schiff E, Peyton C, et al. First ribavirin-free sofosbuvir and simeprevir treatment of Hepatitis C genotype 1 patients with severe renal impairment (GFR №30 ml/min or dialysis). [Abstract P0878]. J Hepatol. 2015;62:S670-S671.</mixed-citation><mixed-citation xml:lang="en">Czul F, Schiff E, Peyton C, et al. First ribavirin-free sofosbuvir and simeprevir treatment of Hepatitis C genotype 1 patients with severe renal impairment (GFR №30 ml/min or dialysis). [Abstract P0878]. J Hepatol. 2015;62:S670-S671.</mixed-citation></citation-alternatives></ref><ref id="cit102"><label>102</label><citation-alternatives><mixed-citation xml:lang="ru">Nazario HE, Ndungu M, Modi A. Safety and efficacy of sofosbuvir + simeprevir without ribavirin in hepatitis C genotype 1-infected patients with end-stage renal disease or GFR №30 ml/min. [Abstract P0802]. J Hepatol. 2015;62:S635.</mixed-citation><mixed-citation xml:lang="en">Nazario HE, Ndungu M, Modi A. Safety and efficacy of sofosbuvir + simeprevir without ribavirin in hepatitis C genotype 1-infected patients with end-stage renal disease or GFR №30 ml/min. [Abstract P0802]. J Hepatol. 2015;62:S635.</mixed-citation></citation-alternatives></ref><ref id="cit103"><label>103</label><citation-alternatives><mixed-citation xml:lang="ru">Perumpail RB, Wong RJ, Pham EA, et al. A new standard of care? standard dose sofosbuvir in an HCV-infected liver transplant recipient undergoing hemodialysis. Dig Dis Sci. 2016;61:39-41.</mixed-citation><mixed-citation xml:lang="en">Perumpail RB, Wong RJ, Pham EA, et al. A new standard of care? standard dose sofosbuvir in an HCV-infected liver transplant recipient undergoing hemodialysis. Dig Dis Sci. 2016;61:39-41.</mixed-citation></citation-alternatives></ref><ref id="cit104"><label>104</label><citation-alternatives><mixed-citation xml:lang="ru">Perumpail RB, Wong RJ, Ha LD, et al. Sofosbuvir and simeprevir combination therapy in the setting of liver transplantation and hemodialysis. Transpl Infect Dis. 2015;17:275-278.</mixed-citation><mixed-citation xml:lang="en">Perumpail RB, Wong RJ, Ha LD, et al. Sofosbuvir and simeprevir combination therapy in the setting of liver transplantation and hemodialysis. Transpl Infect Dis. 2015;17:275-278.</mixed-citation></citation-alternatives></ref><ref id="cit105"><label>105</label><citation-alternatives><mixed-citation xml:lang="ru">Desnoyer A, Pospai D, Le MP, et al. Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C. J Hepatol. 2016;65:40-47.</mixed-citation><mixed-citation xml:lang="en">Desnoyer A, Pospai D, Le MP, et al. Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C. J Hepatol. 2016;65:40-47.</mixed-citation></citation-alternatives></ref><ref id="cit106"><label>106</label><citation-alternatives><mixed-citation xml:lang="ru">Bhamidimarri KR, Czul F, Peyton A, et al. Safety, efficacy and tolerability of half-dose sofosbuvir plus simeprevir in treatment of Hepatitis C in patients with end stage renal disease. J Hepatol. 2015;63:763-765.</mixed-citation><mixed-citation xml:lang="en">Bhamidimarri KR, Czul F, Peyton A, et al. Safety, efficacy and tolerability of half-dose sofosbuvir plus simeprevir in treatment of Hepatitis C in patients with end stage renal disease. J Hepatol. 2015;63:763-765.</mixed-citation></citation-alternatives></ref><ref id="cit107"><label>107</label><citation-alternatives><mixed-citation xml:lang="ru">Saxena V, Koraishy FM, Sise ME, et al. Safety and efficacy of sofosbuvircontaining regimens in hepatitis C-infected patients with impaired renal function. Liver Int. 2016;36:807-816.</mixed-citation><mixed-citation xml:lang="en">Saxena V, Koraishy FM, Sise ME, et al. Safety and efficacy of sofosbuvircontaining regimens in hepatitis C-infected patients with impaired renal function. Liver Int. 2016;36:807-816.</mixed-citation></citation-alternatives></ref><ref id="cit108"><label>108</label><citation-alternatives><mixed-citation xml:lang="ru">Dumortier J, Bailly F, Pageaux GP, et al. Sofosbuvir-based antiviral therapy in hepatitis C virus patients with severe renal failure. Nephrol Dial Transplant. 2017;32:2065-2071.</mixed-citation><mixed-citation xml:lang="en">Dumortier J, Bailly F, Pageaux GP, et al. Sofosbuvir-based antiviral therapy in hepatitis C virus patients with severe renal failure. Nephrol Dial Transplant. 2017;32:2065-2071.</mixed-citation></citation-alternatives></ref><ref id="cit109"><label>109</label><citation-alternatives><mixed-citation xml:lang="ru">Li T, Qu Y, Guo Y, et al. Efficacy and safety of direct-acting antivirals-based antiviral therapies for hepatitis C virus patients with stage 4-5 chronic kidney disease: a meta-analysis. Liver Int. 2017;37:974-981.</mixed-citation><mixed-citation xml:lang="en">Li T, Qu Y, Guo Y, et al. Efficacy and safety of direct-acting antivirals-based antiviral therapies for hepatitis C virus patients with stage 4-5 chronic kidney disease: a meta-analysis. Liver Int. 2017;37:974-981.</mixed-citation></citation-alternatives></ref><ref id="cit110"><label>110</label><citation-alternatives><mixed-citation xml:lang="ru">Gonzalez-Parra E, Soledad PS, et al. Renal function evolution in patients infected with HCV and basal estimated glomerular filtration rate (GFRE) between 30-60 ml/min/1.73 m2 treated with ombitasvir/paritaprevir/ ritonavir and dasabuvir (3D) vs regimens based on sofosbuvir (SOF). EASL Special Conference, September 23-24, 2016. Available at: http:// www.easloffice.eu/office/paris2016/mobile/index.html#p¼172. Accessed February 25, 2018.</mixed-citation><mixed-citation xml:lang="en">Gonzalez-Parra E, Soledad PS, et al. Renal function evolution in patients infected with HCV and basal estimated glomerular filtration rate (GFRE) between 30-60 ml/min/1.73 m2 treated with ombitasvir/paritaprevir/ ritonavir and dasabuvir (3D) vs regimens based on sofosbuvir (SOF). EASL Special Conference, September 23-24, 2016. Available at: http:// www.easloffice.eu/office/paris2016/mobile/index.html#p¼172. Accessed February 25, 2018.</mixed-citation></citation-alternatives></ref><ref id="cit111"><label>111</label><citation-alternatives><mixed-citation xml:lang="ru">Rosenblatt R, Mehta A,Wagner M, Kumar S. Baseline creatinine clearance is a predictor of worsening renal function while on HCV treatment with sofosbuvir-ledipasvir. J Hepatol. 2016;64 Suppl:S819.</mixed-citation><mixed-citation xml:lang="en">Rosenblatt R, Mehta A,Wagner M, Kumar S. Baseline creatinine clearance is a predictor of worsening renal function while on HCV treatment with sofosbuvir-ledipasvir. J Hepatol. 2016;64 Suppl:S819.</mixed-citation></citation-alternatives></ref><ref id="cit112"><label>112</label><citation-alternatives><mixed-citation xml:lang="ru">Mallet V, Parlati L, Dorval O, et al. Estimated glomerular filtration rate variations and direct acting antivirals treatment for chronic hepatitis C: a retrospective longitudinal study. J Hepatol. 2018;68:S22.</mixed-citation><mixed-citation xml:lang="en">Mallet V, Parlati L, Dorval O, et al. Estimated glomerular filtration rate variations and direct acting antivirals treatment for chronic hepatitis C: a retrospective longitudinal study. J Hepatol. 2018;68:S22.</mixed-citation></citation-alternatives></ref><ref id="cit113"><label>113</label><citation-alternatives><mixed-citation xml:lang="ru">Sise ME, Backman E, Ortiz GA, et al. Effect of sofosbuvir-based hepatitis C virus therapy on kidney function in patients with CKD. Clin J Am Soc Nephrol. 2017;12:1615-1623.</mixed-citation><mixed-citation xml:lang="en">Sise ME, Backman E, Ortiz GA, et al. Effect of sofosbuvir-based hepatitis C virus therapy on kidney function in patients with CKD. Clin J Am Soc Nephrol. 2017;12:1615-1623.</mixed-citation></citation-alternatives></ref><ref id="cit114"><label>114</label><citation-alternatives><mixed-citation xml:lang="ru">Stark JE, Cole J. Successful treatment of chronic hepatitis C virus infection in a patient receiving daily peritoneal dialysis. Am J Health Syst Pharm. 2017;74:1541-1544.</mixed-citation><mixed-citation xml:lang="en">Stark JE, Cole J. Successful treatment of chronic hepatitis C virus infection in a patient receiving daily peritoneal dialysis. Am J Health Syst Pharm. 2017;74:1541-1544.</mixed-citation></citation-alternatives></ref><ref id="cit115"><label>115</label><citation-alternatives><mixed-citation xml:lang="ru">Lin MV, Sise ME, Pavlakis M, et al. Safety and efficacy of novel antivirals in kidney transplant recipients with chronic hepatitis C virus (HCV) infection. [Abstract LP42]. Journal of Hepatol. 2015;62:S284-S285.</mixed-citation><mixed-citation xml:lang="en">Lin MV, Sise ME, Pavlakis M, et al. Safety and efficacy of novel antivirals in kidney transplant recipients with chronic hepatitis C virus (HCV) infection. [Abstract LP42]. Journal of Hepatol. 2015;62:S284-S285.</mixed-citation></citation-alternatives></ref><ref id="cit116"><label>116</label><citation-alternatives><mixed-citation xml:lang="ru">Colombo M, Aghemo A, Liu H, et al. Treatment with ledipasvir-sofosbuvir for 12 or 24 weeks in kidney transplant recipients with chronic hepatitis C virus genotype 1 or 4 infection: a randomized trial. Ann Intern Med. 2017;166:109-117.</mixed-citation><mixed-citation xml:lang="en">Colombo M, Aghemo A, Liu H, et al. Treatment with ledipasvir-sofosbuvir for 12 or 24 weeks in kidney transplant recipients with chronic hepatitis C virus genotype 1 or 4 infection: a randomized trial. Ann Intern Med. 2017;166:109-117.</mixed-citation></citation-alternatives></ref><ref id="cit117"><label>117</label><citation-alternatives><mixed-citation xml:lang="ru">Fernandez I, Munoz-Gomez R, Pascasio JM, et al. Efficacy and tolerability of interferon-free antiviral therapy in kidney transplant recipients with chronic hepatitis C. J Hepatol. 2017;66:718-723.</mixed-citation><mixed-citation xml:lang="en">Fernandez I, Munoz-Gomez R, Pascasio JM, et al. Efficacy and tolerability of interferon-free antiviral therapy in kidney transplant recipients with chronic hepatitis C. J Hepatol. 2017;66:718-723.</mixed-citation></citation-alternatives></ref><ref id="cit118"><label>118</label><citation-alternatives><mixed-citation xml:lang="ru">Kamar N, Marion O, Rostaing L, et al. Efficacy and safety of sofosbuvirbased antiviral therapy to treat hepatitis C virus infection after kidney transplantation. Am J Transplant. 2016;16:1474-1479.</mixed-citation><mixed-citation xml:lang="en">Kamar N, Marion O, Rostaing L, et al. Efficacy and safety of sofosbuvirbased antiviral therapy to treat hepatitis C virus infection after kidney transplantation. Am J Transplant. 2016;16:1474-1479.</mixed-citation></citation-alternatives></ref><ref id="cit119"><label>119</label><citation-alternatives><mixed-citation xml:lang="ru">Sawinski D, Kaur N, Ajeti A, et al. Successful treatment of hepatitis C in renal transplant recipients with direct-acting antiviral agents. Am J Transplant. 2016;16:1588-1595.</mixed-citation><mixed-citation xml:lang="en">Sawinski D, Kaur N, Ajeti A, et al. Successful treatment of hepatitis C in renal transplant recipients with direct-acting antiviral agents. Am J Transplant. 2016;16:1588-1595.</mixed-citation></citation-alternatives></ref><ref id="cit120"><label>120</label><citation-alternatives><mixed-citation xml:lang="ru">Agarwal K, Castells L, Mullhaupt B, et al. Sofosbuvir/velpatasvir for 12 weeks in genotype 1-4 HCV-infected liver transplant recipients [e-pub ahead of print]. J Hepatol. https://doi.org/10.1016/j.jhep.2018.05.039. Accessed July 28, 2018.</mixed-citation><mixed-citation xml:lang="en">Agarwal K, Castells L, Mullhaupt B, et al. Sofosbuvir/velpatasvir for 12 weeks in genotype 1-4 HCV-infected liver transplant recipients [e-pub ahead of print]. J Hepatol. https://doi.org/10.1016/j.jhep.2018.05.039. Accessed July 28, 2018.</mixed-citation></citation-alternatives></ref><ref id="cit121"><label>121</label><citation-alternatives><mixed-citation xml:lang="ru">Morelle J, Goffin E, Wallemacq P, et al. Extended release tacrolimus and antiretroviral therapy in a renal transplant recipient: so extended! Transpl Int. 2010;23:1065-1067.</mixed-citation><mixed-citation xml:lang="en">Morelle J, Goffin E, Wallemacq P, et al. Extended release tacrolimus and antiretroviral therapy in a renal transplant recipient: so extended! Transpl Int. 2010;23:1065-1067.</mixed-citation></citation-alternatives></ref><ref id="cit122"><label>122</label><citation-alternatives><mixed-citation xml:lang="ru">Kucirka LM, Singer AL, Ros RL, et al. Underutilization of hepatitis C-positive kidneys for hepatitis C-positive recipients. Am J Transplant. 2010;10:1238-1246.</mixed-citation><mixed-citation xml:lang="en">Kucirka LM, Singer AL, Ros RL, et al. Underutilization of hepatitis C-positive kidneys for hepatitis C-positive recipients. Am J Transplant. 2010;10:1238-1246.</mixed-citation></citation-alternatives></ref><ref id="cit123"><label>123</label><citation-alternatives><mixed-citation xml:lang="ru">Goldberg DS, Abt PL, Blumberg EA, et al. Trial of transplantation of HCVinfected kidneys into uninfected recipients.NEnglJMed. 2017;376:2394-2395.</mixed-citation><mixed-citation xml:lang="en">Goldberg DS, Abt PL, Blumberg EA, et al. Trial of transplantation of HCVinfected kidneys into uninfected recipients.NEnglJMed. 2017;376:2394-2395.</mixed-citation></citation-alternatives></ref><ref id="cit124"><label>124</label><citation-alternatives><mixed-citation xml:lang="ru">Durand CM, Bowring MG, Brown DM, et al. Direct-acting antiviral prophylaxis in kidney transplantation from hepatitis C virus-infected donors to noninfected recipients: an open-label nonrandomized trial. Ann Intern Med. 2018;168:533-540.</mixed-citation><mixed-citation xml:lang="en">Durand CM, Bowring MG, Brown DM, et al. Direct-acting antiviral prophylaxis in kidney transplantation from hepatitis C virus-infected donors to noninfected recipients: an open-label nonrandomized trial. Ann Intern Med. 2018;168:533-540.</mixed-citation></citation-alternatives></ref><ref id="cit125"><label>125</label><citation-alternatives><mixed-citation xml:lang="ru">Chen G, Wang C, Chen J, et al. Hepatitis B reactivation in hepatitis B and C coinfected patients treated with antiviral agents: a systematic review and meta-analysis. Hepatology. 2017;66:13-26.</mixed-citation><mixed-citation xml:lang="en">Chen G, Wang C, Chen J, et al. Hepatitis B reactivation in hepatitis B and C coinfected patients treated with antiviral agents: a systematic review and meta-analysis. Hepatology. 2017;66:13-26.</mixed-citation></citation-alternatives></ref><ref id="cit126"><label>126</label><citation-alternatives><mixed-citation xml:lang="ru">Mucke MM, Backus LI, Mucke VT, et al. Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2018;3:172-180.</mixed-citation><mixed-citation xml:lang="en">Mucke MM, Backus LI, Mucke VT, et al. Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2018;3:172-180.</mixed-citation></citation-alternatives></ref><ref id="cit127"><label>127</label><citation-alternatives><mixed-citation xml:lang="ru">Bersoff-Matcha SJ, Cao K, Jason M, et al. Hepatitis B virus reactivation associated with direct-acting antiviral therapy for chronic hepatitis C virus: a review of cases reported to the U.S. Food and Drug administration adverse event reporting system. Ann Intern Med. 2017;166:792-798.</mixed-citation><mixed-citation xml:lang="en">Bersoff-Matcha SJ, Cao K, Jason M, et al. Hepatitis B virus reactivation associated with direct-acting antiviral therapy for chronic hepatitis C virus: a review of cases reported to the U.S. Food and Drug administration adverse event reporting system. Ann Intern Med. 2017;166:792-798.</mixed-citation></citation-alternatives></ref><ref id="cit128"><label>128</label><citation-alternatives><mixed-citation xml:lang="ru">Fabrizi F, Martin P, Dixit V, et al. Hepatitis C virus infection and kidney disease: a meta-analysis. Clin J Am Soc Nephrol. 2012;7:549-557.</mixed-citation><mixed-citation xml:lang="en">Fabrizi F, Martin P, Dixit V, et al. Hepatitis C virus infection and kidney disease: a meta-analysis. Clin J Am Soc Nephrol. 2012;7:549-557.</mixed-citation></citation-alternatives></ref><ref id="cit129"><label>129</label><citation-alternatives><mixed-citation xml:lang="ru">Schneeberger PM, Keur I, van Loon AM, et al. The prevalence and incidence of hepatitis C virus infections among dialysis patients in the Netherlands: a nationwide prospective study. J Infect Dis. 2000;182:1291-1299.</mixed-citation><mixed-citation xml:lang="en">Schneeberger PM, Keur I, van Loon AM, et al. The prevalence and incidence of hepatitis C virus infections among dialysis patients in the Netherlands: a nationwide prospective study. J Infect Dis. 2000;182:1291-1299.</mixed-citation></citation-alternatives></ref><ref id="cit130"><label>130</label><citation-alternatives><mixed-citation xml:lang="ru">Vladutiu DS, Cosa A, Neamtu A, et al. Infections with hepatitis B and C viruses in patients on maintenance dialysis in Romania and in former communist countries: yellow spots on a blank map? J Viral Hepat. 2000;7:313-319.</mixed-citation><mixed-citation xml:lang="en">Vladutiu DS, Cosa A, Neamtu A, et al. Infections with hepatitis B and C viruses in patients on maintenance dialysis in Romania and in former communist countries: yellow spots on a blank map? J Viral Hepat. 2000;7:313-319.</mixed-citation></citation-alternatives></ref><ref id="cit131"><label>131</label><citation-alternatives><mixed-citation xml:lang="ru">Sun J, Yu R, Zhu B, et al. Hepatitis C infection and related factors in hemodialysis patients in China: systematic review and meta-analysis. Ren Fail. 2009;31:610-620.</mixed-citation><mixed-citation xml:lang="en">Sun J, Yu R, Zhu B, et al. Hepatitis C infection and related factors in hemodialysis patients in China: systematic review and meta-analysis. Ren Fail. 2009;31:610-620.</mixed-citation></citation-alternatives></ref><ref id="cit132"><label>132</label><citation-alternatives><mixed-citation xml:lang="ru">Voiculescu M, Iliescu L, Ionescu C, et al. A cross-sectional epidemiological study of HBV, HCV, HDV and HEV prevalence in the SubCarpathian and South-Eastern regions of Romania. J Gastrointestin Liver Dis. 2010;19:43-48.</mixed-citation><mixed-citation xml:lang="en">Voiculescu M, Iliescu L, Ionescu C, et al. A cross-sectional epidemiological study of HBV, HCV, HDV and HEV prevalence in the SubCarpathian and South-Eastern regions of Romania. J Gastrointestin Liver Dis. 2010;19:43-48.</mixed-citation></citation-alternatives></ref><ref id="cit133"><label>133</label><citation-alternatives><mixed-citation xml:lang="ru">Selm SB. Prevalence of hepatitis C virus infection among hemodialysis patients in a single center in Yemen. Saudi J Kidney Dis Transpl. 2010;21:1165-1168.</mixed-citation><mixed-citation xml:lang="en">Selm SB. Prevalence of hepatitis C virus infection among hemodialysis patients in a single center in Yemen. Saudi J Kidney Dis Transpl. 2010;21:1165-1168.</mixed-citation></citation-alternatives></ref><ref id="cit134"><label>134</label><citation-alternatives><mixed-citation xml:lang="ru">Ali I, Siddique L, Rehman LU, et al. Prevalence of HCVamong the high risk groups in Khyber Pakhtunkhwa. Virol J. 2011;8:296.</mixed-citation><mixed-citation xml:lang="en">Ali I, Siddique L, Rehman LU, et al. Prevalence of HCVamong the high risk groups in Khyber Pakhtunkhwa. Virol J. 2011;8:296.</mixed-citation></citation-alternatives></ref><ref id="cit135"><label>135</label><citation-alternatives><mixed-citation xml:lang="ru">Su Y, Norris JL, Zang C, et al. Incidence of hepatitis C virus infection in patients on hemodialysis: a systematic review and meta-analysis. Hemodial Int. 2013;17:532-541.</mixed-citation><mixed-citation xml:lang="en">Su Y, Norris JL, Zang C, et al. Incidence of hepatitis C virus infection in patients on hemodialysis: a systematic review and meta-analysis. Hemodial Int. 2013;17:532-541.</mixed-citation></citation-alternatives></ref><ref id="cit136"><label>136</label><citation-alternatives><mixed-citation xml:lang="ru">Marwaha N, Sachdev S. Current testing strategies for hepatitis C virus infection in blood donors and the way forward. World J Gastroenterol. 2014;20:2948-2954.</mixed-citation><mixed-citation xml:lang="en">Marwaha N, Sachdev S. Current testing strategies for hepatitis C virus infection in blood donors and the way forward. World J Gastroenterol. 2014;20:2948-2954.</mixed-citation></citation-alternatives></ref><ref id="cit137"><label>137</label><citation-alternatives><mixed-citation xml:lang="ru">Thompson ND, Novak RT, White-Comstock MB, et al. Patient-to-patient hepatitis C virus transmissions associated with infection control breaches in a hemodialysis unit. J Nephrol Therapeutics. 2012;S10:002.</mixed-citation><mixed-citation xml:lang="en">Thompson ND, Novak RT, White-Comstock MB, et al. Patient-to-patient hepatitis C virus transmissions associated with infection control breaches in a hemodialysis unit. J Nephrol Therapeutics. 2012;S10:002.</mixed-citation></citation-alternatives></ref><ref id="cit138"><label>138</label><citation-alternatives><mixed-citation xml:lang="ru">Aho-Glele LS, Giraudon H, Astruc K, et al. Investigation of a case of genotype 5a hepatitis C virus transmission in a french hemodialysis unit using epidemiologic data and deep sequencing. Infect Control Hosp Epidemiol. 2016;37:134-139.</mixed-citation><mixed-citation xml:lang="en">Aho-Glele LS, Giraudon H, Astruc K, et al. Investigation of a case of genotype 5a hepatitis C virus transmission in a french hemodialysis unit using epidemiologic data and deep sequencing. Infect Control Hosp Epidemiol. 2016;37:134-139.</mixed-citation></citation-alternatives></ref><ref id="cit139"><label>139</label><citation-alternatives><mixed-citation xml:lang="ru">Thompson ND, Novak RT, Datta D, et al. Hepatitis C virus transmission in hemodialysis units: importance of infection control practices and aseptic technique. Infect Control Hosp Epidemiol. 2009;30:900-903.</mixed-citation><mixed-citation xml:lang="en">Thompson ND, Novak RT, Datta D, et al. Hepatitis C virus transmission in hemodialysis units: importance of infection control practices and aseptic technique. Infect Control Hosp Epidemiol. 2009;30:900-903.</mixed-citation></citation-alternatives></ref><ref id="cit140"><label>140</label><citation-alternatives><mixed-citation xml:lang="ru">Fabrizi F, Messa P. Transmission of hepatitis C virus in dialysis units: a systematic review of reports on outbreaks. Int J Artif Organs. 2015;38:471-480.</mixed-citation><mixed-citation xml:lang="en">Fabrizi F, Messa P. Transmission of hepatitis C virus in dialysis units: a systematic review of reports on outbreaks. Int J Artif Organs. 2015;38:471-480.</mixed-citation></citation-alternatives></ref><ref id="cit141"><label>141</label><citation-alternatives><mixed-citation xml:lang="ru">Jadoul M, Poignet JL, Geddes C, et al. The changing epidemiology of hepatitis C virus (HCV) infection in haemodialysis: European multicentre study. Nephrol Dial Transplant. 2004;19:904-909.</mixed-citation><mixed-citation xml:lang="en">Jadoul M, Poignet JL, Geddes C, et al. The changing epidemiology of hepatitis C virus (HCV) infection in haemodialysis: European multicentre study. Nephrol Dial Transplant. 2004;19:904-909.</mixed-citation></citation-alternatives></ref><ref id="cit142"><label>142</label><citation-alternatives><mixed-citation xml:lang="ru">Centers for Disease Control and Prevention. Healthcare-associated hepatitis B and C outbreaks reported to the Centers for Disease Control and Prevention, 2008-2015. Available at: https://www.cdc.gov/hepatitis/ outbreaks/healthcarehepoutbreaktable.htm. Accessed July 27, 2018.</mixed-citation><mixed-citation xml:lang="en">Centers for Disease Control and Prevention. Healthcare-associated hepatitis B and C outbreaks reported to the Centers for Disease Control and Prevention, 2008-2015. Available at: https://www.cdc.gov/hepatitis/ outbreaks/healthcarehepoutbreaktable.htm. Accessed July 27, 2018.</mixed-citation></citation-alternatives></ref><ref id="cit143"><label>143</label><citation-alternatives><mixed-citation xml:lang="ru">The Centers for Disease Control and Prevention. CDC urging dialysis providers and facilities to assess and improve infection control practices to stop hepatitis C virus transmission in patients undergoing hemodialysis. Am J Transplant. 2016;16:1633-1634.</mixed-citation><mixed-citation xml:lang="en">The Centers for Disease Control and Prevention. CDC urging dialysis providers and facilities to assess and improve infection control practices to stop hepatitis C virus transmission in patients undergoing hemodialysis. Am J Transplant. 2016;16:1633-1634.</mixed-citation></citation-alternatives></ref><ref id="cit144"><label>144</label><citation-alternatives><mixed-citation xml:lang="ru">Thompson ND, Perz JF, Moorman AC, et al. Nonhospital health careassociated hepatitis B and C virus transmission: United States, 1998-2008. Ann Intern Med. 2009;150:33-39.</mixed-citation><mixed-citation xml:lang="en">Thompson ND, Perz JF, Moorman AC, et al. Nonhospital health careassociated hepatitis B and C virus transmission: United States, 1998-2008. Ann Intern Med. 2009;150:33-39.</mixed-citation></citation-alternatives></ref><ref id="cit145"><label>145</label><citation-alternatives><mixed-citation xml:lang="ru">de Lamballerie X, Olmer M, Bouchouareb D, et al. Nosocomial transmission of hepatitis C virus in haemodialysis patients. J Med Virol. 1996;49:296-302.</mixed-citation><mixed-citation xml:lang="en">de Lamballerie X, Olmer M, Bouchouareb D, et al. Nosocomial transmission of hepatitis C virus in haemodialysis patients. J Med Virol. 1996;49:296-302.</mixed-citation></citation-alternatives></ref><ref id="cit146"><label>146</label><citation-alternatives><mixed-citation xml:lang="ru">McLaughlin KJ, Cameron SO, Good T, et al. Nosocomial transmission of hepatitis C virus within a British dialysis centre. Nephrol Dial Transplant. 1997;12:304-309.</mixed-citation><mixed-citation xml:lang="en">McLaughlin KJ, Cameron SO, Good T, et al. Nosocomial transmission of hepatitis C virus within a British dialysis centre. Nephrol Dial Transplant. 1997;12:304-309.</mixed-citation></citation-alternatives></ref><ref id="cit147"><label>147</label><citation-alternatives><mixed-citation xml:lang="ru">Bieber B, Goodkin DA, Nwankwo C, et al. Hepatitis C prevalence and clinical outcomes in the Dialysis Outcomes and Practice Patterns Study. Neph Dial Transpl. 2015;30 Suppl 3:iii314.</mixed-citation><mixed-citation xml:lang="en">Bieber B, Goodkin DA, Nwankwo C, et al. Hepatitis C prevalence and clinical outcomes in the Dialysis Outcomes and Practice Patterns Study. Neph Dial Transpl. 2015;30 Suppl 3:iii314.</mixed-citation></citation-alternatives></ref><ref id="cit148"><label>148</label><citation-alternatives><mixed-citation xml:lang="ru">de Jesus Rodrigues de Freitas M, Fecury AA, de Almeida MK, et al. Prevalence of hepatitis C virus infection and genotypes in patient with chronic kidney disease undergoing hemodialysis. J Med Virol. 2013;85:1741-1745.</mixed-citation><mixed-citation xml:lang="en">de Jesus Rodrigues de Freitas M, Fecury AA, de Almeida MK, et al. Prevalence of hepatitis C virus infection and genotypes in patient with chronic kidney disease undergoing hemodialysis. J Med Virol. 2013;85:1741-1745.</mixed-citation></citation-alternatives></ref><ref id="cit149"><label>149</label><citation-alternatives><mixed-citation xml:lang="ru">Santana RR, Martínez Z, Martínez MT, Mato J. Hepatitis C virus present in hemodialysis units from Cuban western region. Rev Cub Meda. 2009;48:28-35.149a.</mixed-citation><mixed-citation xml:lang="en">Santana RR, Martínez Z, Martínez MT, Mato J. Hepatitis C virus present in hemodialysis units from Cuban western region. Rev Cub Meda. 2009;48:28-35.149a.</mixed-citation></citation-alternatives></ref><ref id="cit150"><label>150</label><citation-alternatives><mixed-citation xml:lang="ru">Ashkani-Esfahani S, Alavian SM, Salehi-Marzijarani M. Prevalence of hepatitis C virus infection among hemodialysis patients in the Middle- East: a systematic review and meta-analysis. World J Gastroenterol. 2017;23:151-166.</mixed-citation><mixed-citation xml:lang="en">Ashkani-Esfahani S, Alavian SM, Salehi-Marzijarani M. Prevalence of hepatitis C virus infection among hemodialysis patients in the Middle- East: a systematic review and meta-analysis. World J Gastroenterol. 2017;23:151-166.</mixed-citation></citation-alternatives></ref><ref id="cit151"><label>151</label><citation-alternatives><mixed-citation xml:lang="ru">Abou Rached A, El Khoury L, El Imad T, et al. Incidence and prevalence of hepatitis B and hepatitis C viruses in hemodialysis patients in Lebanon. World J Nephrol. 2016;5:101-107.</mixed-citation><mixed-citation xml:lang="en">Abou Rached A, El Khoury L, El Imad T, et al. Incidence and prevalence of hepatitis B and hepatitis C viruses in hemodialysis patients in Lebanon. World J Nephrol. 2016;5:101-107.</mixed-citation></citation-alternatives></ref><ref id="cit152"><label>152</label><citation-alternatives><mixed-citation xml:lang="ru">Alashek WA, McIntyre CW, Taal MW. Hepatitis B and C infection in haemodialysis patients in Libya: prevalence, incidence and risk factors. BMC Infect Dis. 2012;12:265.</mixed-citation><mixed-citation xml:lang="en">Alashek WA, McIntyre CW, Taal MW. Hepatitis B and C infection in haemodialysis patients in Libya: prevalence, incidence and risk factors. BMC Infect Dis. 2012;12:265.</mixed-citation></citation-alternatives></ref><ref id="cit153"><label>153</label><citation-alternatives><mixed-citation xml:lang="ru">Ummate I, Denue BA, Kida IM, et al. Risk factors for hepatitis C virus sero-positivity among haemodialysis patients receiving care at kidney centre in a tertiary health facility in Maiduguri, Nigeria. Pan Afr Med.J. 2014;19:305.</mixed-citation><mixed-citation xml:lang="en">Ummate I, Denue BA, Kida IM, et al. Risk factors for hepatitis C virus sero-positivity among haemodialysis patients receiving care at kidney centre in a tertiary health facility in Maiduguri, Nigeria. Pan Afr Med.J. 2014;19:305.</mixed-citation></citation-alternatives></ref><ref id="cit154"><label>154</label><citation-alternatives><mixed-citation xml:lang="ru">Schiller A, Timar R, Siriopol D, et al. Hepatitis B and C virus infection in the hemodialysis population from three romanian regions. Nephron. 2015;129:202-208.</mixed-citation><mixed-citation xml:lang="en">Schiller A, Timar R, Siriopol D, et al. Hepatitis B and C virus infection in the hemodialysis population from three romanian regions. Nephron. 2015;129:202-208.</mixed-citation></citation-alternatives></ref><ref id="cit155"><label>155</label><citation-alternatives><mixed-citation xml:lang="ru">Seck SM, Dahaba M, Gueye S, et al. Trends in hepatitis C infection among hemodialysis patients in Senegal: results of a decade of prevention. Saudi J Kidney Dis Transpl. 2014;25:1341-1345.</mixed-citation><mixed-citation xml:lang="en">Seck SM, Dahaba M, Gueye S, et al. Trends in hepatitis C infection among hemodialysis patients in Senegal: results of a decade of prevention. Saudi J Kidney Dis Transpl. 2014;25:1341-1345.</mixed-citation></citation-alternatives></ref><ref id="cit156"><label>156</label><citation-alternatives><mixed-citation xml:lang="ru">Alfurayh O, Sabeel A, Al Ahdal MN, et al. Hand contamination with hepatitis C virus in staff looking after hepatitis C-positive hemodialysis patients. Am J Nephrol. 2000;20:103-106.</mixed-citation><mixed-citation xml:lang="en">Alfurayh O, Sabeel A, Al Ahdal MN, et al. Hand contamination with hepatitis C virus in staff looking after hepatitis C-positive hemodialysis patients. Am J Nephrol. 2000;20:103-106.</mixed-citation></citation-alternatives></ref><ref id="cit157"><label>157</label><citation-alternatives><mixed-citation xml:lang="ru">Bergervoet PW, van Riessen N, Sebens FW, et al. Application of the forensic Luminol for blood in infection control. J Hosp Infect. 2008;68:329-333.</mixed-citation><mixed-citation xml:lang="en">Bergervoet PW, van Riessen N, Sebens FW, et al. Application of the forensic Luminol for blood in infection control. J Hosp Infect. 2008;68:329-333.</mixed-citation></citation-alternatives></ref><ref id="cit158"><label>158</label><citation-alternatives><mixed-citation xml:lang="ru">Caramelo C, de Sequera P, Lopez MD, et al. Hand-borne mechanisms of dissemination of hepatitis C virus in dialysis units: basis for new addenda to the present preventive strategies. Clin Nephrol. 1999;51:59-60.</mixed-citation><mixed-citation xml:lang="en">Caramelo C, de Sequera P, Lopez MD, et al. Hand-borne mechanisms of dissemination of hepatitis C virus in dialysis units: basis for new addenda to the present preventive strategies. Clin Nephrol. 1999;51:59-60.</mixed-citation></citation-alternatives></ref><ref id="cit159"><label>159</label><citation-alternatives><mixed-citation xml:lang="ru">Froio N, Nicastri E, Comandini UV, et al. Contamination by hepatitis B and C viruses in the dialysis setting. Am J Kidney Dis. 2003;42:546-550.</mixed-citation><mixed-citation xml:lang="en">Froio N, Nicastri E, Comandini UV, et al. Contamination by hepatitis B and C viruses in the dialysis setting. Am J Kidney Dis. 2003;42:546-550.</mixed-citation></citation-alternatives></ref><ref id="cit160"><label>160</label><citation-alternatives><mixed-citation xml:lang="ru">Girou E, Chevaliez S, Challine D, et al. Determinant roles of environmental contamination and noncompliance with standard precautions in the risk of hepatitis C virus transmission in a hemodialysis unit. Clin Infect Dis. 2008;47:627-633.</mixed-citation><mixed-citation xml:lang="en">Girou E, Chevaliez S, Challine D, et al. Determinant roles of environmental contamination and noncompliance with standard precautions in the risk of hepatitis C virus transmission in a hemodialysis unit. Clin Infect Dis. 2008;47:627-633.</mixed-citation></citation-alternatives></ref><ref id="cit161"><label>161</label><citation-alternatives><mixed-citation xml:lang="ru">Kamili S, Krawczynski K, McCaustland K, et al. Infectivity of hepatitis C virus in plasma after drying and storing at room temperature. Infect Control Hosp Epidemiol. 2007;28:519-524.</mixed-citation><mixed-citation xml:lang="en">Kamili S, Krawczynski K, McCaustland K, et al. Infectivity of hepatitis C virus in plasma after drying and storing at room temperature. Infect Control Hosp Epidemiol. 2007;28:519-524.</mixed-citation></citation-alternatives></ref><ref id="cit162"><label>162</label><citation-alternatives><mixed-citation xml:lang="ru">Patel PR, Thompson ND, Kallen AJ, et al. Epidemiology, surveillance, and prevention of hepatitis C virus infections in hemodialysis patients. Am J Kidney Dis. 2010;56:371-378.</mixed-citation><mixed-citation xml:lang="en">Patel PR, Thompson ND, Kallen AJ, et al. Epidemiology, surveillance, and prevention of hepatitis C virus infections in hemodialysis patients. Am J Kidney Dis. 2010;56:371-378.</mixed-citation></citation-alternatives></ref><ref id="cit163"><label>163</label><citation-alternatives><mixed-citation xml:lang="ru">Paintsil E, Binka M, Patel A, et al. Hepatitis C virus maintains infectivity for weeks after drying on inanimate surfaces at room temperature: implications for risks of transmission. J Infect Dis. 2014;209:1205-1211.</mixed-citation><mixed-citation xml:lang="en">Paintsil E, Binka M, Patel A, et al. Hepatitis C virus maintains infectivity for weeks after drying on inanimate surfaces at room temperature: implications for risks of transmission. J Infect Dis. 2014;209:1205-1211.</mixed-citation></citation-alternatives></ref><ref id="cit164"><label>164</label><citation-alternatives><mixed-citation xml:lang="ru">Laporte F, Tap G, Jaafar A, et al. Mathematical modeling of hepatitis C virus transmission in hemodialysis. Am J Infect Control. 2009;37:403-407.</mixed-citation><mixed-citation xml:lang="en">Laporte F, Tap G, Jaafar A, et al. Mathematical modeling of hepatitis C virus transmission in hemodialysis. Am J Infect Control. 2009;37:403-407.</mixed-citation></citation-alternatives></ref><ref id="cit165"><label>165</label><citation-alternatives><mixed-citation xml:lang="ru">Petrosillo N, Gilli P, Serraino D, et al. Prevalence of infected patients and understaffing have a role in hepatitis C virus transmission in dialysis. Am J Kidney Dis. 2001;37:1004-1010.</mixed-citation><mixed-citation xml:lang="en">Petrosillo N, Gilli P, Serraino D, et al. Prevalence of infected patients and understaffing have a role in hepatitis C virus transmission in dialysis. Am J Kidney Dis. 2001;37:1004-1010.</mixed-citation></citation-alternatives></ref><ref id="cit166"><label>166</label><citation-alternatives><mixed-citation xml:lang="ru">Shimokura G, Chai F, Weber DJ, et al. Patient-care practices associated with an increased prevalence of hepatitis C virus infection among chronic hemodialysis patients. Infect Control Hosp Epidemiol. 2011;32:415-424.</mixed-citation><mixed-citation xml:lang="en">Shimokura G, Chai F, Weber DJ, et al. Patient-care practices associated with an increased prevalence of hepatitis C virus infection among chronic hemodialysis patients. Infect Control Hosp Epidemiol. 2011;32:415-424.</mixed-citation></citation-alternatives></ref><ref id="cit167"><label>167</label><citation-alternatives><mixed-citation xml:lang="ru">Centers for Disease Control and Prevention. Dialysis safety audit tools and checklists. Available at: http://www.cdc.gov/dialysis/prevention-tools/audittools. html. Accessed July 27, 2018.</mixed-citation><mixed-citation xml:lang="en">Centers for Disease Control and Prevention. Dialysis safety audit tools and checklists. Available at: http://www.cdc.gov/dialysis/prevention-tools/audittools. html. Accessed July 27, 2018.</mixed-citation></citation-alternatives></ref><ref id="cit168"><label>168</label><citation-alternatives><mixed-citation xml:lang="ru">Labriola L, Jadoul M. The decades-long fight against HBV transmission to dialysis patients: slow but definite progress. Nephrol Dial Transplant. 2010;25:2047-2049.</mixed-citation><mixed-citation xml:lang="en">Labriola L, Jadoul M. The decades-long fight against HBV transmission to dialysis patients: slow but definite progress. Nephrol Dial Transplant. 2010;25:2047-2049.</mixed-citation></citation-alternatives></ref><ref id="cit169"><label>169</label><citation-alternatives><mixed-citation xml:lang="ru">Jadoul M. Should hemodialysis patients with hepatitis C virus antibodies be isolated? Semin Dial. 1995;8:1-3.</mixed-citation><mixed-citation xml:lang="en">Jadoul M. Should hemodialysis patients with hepatitis C virus antibodies be isolated? Semin Dial. 1995;8:1-3.</mixed-citation></citation-alternatives></ref><ref id="cit170"><label>170</label><citation-alternatives><mixed-citation xml:lang="ru">Sypsa V, Psichogiou M, Katsoulidou A, et al. Incidence and patterns of hepatitis C virus seroconversion in a cohort of hemodialysis patients. Am J Kidney Dis. 2005;45:334-343.</mixed-citation><mixed-citation xml:lang="en">Sypsa V, Psichogiou M, Katsoulidou A, et al. Incidence and patterns of hepatitis C virus seroconversion in a cohort of hemodialysis patients. Am J Kidney Dis. 2005;45:334-343.</mixed-citation></citation-alternatives></ref><ref id="cit171"><label>171</label><citation-alternatives><mixed-citation xml:lang="ru">Bravo Zuniga JI, Loza Munarriz C, Lopez-Alcalde J. Isolation as a strategy for controlling the transmission of hepatitis C virus (HCV) infection in haemodialysis units. Cochrane Database Syst Rev. 2016:CD006420.</mixed-citation><mixed-citation xml:lang="en">Bravo Zuniga JI, Loza Munarriz C, Lopez-Alcalde J. Isolation as a strategy for controlling the transmission of hepatitis C virus (HCV) infection in haemodialysis units. Cochrane Database Syst Rev. 2016:CD006420.</mixed-citation></citation-alternatives></ref><ref id="cit172"><label>172</label><citation-alternatives><mixed-citation xml:lang="ru">Shamshirsaz AA, Kamgar M, Bekheirnia MR, et al. The role of hemodialysis machines dedication in reducing Hepatitis C transmission in the dialysis setting in Iran: a multicenter prospective interventional study. BMC Nephrol. 2004;5:13.</mixed-citation><mixed-citation xml:lang="en">Shamshirsaz AA, Kamgar M, Bekheirnia MR, et al. The role of hemodialysis machines dedication in reducing Hepatitis C transmission in the dialysis setting in Iran: a multicenter prospective interventional study. BMC Nephrol. 2004;5:13.</mixed-citation></citation-alternatives></ref><ref id="cit173"><label>173</label><citation-alternatives><mixed-citation xml:lang="ru">Karkar A, Abdelrahman M, Ghacha R, et al. Prevention of viral transmission in HD units: the value of isolation. Saudi J Kidney Dis Transpl. 2006;17:183- 188.</mixed-citation><mixed-citation xml:lang="en">Karkar A, Abdelrahman M, Ghacha R, et al. Prevention of viral transmission in HD units: the value of isolation. Saudi J Kidney Dis Transpl. 2006;17:183- 188.</mixed-citation></citation-alternatives></ref><ref id="cit174"><label>174</label><citation-alternatives><mixed-citation xml:lang="ru">Harmankaya O, Cetin B, Erimez D, et al. Patient isolation prevents the transmission of hepatitis C virus infection in hemodialysis units. Dialysis Transpl. 2002;31:859-861.</mixed-citation><mixed-citation xml:lang="en">Harmankaya O, Cetin B, Erimez D, et al. Patient isolation prevents the transmission of hepatitis C virus infection in hemodialysis units. Dialysis Transpl. 2002;31:859-861.</mixed-citation></citation-alternatives></ref><ref id="cit175"><label>175</label><citation-alternatives><mixed-citation xml:lang="ru">Dzekova-Vidimliski P, Pavleska-Kuzmanovska S, Trajceska L, et al. Decreasing prevalence of hepatitis C virus infection in hemodialysis patients: Following KDIGO guidelines. Neph Dialysis Transpl. 2012;27(Suppl 2):ii294.</mixed-citation><mixed-citation xml:lang="en">Dzekova-Vidimliski P, Pavleska-Kuzmanovska S, Trajceska L, et al. Decreasing prevalence of hepatitis C virus infection in hemodialysis patients: Following KDIGO guidelines. Neph Dialysis Transpl. 2012;27(Suppl 2):ii294.</mixed-citation></citation-alternatives></ref><ref id="cit176"><label>176</label><citation-alternatives><mixed-citation xml:lang="ru">Agarwal SK, Dash SC, Gupta S, et al. Hepatitis C virus infection in haemodialysis: the ’no-isolation’ policy should not be generalized. Nephron Clin Pract. 2009;111:c133-c140.</mixed-citation><mixed-citation xml:lang="en">Agarwal SK, Dash SC, Gupta S, et al. Hepatitis C virus infection in haemodialysis: the ’no-isolation’ policy should not be generalized. Nephron Clin Pract. 2009;111:c133-c140.</mixed-citation></citation-alternatives></ref><ref id="cit177"><label>177</label><citation-alternatives><mixed-citation xml:lang="ru">Gallego E, Lopez A, Perez J, et al. Effect of isolation measures on the incidence and prevalence of hepatitis C virus infection in hemodialysis. Nephron Clin Pract. 2006;104:c1-c6.</mixed-citation><mixed-citation xml:lang="en">Gallego E, Lopez A, Perez J, et al. Effect of isolation measures on the incidence and prevalence of hepatitis C virus infection in hemodialysis. Nephron Clin Pract. 2006;104:c1-c6.</mixed-citation></citation-alternatives></ref><ref id="cit178"><label>178</label><citation-alternatives><mixed-citation xml:lang="ru">Shebeb AM, Kotkat AM, Abd El Reheim SM, et al. An intervention study for prevention of HCV infection in some hemodialysis units in Alexandria. J Egypt Public Health Assoc. 2006;81:119-141.</mixed-citation><mixed-citation xml:lang="en">Shebeb AM, Kotkat AM, Abd El Reheim SM, et al. An intervention study for prevention of HCV infection in some hemodialysis units in Alexandria. J Egypt Public Health Assoc. 2006;81:119-141.</mixed-citation></citation-alternatives></ref><ref id="cit179"><label>179</label><citation-alternatives><mixed-citation xml:lang="ru">Yang CS, Chang HH, Chou CC, et al. Isolation effectively prevents the transmission of hepatitis C virus in the hemodialysis unit. J Formos Med Assoc. 2003;102:79-85.</mixed-citation><mixed-citation xml:lang="en">Yang CS, Chang HH, Chou CC, et al. Isolation effectively prevents the transmission of hepatitis C virus in the hemodialysis unit. J Formos Med Assoc. 2003;102:79-85.</mixed-citation></citation-alternatives></ref><ref id="cit180"><label>180</label><citation-alternatives><mixed-citation xml:lang="ru">Schvarcz R, Johansson B, Nystrom B, et al. Nosocomial transmission of hepatitis C virus. Infection. 1997;25:74-77.</mixed-citation><mixed-citation xml:lang="en">Schvarcz R, Johansson B, Nystrom B, et al. Nosocomial transmission of hepatitis C virus. Infection. 1997;25:74-77.</mixed-citation></citation-alternatives></ref><ref id="cit181"><label>181</label><citation-alternatives><mixed-citation xml:lang="ru">Jadoul M, Cornu C, van Ypersele de Strihou C. Universal precautions prevent hepatitis C virus transmission: a 54 month follow-up of the Belgian Multicenter Study. The Universitaires Cliniques St-Luc (UCL) Collaborative Group. Kidney Int. 1998;53:1022-1025.</mixed-citation><mixed-citation xml:lang="en">Jadoul M, Cornu C, van Ypersele de Strihou C. Universal precautions prevent hepatitis C virus transmission: a 54 month follow-up of the Belgian Multicenter Study. The Universitaires Cliniques St-Luc (UCL) Collaborative Group. Kidney Int. 1998;53:1022-1025.</mixed-citation></citation-alternatives></ref><ref id="cit182"><label>182</label><citation-alternatives><mixed-citation xml:lang="ru">Mactier R, Davies S, Dudley C, et al. Summary of the 5th edition of the Renal Association Clinical Practice Guidelines (2009-2012). Nephron Clin Pract. 2011;118 Suppl 1:c27-c70.</mixed-citation><mixed-citation xml:lang="en">Mactier R, Davies S, Dudley C, et al. Summary of the 5th edition of the Renal Association Clinical Practice Guidelines (2009-2012). Nephron Clin Pract. 2011;118 Suppl 1:c27-c70.</mixed-citation></citation-alternatives></ref><ref id="cit183"><label>183</label><citation-alternatives><mixed-citation xml:lang="ru">European Best Practice Guidelines Expert Group on Hemodialysis, European Renal Association. Section VI. Haemodialysis-associated infection. Nephrol Dial Transplant. 2002;17 Suppl 7:72-87.</mixed-citation><mixed-citation xml:lang="en">European Best Practice Guidelines Expert Group on Hemodialysis, European Renal Association. Section VI. Haemodialysis-associated infection. Nephrol Dial Transplant. 2002;17 Suppl 7:72-87.</mixed-citation></citation-alternatives></ref><ref id="cit184"><label>184</label><citation-alternatives><mixed-citation xml:lang="ru">Jadoul M. Transmission routes of HCV infection in dialysis. Nephrol Dial Transplant. 1996;11 Suppl 4:36-38.</mixed-citation><mixed-citation xml:lang="en">Jadoul M. Transmission routes of HCV infection in dialysis. Nephrol Dial Transplant. 1996;11 Suppl 4:36-38.</mixed-citation></citation-alternatives></ref><ref id="cit185"><label>185</label><citation-alternatives><mixed-citation xml:lang="ru">Finelli L, Miller JT, Tokars JI, et al. National surveillance of dialysisassociated diseases in the United States, 2002. Semin Dial. 2005;18:52-61.</mixed-citation><mixed-citation xml:lang="en">Finelli L, Miller JT, Tokars JI, et al. National surveillance of dialysisassociated diseases in the United States, 2002. Semin Dial. 2005;18:52-61.</mixed-citation></citation-alternatives></ref><ref id="cit186"><label>186</label><citation-alternatives><mixed-citation xml:lang="ru">dos Santos JP, Loureiro A, Cendoroglo Neto M, et al. Impact of dialysis room and reuse strategies on the incidence of hepatitis C virus infection in haemodialysis units. Nephrol Dial Transplant. 1996;11:2017-2022.</mixed-citation><mixed-citation xml:lang="en">dos Santos JP, Loureiro A, Cendoroglo Neto M, et al. Impact of dialysis room and reuse strategies on the incidence of hepatitis C virus infection in haemodialysis units. Nephrol Dial Transplant. 1996;11:2017-2022.</mixed-citation></citation-alternatives></ref><ref id="cit187"><label>187</label><citation-alternatives><mixed-citation xml:lang="ru">Patel PR, Yi SH, Booth S, et al. Bloodstream infection rates in outpatient hemodialysis facilities participating in a collaborative prevention effort: a quality improvement report. Am J Kidney Dis. 2013;62:322-330.</mixed-citation><mixed-citation xml:lang="en">Patel PR, Yi SH, Booth S, et al. Bloodstream infection rates in outpatient hemodialysis facilities participating in a collaborative prevention effort: a quality improvement report. Am J Kidney Dis. 2013;62:322-330.</mixed-citation></citation-alternatives></ref><ref id="cit188"><label>188</label><citation-alternatives><mixed-citation xml:lang="ru">Yi SH, Kallen AJ, Hess S, et al. Sustained infection reduction in outpatient hemodialysis centers participating in a collaborative bloodstream infection prevention effort. Infect Control Hosp Epidemiol. 2016;37:863-866.</mixed-citation><mixed-citation xml:lang="en">Yi SH, Kallen AJ, Hess S, et al. Sustained infection reduction in outpatient hemodialysis centers participating in a collaborative bloodstream infection prevention effort. Infect Control Hosp Epidemiol. 2016;37:863-866.</mixed-citation></citation-alternatives></ref><ref id="cit189"><label>189</label><citation-alternatives><mixed-citation xml:lang="ru">Arenas MD, Sanchez-Paya J, Barril G, et al. A multicentric survey of the practice of hand hygiene in haemodialysis units: factors affecting compliance. Nephrol Dial Transplant. 2005;20:1164-1171.</mixed-citation><mixed-citation xml:lang="en">Arenas MD, Sanchez-Paya J, Barril G, et al. A multicentric survey of the practice of hand hygiene in haemodialysis units: factors affecting compliance. Nephrol Dial Transplant. 2005;20:1164-1171.</mixed-citation></citation-alternatives></ref><ref id="cit190"><label>190</label><citation-alternatives><mixed-citation xml:lang="ru">Shimokura G, Weber DJ, Miller WC, et al. Factors associated with personal protection equipment use and hand hygiene among hemodialysis staff. Am J Infect Control. 2006;34:100-107.</mixed-citation><mixed-citation xml:lang="en">Shimokura G, Weber DJ, Miller WC, et al. Factors associated with personal protection equipment use and hand hygiene among hemodialysis staff. Am J Infect Control. 2006;34:100-107.</mixed-citation></citation-alternatives></ref><ref id="cit191"><label>191</label><citation-alternatives><mixed-citation xml:lang="ru">Ball LK, George CA, Duval L, et al. Reducing blood stream infection in patients on hemodialysis: Incorporating patient engagement into a quality improvement activity. Hemodial Int. 2016;20 Suppl 1:S7-S11.</mixed-citation><mixed-citation xml:lang="en">Ball LK, George CA, Duval L, et al. Reducing blood stream infection in patients on hemodialysis: Incorporating patient engagement into a quality improvement activity. Hemodial Int. 2016;20 Suppl 1:S7-S11.</mixed-citation></citation-alternatives></ref><ref id="cit192"><label>192</label><citation-alternatives><mixed-citation xml:lang="ru">Sanchez-Carrillo LA, Rodriguez-Lopez JM, Galarza-Delgado DA, et al. Enhancement of hand hygiene compliance among health care workers from a hemodialysis unit using video-monitoring feedback. Am J Infect Control. 2016;44:868-872.</mixed-citation><mixed-citation xml:lang="en">Sanchez-Carrillo LA, Rodriguez-Lopez JM, Galarza-Delgado DA, et al. Enhancement of hand hygiene compliance among health care workers from a hemodialysis unit using video-monitoring feedback. Am J Infect Control. 2016;44:868-872.</mixed-citation></citation-alternatives></ref><ref id="cit193"><label>193</label><citation-alternatives><mixed-citation xml:lang="ru">CDC recommendations for preventing transmission of infections among chronic hemodialysis patients. MMWR Morb Mortal Wkly Rep. 2001;50:1-43.</mixed-citation><mixed-citation xml:lang="en">CDC recommendations for preventing transmission of infections among chronic hemodialysis patients. MMWR Morb Mortal Wkly Rep. 2001;50:1-43.</mixed-citation></citation-alternatives></ref><ref id="cit194"><label>194</label><citation-alternatives><mixed-citation xml:lang="ru">Frieden TR. A framework for public health action: the health impact pyramid. Am J Public Health. 2010;100:590-595.</mixed-citation><mixed-citation xml:lang="en">Frieden TR. A framework for public health action: the health impact pyramid. Am J Public Health. 2010;100:590-595.</mixed-citation></citation-alternatives></ref><ref id="cit195"><label>195</label><citation-alternatives><mixed-citation xml:lang="ru">Morales JM, Fabrizi F. Hepatitis C and its impact on renal transplantation. Nat Rev Nephrol. 2015;11:172-182.</mixed-citation><mixed-citation xml:lang="en">Morales JM, Fabrizi F. Hepatitis C and its impact on renal transplantation. Nat Rev Nephrol. 2015;11:172-182.</mixed-citation></citation-alternatives></ref><ref id="cit196"><label>196</label><citation-alternatives><mixed-citation xml:lang="ru">Fabrizi F, Martin P, Dixit V, et al. Acquisition of hepatitis C virus in hemodialysis patients: a prospective study by branched DNA signal amplification assay. Am J Kidney Dis. 1998;31:647-654.</mixed-citation><mixed-citation xml:lang="en">Fabrizi F, Martin P, Dixit V, et al. Acquisition of hepatitis C virus in hemodialysis patients: a prospective study by branched DNA signal amplification assay. Am J Kidney Dis. 1998;31:647-654.</mixed-citation></citation-alternatives></ref><ref id="cit197"><label>197</label><citation-alternatives><mixed-citation xml:lang="ru">Pereira BJ, Milford EL, Kirkman RL, et al. Transmission of hepatitis C virus by organ transplantation. N Engl J Med. 1991;325:454-460.</mixed-citation><mixed-citation xml:lang="en">Pereira BJ, Milford EL, Kirkman RL, et al. Transmission of hepatitis C virus by organ transplantation. N Engl J Med. 1991;325:454-460.</mixed-citation></citation-alternatives></ref><ref id="cit198"><label>198</label><citation-alternatives><mixed-citation xml:lang="ru">Kamar N, Ribes D, Izopet J, et al. Treatment of hepatitis C virus infection (HCV) after renal transplantation: implications for HCV-positive dialysis patients awaiting a kidney transplant. Transplantation. 2006;82:853-856.</mixed-citation><mixed-citation xml:lang="en">Kamar N, Ribes D, Izopet J, et al. Treatment of hepatitis C virus infection (HCV) after renal transplantation: implications for HCV-positive dialysis patients awaiting a kidney transplant. Transplantation. 2006;82:853-856.</mixed-citation></citation-alternatives></ref><ref id="cit199"><label>199</label><citation-alternatives><mixed-citation xml:lang="ru">Knoll GA, Tankersley MR, Lee JY, et al. The impact of renal transplantation on survival in hepatitis C-positive end-stage renal disease patients. Am J Kidney Dis. 1997;29:608-614.</mixed-citation><mixed-citation xml:lang="en">Knoll GA, Tankersley MR, Lee JY, et al. The impact of renal transplantation on survival in hepatitis C-positive end-stage renal disease patients. Am J Kidney Dis. 1997;29:608-614.</mixed-citation></citation-alternatives></ref><ref id="cit200"><label>200</label><citation-alternatives><mixed-citation xml:lang="ru">Stehman-Breen CO, Emerson S, Gretch D, et al. Risk of death among chronic dialysis patients infected with hepatitis C virus. Am J Kidney Dis. 1998;32:629-634.</mixed-citation><mixed-citation xml:lang="en">Stehman-Breen CO, Emerson S, Gretch D, et al. Risk of death among chronic dialysis patients infected with hepatitis C virus. Am J Kidney Dis. 1998;32:629-634.</mixed-citation></citation-alternatives></ref><ref id="cit201"><label>201</label><citation-alternatives><mixed-citation xml:lang="ru">Legendre C, Garrigue V, Le Bihan C, et al. Harmful long-term impact of hepatitis C virus infection in kidney transplant recipients. Transplantation. 1998;65:667-670.</mixed-citation><mixed-citation xml:lang="en">Legendre C, Garrigue V, Le Bihan C, et al. Harmful long-term impact of hepatitis C virus infection in kidney transplant recipients. Transplantation. 1998;65:667-670.</mixed-citation></citation-alternatives></ref><ref id="cit202"><label>202</label><citation-alternatives><mixed-citation xml:lang="ru">Mathurin P, Mouquet C, Poynard T, et al. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology. 1999;29:257-263.</mixed-citation><mixed-citation xml:lang="en">Mathurin P, Mouquet C, Poynard T, et al. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology. 1999;29:257-263.</mixed-citation></citation-alternatives></ref><ref id="cit203"><label>203</label><citation-alternatives><mixed-citation xml:lang="ru">Bruchfeld A, Wilczek H, Elinder CG. Hepatitis C infection, time in renalreplacement therapy, and outcome after kidney transplantation. Transplantation. 2004;78:745-750.</mixed-citation><mixed-citation xml:lang="en">Bruchfeld A, Wilczek H, Elinder CG. Hepatitis C infection, time in renalreplacement therapy, and outcome after kidney transplantation. Transplantation. 2004;78:745-750.</mixed-citation></citation-alternatives></ref><ref id="cit204"><label>204</label><citation-alternatives><mixed-citation xml:lang="ru">Fabrizi F, Takkouche B, Lunghi G, et al. The impact of hepatitis C virus infection on survival in dialysis patients: meta-analysis of observational studies. J Viral Hepat. 2007;14:697-703.</mixed-citation><mixed-citation xml:lang="en">Fabrizi F, Takkouche B, Lunghi G, et al. The impact of hepatitis C virus infection on survival in dialysis patients: meta-analysis of observational studies. J Viral Hepat. 2007;14:697-703.</mixed-citation></citation-alternatives></ref><ref id="cit205"><label>205</label><citation-alternatives><mixed-citation xml:lang="ru">Scott DR, Wong JK, Spicer TS, et al. Adverse impact of hepatitis C virus infection on renal replacement therapy and renal transplant patients in Australia and New Zealand. Transplantation. 2010;90:1165-1171.</mixed-citation><mixed-citation xml:lang="en">Scott DR, Wong JK, Spicer TS, et al. Adverse impact of hepatitis C virus infection on renal replacement therapy and renal transplant patients in Australia and New Zealand. Transplantation. 2010;90:1165-1171.</mixed-citation></citation-alternatives></ref><ref id="cit206"><label>206</label><citation-alternatives><mixed-citation xml:lang="ru">Port FK, Wolfe RA, Mauger EA, et al. Comparison of survival probabilities for dialysis patients vs cadaveric renal transplant recipients. JAMA. 1993;270:1339-1343.</mixed-citation><mixed-citation xml:lang="en">Port FK, Wolfe RA, Mauger EA, et al. Comparison of survival probabilities for dialysis patients vs cadaveric renal transplant recipients. JAMA. 1993;270:1339-1343.</mixed-citation></citation-alternatives></ref><ref id="cit207"><label>207</label><citation-alternatives><mixed-citation xml:lang="ru">Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med. 1999;341:1725-1730.</mixed-citation><mixed-citation xml:lang="en">Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med. 1999;341:1725-1730.</mixed-citation></citation-alternatives></ref><ref id="cit208"><label>208</label><citation-alternatives><mixed-citation xml:lang="ru">Pereira BJ, Natov SN, Bouthot BA, et al. Effects of hepatitis C infection and renal transplantation on survival in end-stage renal disease. The New England Organ Bank Hepatitis C Study Group. Kidney Int. 1998;53:1374-1381.</mixed-citation><mixed-citation xml:lang="en">Pereira BJ, Natov SN, Bouthot BA, et al. Effects of hepatitis C infection and renal transplantation on survival in end-stage renal disease. The New England Organ Bank Hepatitis C Study Group. Kidney Int. 1998;53:1374-1381.</mixed-citation></citation-alternatives></ref><ref id="cit209"><label>209</label><citation-alternatives><mixed-citation xml:lang="ru">Bloom RD, Sayer G, Fa K, et al. Outcome of hepatitis C virus-infected kidney transplant candidates who remain on the waiting list. Am J Transplant. 2005;5:139-144.</mixed-citation><mixed-citation xml:lang="en">Bloom RD, Sayer G, Fa K, et al. Outcome of hepatitis C virus-infected kidney transplant candidates who remain on the waiting list. Am J Transplant. 2005;5:139-144.</mixed-citation></citation-alternatives></ref><ref id="cit210"><label>210</label><citation-alternatives><mixed-citation xml:lang="ru">Kamar N, Toupance O, Buchler M, et al. Evidence that clearance of hepatitis C virus RNA after alpha-interferon therapy in dialysis patients is sustained after renal transplantation. J Am Soc Nephrol. 2003;14:2092-2098.</mixed-citation><mixed-citation xml:lang="en">Kamar N, Toupance O, Buchler M, et al. Evidence that clearance of hepatitis C virus RNA after alpha-interferon therapy in dialysis patients is sustained after renal transplantation. J Am Soc Nephrol. 2003;14:2092-2098.</mixed-citation></citation-alternatives></ref><ref id="cit211"><label>211</label><citation-alternatives><mixed-citation xml:lang="ru">Nicot F, Kamar N, Mariame B, et al. No evidence of occult hepatitis C virus (HCV) infection in serum of HCV antibody-positive HCV RNA-negative kidney-transplant patients. Transpl Int. 2010;23:594-601.</mixed-citation><mixed-citation xml:lang="en">Nicot F, Kamar N, Mariame B, et al. No evidence of occult hepatitis C virus (HCV) infection in serum of HCV antibody-positive HCV RNA-negative kidney-transplant patients. Transpl Int. 2010;23:594-601.</mixed-citation></citation-alternatives></ref><ref id="cit212"><label>212</label><citation-alternatives><mixed-citation xml:lang="ru">Cruzado JM, Casanovas-Taltavull T, Torras J, et al. Pretransplant interferon prevents hepatitis C virus-associated glomerulonephritis in renal allografts by HCV-RNA clearance. Am J Transplant. 2003;3:357-360.</mixed-citation><mixed-citation xml:lang="en">Cruzado JM, Casanovas-Taltavull T, Torras J, et al. Pretransplant interferon prevents hepatitis C virus-associated glomerulonephritis in renal allografts by HCV-RNA clearance. Am J Transplant. 2003;3:357-360.</mixed-citation></citation-alternatives></ref><ref id="cit213"><label>213</label><citation-alternatives><mixed-citation xml:lang="ru">Forman JP, Tolkoff-Rubin N, Pascual M, et al. Hepatitis C, acute humoral rejection, and renal allograft survival. J Am Soc Nephrol. 2004;15:3249-3255.</mixed-citation><mixed-citation xml:lang="en">Forman JP, Tolkoff-Rubin N, Pascual M, et al. Hepatitis C, acute humoral rejection, and renal allograft survival. J Am Soc Nephrol. 2004;15:3249-3255.</mixed-citation></citation-alternatives></ref><ref id="cit214"><label>214</label><citation-alternatives><mixed-citation xml:lang="ru">Alric L, Di-Martino V, Selves J, et al. Long-term impact of renal transplantation on liver fibrosis during hepatitis C virus infection. Gastroenterology. 2002;123:1494-1499.</mixed-citation><mixed-citation xml:lang="en">Alric L, Di-Martino V, Selves J, et al. Long-term impact of renal transplantation on liver fibrosis during hepatitis C virus infection. Gastroenterology. 2002;123:1494-1499.</mixed-citation></citation-alternatives></ref><ref id="cit215"><label>215</label><citation-alternatives><mixed-citation xml:lang="ru">Fehr T, Riehle HM, Nigg L, et al. Evaluation of hepatitis B and hepatitis C virus-infected renal allograft recipients with liver biopsy and noninvasive parameters. Am J Kidney Dis. 2003;42:193-201.</mixed-citation><mixed-citation xml:lang="en">Fehr T, Riehle HM, Nigg L, et al. Evaluation of hepatitis B and hepatitis C virus-infected renal allograft recipients with liver biopsy and noninvasive parameters. Am J Kidney Dis. 2003;42:193-201.</mixed-citation></citation-alternatives></ref><ref id="cit216"><label>216</label><citation-alternatives><mixed-citation xml:lang="ru">Kamar N, Rostaing L, Selves J, et al. Natural history of hepatitis C virusrelated liver fibrosis after renal transplantation. Am J Transplant. 2005;5:1704-1712.</mixed-citation><mixed-citation xml:lang="en">Kamar N, Rostaing L, Selves J, et al. Natural history of hepatitis C virusrelated liver fibrosis after renal transplantation. Am J Transplant. 2005;5:1704-1712.</mixed-citation></citation-alternatives></ref><ref id="cit217"><label>217</label><citation-alternatives><mixed-citation xml:lang="ru">Roth D, Gaynor JJ, Reddy KR, et al. Effect of kidney transplantation on outcomes among patients with hepatitis C. J Am Soc Nephrol. 2011;22:1152-1160.</mixed-citation><mixed-citation xml:lang="en">Roth D, Gaynor JJ, Reddy KR, et al. Effect of kidney transplantation on outcomes among patients with hepatitis C. J Am Soc Nephrol. 2011;22:1152-1160.</mixed-citation></citation-alternatives></ref><ref id="cit218"><label>218</label><citation-alternatives><mixed-citation xml:lang="ru">Pol S, Carnot F, Nalpas B, et al. Reversibility of hepatitis C virus-related cirrhosis. Hum Pathol. 2004;35:107-112.</mixed-citation><mixed-citation xml:lang="en">Pol S, Carnot F, Nalpas B, et al. Reversibility of hepatitis C virus-related cirrhosis. Hum Pathol. 2004;35:107-112.</mixed-citation></citation-alternatives></ref><ref id="cit219"><label>219</label><citation-alternatives><mixed-citation xml:lang="ru">Eason JD, Gonwa TA, Davis CL, et al. Proceedings of Consensus Conference on Simultaneous Liver Kidney Transplantation (SLK). Am J Transplant. 2008;8:2243-2251.</mixed-citation><mixed-citation xml:lang="en">Eason JD, Gonwa TA, Davis CL, et al. Proceedings of Consensus Conference on Simultaneous Liver Kidney Transplantation (SLK). Am J Transplant. 2008;8:2243-2251.</mixed-citation></citation-alternatives></ref><ref id="cit220"><label>220</label><citation-alternatives><mixed-citation xml:lang="ru">Ripoll C, Groszmann R, Garcia-Tsao G, et al. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology. 2007;133:481-488.</mixed-citation><mixed-citation xml:lang="en">Ripoll C, Groszmann R, Garcia-Tsao G, et al. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology. 2007;133:481-488.</mixed-citation></citation-alternatives></ref><ref id="cit221"><label>221</label><citation-alternatives><mixed-citation xml:lang="ru">Rostaing L, Izopet J, Baron E, et al. Treatment of chronic hepatitis C with recombinant interferon alpha in kidney transplant recipients. Transplantation. 1995;59:1426-1431.</mixed-citation><mixed-citation xml:lang="en">Rostaing L, Izopet J, Baron E, et al. Treatment of chronic hepatitis C with recombinant interferon alpha in kidney transplant recipients. Transplantation. 1995;59:1426-1431.</mixed-citation></citation-alternatives></ref><ref id="cit222"><label>222</label><citation-alternatives><mixed-citation xml:lang="ru">Chascsa DM, Mousa OY, Pungpapong S, et al. Clinical outcomes of hepatitis C treatment before and after kidney transplantation and its impact on time to transplant: a multi-center study [e-pub ahead of print]. Am J Transplant. https://doi.org/10.1111/ajt.14931.</mixed-citation><mixed-citation xml:lang="en">Chascsa DM, Mousa OY, Pungpapong S, et al. Clinical outcomes of hepatitis C treatment before and after kidney transplantation and its impact on time to transplant: a multi-center study [e-pub ahead of print]. Am J Transplant. https://doi.org/10.1111/ajt.14931.</mixed-citation></citation-alternatives></ref><ref id="cit223"><label>223</label><citation-alternatives><mixed-citation xml:lang="ru">Diethelm AG, Roth D, Ferguson RM, et al. Transmission of HCV by organ transplantation. N Engl J Med. 1992;326:410-411.</mixed-citation><mixed-citation xml:lang="en">Diethelm AG, Roth D, Ferguson RM, et al. Transmission of HCV by organ transplantation. N Engl J Med. 1992;326:410-411.</mixed-citation></citation-alternatives></ref><ref id="cit224"><label>224</label><citation-alternatives><mixed-citation xml:lang="ru">European Best Practice Guidelines for Renal Transplantation. Section I: Evaluation, selection and preparation of the potential recipient. Nephrol Dial Transplant. 2000;15(suppl 7):3-38.</mixed-citation><mixed-citation xml:lang="en">European Best Practice Guidelines for Renal Transplantation. Section I: Evaluation, selection and preparation of the potential recipient. Nephrol Dial Transplant. 2000;15(suppl 7):3-38.</mixed-citation></citation-alternatives></ref><ref id="cit225"><label>225</label><citation-alternatives><mixed-citation xml:lang="ru">Nowak KM, Witzke O, Sotiropoulos GC, et al. Transplantation of renal allografts from organ donors reactive for HCV antibodies to HCVnegative recipients: safety and clinical outcome. Kidney Int Rep. 2016;2:53-59.</mixed-citation><mixed-citation xml:lang="en">Nowak KM, Witzke O, Sotiropoulos GC, et al. Transplantation of renal allografts from organ donors reactive for HCV antibodies to HCVnegative recipients: safety and clinical outcome. Kidney Int Rep. 2016;2:53-59.</mixed-citation></citation-alternatives></ref><ref id="cit226"><label>226</label><citation-alternatives><mixed-citation xml:lang="ru">Wolfe CR, Michaels MG. Donor-derived hepatitis C transmission from NAT negative donors-Still an unexpected event! Am J Transplant. 2017;17:2989.</mixed-citation><mixed-citation xml:lang="en">Wolfe CR, Michaels MG. Donor-derived hepatitis C transmission from NAT negative donors-Still an unexpected event! Am J Transplant. 2017;17:2989.</mixed-citation></citation-alternatives></ref><ref id="cit227"><label>227</label><citation-alternatives><mixed-citation xml:lang="ru">Levitsky J, Formica RN, Bloom RD, et al. The American Society of Transplantation Consensus Conference on the Use of Hepatitis C Viremic Donors in Solid Organ Transplantation. Am J Transplant. 2017;17:2790- 2802.</mixed-citation><mixed-citation xml:lang="en">Levitsky J, Formica RN, Bloom RD, et al. The American Society of Transplantation Consensus Conference on the Use of Hepatitis C Viremic Donors in Solid Organ Transplantation. Am J Transplant. 2017;17:2790- 2802.</mixed-citation></citation-alternatives></ref><ref id="cit228"><label>228</label><citation-alternatives><mixed-citation xml:lang="ru">Kling CE, Perkins JD, Landis CS, et al. Utilization of organs from donors according to hepatitis C antibody and nucleic acid testing status: time for change. Am J Transplant. 2017;17:2863-2868.</mixed-citation><mixed-citation xml:lang="en">Kling CE, Perkins JD, Landis CS, et al. Utilization of organs from donors according to hepatitis C antibody and nucleic acid testing status: time for change. Am J Transplant. 2017;17:2863-2868.</mixed-citation></citation-alternatives></ref><ref id="cit229"><label>229</label><citation-alternatives><mixed-citation xml:lang="ru">Morales JM, Andres A, Campistol JM. Hepatitis C virus and organ transplantation. N Engl J Med. 1993;328:511-512.</mixed-citation><mixed-citation xml:lang="en">Morales JM, Andres A, Campistol JM. Hepatitis C virus and organ transplantation. N Engl J Med. 1993;328:511-512.</mixed-citation></citation-alternatives></ref><ref id="cit230"><label>230</label><citation-alternatives><mixed-citation xml:lang="ru">Morales JM, Campistol JM, Castellano G, et al. Transplantation of kidneys from donors with hepatitis C antibody into recipients with pretransplantation anti-HCV. Kidney Int. 1995;47:236-240.</mixed-citation><mixed-citation xml:lang="en">Morales JM, Campistol JM, Castellano G, et al. Transplantation of kidneys from donors with hepatitis C antibody into recipients with pretransplantation anti-HCV. Kidney Int. 1995;47:236-240.</mixed-citation></citation-alternatives></ref><ref id="cit231"><label>231</label><citation-alternatives><mixed-citation xml:lang="ru">Abbott KC, Lentine KL, Bucci JR, et al. The impact of transplantation with deceased donor hepatitis C-positive kidneys on survival in wait-listed longterm dialysis patients. Am J Transplant. 2004;4:2032-2037.</mixed-citation><mixed-citation xml:lang="en">Abbott KC, Lentine KL, Bucci JR, et al. The impact of transplantation with deceased donor hepatitis C-positive kidneys on survival in wait-listed longterm dialysis patients. Am J Transplant. 2004;4:2032-2037.</mixed-citation></citation-alternatives></ref><ref id="cit232"><label>232</label><citation-alternatives><mixed-citation xml:lang="ru">Ali MK, Light JA, Barhyte DY, et al. Donor hepatitis C virus status does not adversely affect short-term outcomes in HCV+ recipients in renal transplantation. Transplantation. 1998;66:1694-1697.</mixed-citation><mixed-citation xml:lang="en">Ali MK, Light JA, Barhyte DY, et al. Donor hepatitis C virus status does not adversely affect short-term outcomes in HCV+ recipients in renal transplantation. Transplantation. 1998;66:1694-1697.</mixed-citation></citation-alternatives></ref><ref id="cit233"><label>233</label><citation-alternatives><mixed-citation xml:lang="ru">Bucci JR, Lentine KL, Agodoa LY, et al. Outcomes associated with recipient and donor hepatitis C serology status after kidney transplantation in the United States: analysis of the USRDS/UNOS database. Clin Transpl. 2004:51-61.</mixed-citation><mixed-citation xml:lang="en">Bucci JR, Lentine KL, Agodoa LY, et al. Outcomes associated with recipient and donor hepatitis C serology status after kidney transplantation in the United States: analysis of the USRDS/UNOS database. Clin Transpl. 2004:51-61.</mixed-citation></citation-alternatives></ref><ref id="cit234"><label>234</label><citation-alternatives><mixed-citation xml:lang="ru">Bucci JR, Matsumoto CS, Swanson SJ, et al. Donor hepatitis C seropositivity: clinical correlates and effect on early graft and patient survival in adult cadaveric kidney transplantation. J Am Soc Nephrol. 2002;13:2974-2982.</mixed-citation><mixed-citation xml:lang="en">Bucci JR, Matsumoto CS, Swanson SJ, et al. Donor hepatitis C seropositivity: clinical correlates and effect on early graft and patient survival in adult cadaveric kidney transplantation. J Am Soc Nephrol. 2002;13:2974-2982.</mixed-citation></citation-alternatives></ref><ref id="cit235"><label>235</label><citation-alternatives><mixed-citation xml:lang="ru">Maluf DG, Archer KJ, Mas VR. Kidney grafts from HCV-positive donors: advantages and disadvantages. Transplant Proc. 2010;42:2436-2446.</mixed-citation><mixed-citation xml:lang="en">Maluf DG, Archer KJ, Mas VR. Kidney grafts from HCV-positive donors: advantages and disadvantages. Transplant Proc. 2010;42:2436-2446.</mixed-citation></citation-alternatives></ref><ref id="cit236"><label>236</label><citation-alternatives><mixed-citation xml:lang="ru">Mandal AK, Kraus ES, Samaniego M, et al. Shorter waiting times for hepatitis C virus seropositive recipients of cadaveric renal allografts from hepatitis C virus seropositive donors. Clin Transplant. 2000;14:391-396.</mixed-citation><mixed-citation xml:lang="en">Mandal AK, Kraus ES, Samaniego M, et al. Shorter waiting times for hepatitis C virus seropositive recipients of cadaveric renal allografts from hepatitis C virus seropositive donors. Clin Transplant. 2000;14:391-396.</mixed-citation></citation-alternatives></ref><ref id="cit237"><label>237</label><citation-alternatives><mixed-citation xml:lang="ru">Singh N, Neidlinger N, Djamali A, et al. The impact of hepatitis C virus donor and recipient status on long-term kidney transplant outcomes: University of Wisconsin experience. Clin Transplant. 2012;26:684-693.</mixed-citation><mixed-citation xml:lang="en">Singh N, Neidlinger N, Djamali A, et al. The impact of hepatitis C virus donor and recipient status on long-term kidney transplant outcomes: University of Wisconsin experience. Clin Transplant. 2012;26:684-693.</mixed-citation></citation-alternatives></ref><ref id="cit238"><label>238</label><citation-alternatives><mixed-citation xml:lang="ru">Morales JM, Campistol JM, Dominguez-Gil B, et al. Long-term experience with kidney transplantation from hepatitis C-positive donors into hepatitis C-positive recipients. Am J Transplant. 2010;10:2453-2462.</mixed-citation><mixed-citation xml:lang="en">Morales JM, Campistol JM, Dominguez-Gil B, et al. Long-term experience with kidney transplantation from hepatitis C-positive donors into hepatitis C-positive recipients. Am J Transplant. 2010;10:2453-2462.</mixed-citation></citation-alternatives></ref><ref id="cit239"><label>239</label><citation-alternatives><mixed-citation xml:lang="ru">Jawa P, Knorr J, Torres E, et al. Donor hepatitis C status does not impact outcomes in hepatitis C positive kidney transplant recipients [abstract]. Am J Transplant. 2013;13(suppl 5):403.</mixed-citation><mixed-citation xml:lang="en">Jawa P, Knorr J, Torres E, et al. Donor hepatitis C status does not impact outcomes in hepatitis C positive kidney transplant recipients [abstract]. Am J Transplant. 2013;13(suppl 5):403.</mixed-citation></citation-alternatives></ref><ref id="cit240"><label>240</label><citation-alternatives><mixed-citation xml:lang="ru">Scalea JR, Barth RN, Munivenkatappa R, et al. Shorter waitlist times and improved graft survivals are observed in patients who accept hepatitis C virus+ renal allografts. Transplantation. 2015;99:1192-1196.</mixed-citation><mixed-citation xml:lang="en">Scalea JR, Barth RN, Munivenkatappa R, et al. Shorter waitlist times and improved graft survivals are observed in patients who accept hepatitis C virus+ renal allografts. Transplantation. 2015;99:1192-1196.</mixed-citation></citation-alternatives></ref><ref id="cit241"><label>241</label><citation-alternatives><mixed-citation xml:lang="ru">Myint T, Wright A, Rose C, et al. The benefit of hepatitis C donor kidney transplantation is limited to hepatitis C positive patients over 50 years of age [abstract]. Am J Transplant. 2015;15(suppl 3). Available at: https:// atcmeetingabstracts.com/abstract/the-benefit-of-hepatitis-c-donor-kidneytransplantation- is-limited-to-hepatitis-c-positive-patients-over-50-years-ofage/. Accessed July 27, 2018.</mixed-citation><mixed-citation xml:lang="en">Myint T, Wright A, Rose C, et al. The benefit of hepatitis C donor kidney transplantation is limited to hepatitis C positive patients over 50 years of age [abstract]. Am J Transplant. 2015;15(suppl 3). Available at: https:// atcmeetingabstracts.com/abstract/the-benefit-of-hepatitis-c-donor-kidneytransplantation- is-limited-to-hepatitis-c-positive-patients-over-50-years-ofage/. Accessed July 27, 2018.</mixed-citation></citation-alternatives></ref><ref id="cit242"><label>242</label><citation-alternatives><mixed-citation xml:lang="ru">Bhamidimarri KR, Ladino M, Pedraza F, et al. Transplantation of kidneys from hepatitis C-positive donors into hepatitis C virus-infected recipients followed by early initiation of direct acting antiviral therapy: a singlecenter retrospective study. Transpl Int. 2017;30:865-873.</mixed-citation><mixed-citation xml:lang="en">Bhamidimarri KR, Ladino M, Pedraza F, et al. Transplantation of kidneys from hepatitis C-positive donors into hepatitis C virus-infected recipients followed by early initiation of direct acting antiviral therapy: a singlecenter retrospective study. Transpl Int. 2017;30:865-873.</mixed-citation></citation-alternatives></ref><ref id="cit243"><label>243</label><citation-alternatives><mixed-citation xml:lang="ru">Widell A, Mansson S, Persson NH, et al. Hepatitis C superinfection in hepatitis C virus (HCV)-infected patients transplanted with an HCVinfected kidney. Transplantation. 1995;60:642-647.</mixed-citation><mixed-citation xml:lang="en">Widell A, Mansson S, Persson NH, et al. Hepatitis C superinfection in hepatitis C virus (HCV)-infected patients transplanted with an HCVinfected kidney. Transplantation. 1995;60:642-647.</mixed-citation></citation-alternatives></ref><ref id="cit244"><label>244</label><citation-alternatives><mixed-citation xml:lang="ru">Ladino M, Pedraza F, Roth D. Hepatitis C virus infection in chronic kidney disease. J Am Soc Nephrol. 2016;27:2238-2246.</mixed-citation><mixed-citation xml:lang="en">Ladino M, Pedraza F, Roth D. Hepatitis C virus infection in chronic kidney disease. J Am Soc Nephrol. 2016;27:2238-2246.</mixed-citation></citation-alternatives></ref><ref id="cit245"><label>245</label><citation-alternatives><mixed-citation xml:lang="ru">Sawinski D, Bloom RD. Novel hepatitis C treatment and the impact on kidney transplantation. Transplantation. 2015;99:2458-2466.</mixed-citation><mixed-citation xml:lang="en">Sawinski D, Bloom RD. Novel hepatitis C treatment and the impact on kidney transplantation. Transplantation. 2015;99:2458-2466.</mixed-citation></citation-alternatives></ref><ref id="cit246"><label>246</label><citation-alternatives><mixed-citation xml:lang="ru">Limkemann A, Ramanathan R, Benhke M, et al. Inferior outcomes in hepatitis C virus positive donors to hepatitis C virus negative kidney recipients: analysis from National data 2015 [abstract]. Am J Transplant. 2015;suppl 1:76.</mixed-citation><mixed-citation xml:lang="en">Limkemann A, Ramanathan R, Benhke M, et al. Inferior outcomes in hepatitis C virus positive donors to hepatitis C virus negative kidney recipients: analysis from National data 2015 [abstract]. Am J Transplant. 2015;suppl 1:76.</mixed-citation></citation-alternatives></ref><ref id="cit247"><label>247</label><citation-alternatives><mixed-citation xml:lang="ru">Reese PP, Abt PL, Blumberg EA, et al. Transplanting hepatitis C-positive kidneys. N Engl J Med. 2015;373:303-305.</mixed-citation><mixed-citation xml:lang="en">Reese PP, Abt PL, Blumberg EA, et al. Transplanting hepatitis C-positive kidneys. N Engl J Med. 2015;373:303-305.</mixed-citation></citation-alternatives></ref><ref id="cit248"><label>248</label><citation-alternatives><mixed-citation xml:lang="ru">Cortijo C. Impacto de la terapia de induccion con agents biologicos en los resultados del trasplante renal en pacientes con infeccion por le virus de la hepatitis C. Doctoral Thesis, Universidad Europea de Madrid, Madrid (Spain) 2012.</mixed-citation><mixed-citation xml:lang="en">Cortijo C. Impacto de la terapia de induccion con agents biologicos en los resultados del trasplante renal en pacientes con infeccion por le virus de la hepatitis C. Doctoral Thesis, Universidad Europea de Madrid, Madrid (Spain) 2012.</mixed-citation></citation-alternatives></ref><ref id="cit249"><label>249</label><citation-alternatives><mixed-citation xml:lang="ru">Sureshkumar KK, Hussein SM, Thai NI, Marcus RJ. Kidney transplant outcomes in African American patients with hepatitis C: influence of induction agent [abstract]. Am J Transplant. 2012;suppl 3:320.</mixed-citation><mixed-citation xml:lang="en">Sureshkumar KK, Hussein SM, Thai NI, Marcus RJ. Kidney transplant outcomes in African American patients with hepatitis C: influence of induction agent [abstract]. Am J Transplant. 2012;suppl 3:320.</mixed-citation></citation-alternatives></ref><ref id="cit250"><label>250</label><citation-alternatives><mixed-citation xml:lang="ru">Linatoc Q, Ren M, Behnke, et al. Effect of induction therapy with thymoglobulin on outcome in hepatitis C infected kidney transplant recipients: a single center experience [abstract]. Am J Transplant. 2013;suppl 3:85.</mixed-citation><mixed-citation xml:lang="en">Linatoc Q, Ren M, Behnke, et al. Effect of induction therapy with thymoglobulin on outcome in hepatitis C infected kidney transplant recipients: a single center experience [abstract]. Am J Transplant. 2013;suppl 3:85.</mixed-citation></citation-alternatives></ref><ref id="cit251"><label>251</label><citation-alternatives><mixed-citation xml:lang="ru">Luan FL, Schaubel DE, Zhang H, et al. Impact of immunosuppressive regimen on survival of kidney transplant recipients with hepatitis C. Transplantation. 2008;85:1601-1606.</mixed-citation><mixed-citation xml:lang="en">Luan FL, Schaubel DE, Zhang H, et al. Impact of immunosuppressive regimen on survival of kidney transplant recipients with hepatitis C. Transplantation. 2008;85:1601-1606.</mixed-citation></citation-alternatives></ref><ref id="cit252"><label>252</label><citation-alternatives><mixed-citation xml:lang="ru">Manuel O, Baid-Agrawal S, Moradpour D, et al. Immunosuppression in hepatitis C virus-infected patients after kidney transplantation. Contrib Nephrol. 2012;176:97-107.</mixed-citation><mixed-citation xml:lang="en">Manuel O, Baid-Agrawal S, Moradpour D, et al. Immunosuppression in hepatitis C virus-infected patients after kidney transplantation. Contrib Nephrol. 2012;176:97-107.</mixed-citation></citation-alternatives></ref><ref id="cit253"><label>253</label><citation-alternatives><mixed-citation xml:lang="ru">Bloom RD, Rao V, Weng F, et al. Association of hepatitis C with posttransplant diabetes in renal transplant patients on tacrolimus. J Am Soc Nephrol. 2002;13:1374-1380.</mixed-citation><mixed-citation xml:lang="en">Bloom RD, Rao V, Weng F, et al. Association of hepatitis C with posttransplant diabetes in renal transplant patients on tacrolimus. J Am Soc Nephrol. 2002;13:1374-1380.</mixed-citation></citation-alternatives></ref><ref id="cit254"><label>254</label><citation-alternatives><mixed-citation xml:lang="ru">Watashi K, Hijikata M, Hosaka M, et al. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology. 2003;38:1282-1288.</mixed-citation><mixed-citation xml:lang="en">Watashi K, Hijikata M, Hosaka M, et al. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology. 2003;38:1282-1288.</mixed-citation></citation-alternatives></ref><ref id="cit255"><label>255</label><citation-alternatives><mixed-citation xml:lang="ru">Rostaing L, Izopet J, Sandres K, et al. Changes in hepatitis C virus RNA viremia concentrations in long-term renal transplant patients after introduction of mycophenolate mofetil. Transplantation. 2000;69:991-994.</mixed-citation><mixed-citation xml:lang="en">Rostaing L, Izopet J, Sandres K, et al. Changes in hepatitis C virus RNA viremia concentrations in long-term renal transplant patients after introduction of mycophenolate mofetil. Transplantation. 2000;69:991-994.</mixed-citation></citation-alternatives></ref><ref id="cit256"><label>256</label><citation-alternatives><mixed-citation xml:lang="ru">Gentil Govantes MA, Esforzado N, Cruzado JM, et al. Harmful effects of viral replication in seropositive hepatitis C virus renal transplant recipients. Transplantation. 2012;94:1131-1137.</mixed-citation><mixed-citation xml:lang="en">Gentil Govantes MA, Esforzado N, Cruzado JM, et al. Harmful effects of viral replication in seropositive hepatitis C virus renal transplant recipients. Transplantation. 2012;94:1131-1137.</mixed-citation></citation-alternatives></ref><ref id="cit257"><label>257</label><citation-alternatives><mixed-citation xml:lang="ru">Hestin D, Guillemin F, Castin N, et al. Pretransplant hepatitis C virus infection: a predictor of proteinuria after renal transplantation. Transplantation. 1998;65:741-744.</mixed-citation><mixed-citation xml:lang="en">Hestin D, Guillemin F, Castin N, et al. Pretransplant hepatitis C virus infection: a predictor of proteinuria after renal transplantation. Transplantation. 1998;65:741-744.</mixed-citation></citation-alternatives></ref><ref id="cit258"><label>258</label><citation-alternatives><mixed-citation xml:lang="ru">Cruzado JM, Gil-Vernet S, Ercilla G, et al. Hepatitis C virus-associated membranoproliferative glomerulonephritis in renal allografts. J Am Soc Nephrol. 1996;7:2469-2475.</mixed-citation><mixed-citation xml:lang="en">Cruzado JM, Gil-Vernet S, Ercilla G, et al. Hepatitis C virus-associated membranoproliferative glomerulonephritis in renal allografts. J Am Soc Nephrol. 1996;7:2469-2475.</mixed-citation></citation-alternatives></ref><ref id="cit259"><label>259</label><citation-alternatives><mixed-citation xml:lang="ru">Morales JM, Pascual-Capdevila J, Campistol JM, et al. Membranous glomerulonephritis associated with hepatitis C virus infection in renal transplant patients. Transplantation. 1997;63:1634-1639.</mixed-citation><mixed-citation xml:lang="en">Morales JM, Pascual-Capdevila J, Campistol JM, et al. Membranous glomerulonephritis associated with hepatitis C virus infection in renal transplant patients. Transplantation. 1997;63:1634-1639.</mixed-citation></citation-alternatives></ref><ref id="cit260"><label>260</label><citation-alternatives><mixed-citation xml:lang="ru">Baid S, Pascual M, Williams WW Jr, et al. Renal thrombotic microangiopathy associated with anticardiolipin antibodies in hepatitis C-positive renal allograft recipients. J Am Soc Nephrol. 1999;10:146-153.</mixed-citation><mixed-citation xml:lang="en">Baid S, Pascual M, Williams WW Jr, et al. Renal thrombotic microangiopathy associated with anticardiolipin antibodies in hepatitis C-positive renal allograft recipients. J Am Soc Nephrol. 1999;10:146-153.</mixed-citation></citation-alternatives></ref><ref id="cit261"><label>261</label><citation-alternatives><mixed-citation xml:lang="ru">Baid-Agrawal S, Pascual M, Moradpour D, et al. Hepatitis C virus infection and kidney transplantation in 2014: what’s new? Am J Transplant. 2014;14:2206-2220.</mixed-citation><mixed-citation xml:lang="en">Baid-Agrawal S, Pascual M, Moradpour D, et al. Hepatitis C virus infection and kidney transplantation in 2014: what’s new? Am J Transplant. 2014;14:2206-2220.</mixed-citation></citation-alternatives></ref><ref id="cit262"><label>262</label><citation-alternatives><mixed-citation xml:lang="ru">Bonacci M, Lens S, Londono MC, et al. Virologic, clinical, and immune response outcomes of patients with hepatitis C virus-associated cryoglobulinemia treated with direct-acting antivirals. Clin Gastroenterol Hepatol. 2017;15:575-583.</mixed-citation><mixed-citation xml:lang="en">Bonacci M, Lens S, Londono MC, et al. Virologic, clinical, and immune response outcomes of patients with hepatitis C virus-associated cryoglobulinemia treated with direct-acting antivirals. Clin Gastroenterol Hepatol. 2017;15:575-583.</mixed-citation></citation-alternatives></ref><ref id="cit263"><label>263</label><citation-alternatives><mixed-citation xml:lang="ru">Gragnani L, Piluso A, Urraro T, et al. Virological and clinical response to interferon-free regimens in patients with HCV-related mixed cryoglobulinemia: preliminary results of a prospective pilot study. Curr Drug Targets. 2017;18:772-785.</mixed-citation><mixed-citation xml:lang="en">Gragnani L, Piluso A, Urraro T, et al. Virological and clinical response to interferon-free regimens in patients with HCV-related mixed cryoglobulinemia: preliminary results of a prospective pilot study. Curr Drug Targets. 2017;18:772-785.</mixed-citation></citation-alternatives></ref><ref id="cit264"><label>264</label><citation-alternatives><mixed-citation xml:lang="ru">Gragnani L, Visentini M, Fognani E, et al. Prospective study of guidelinetailored therapy with direct-acting antivirals for hepatitis C virusassociated mixed cryoglobulinemia. Hepatology. 2016;64:1473-1482.</mixed-citation><mixed-citation xml:lang="en">Gragnani L, Visentini M, Fognani E, et al. Prospective study of guidelinetailored therapy with direct-acting antivirals for hepatitis C virusassociated mixed cryoglobulinemia. Hepatology. 2016;64:1473-1482.</mixed-citation></citation-alternatives></ref><ref id="cit265"><label>265</label><citation-alternatives><mixed-citation xml:lang="ru">Saadoun D, Thibault V, Si Ahmed SN, et al. Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC study. Ann Rheum Dis. 2016;75:1777-1782.</mixed-citation><mixed-citation xml:lang="en">Saadoun D, Thibault V, Si Ahmed SN, et al. Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC study. Ann Rheum Dis. 2016;75:1777-1782.</mixed-citation></citation-alternatives></ref><ref id="cit266"><label>266</label><citation-alternatives><mixed-citation xml:lang="ru">Sise ME, Bloom AK, Wisocky J, et al. Treatment of hepatitis C virusassociated mixed cryoglobulinemia with direct-acting antiviral agents. Hepatology. 2016;63:408-417.</mixed-citation><mixed-citation xml:lang="en">Sise ME, Bloom AK, Wisocky J, et al. Treatment of hepatitis C virusassociated mixed cryoglobulinemia with direct-acting antiviral agents. Hepatology. 2016;63:408-417.</mixed-citation></citation-alternatives></ref><ref id="cit267"><label>267</label><citation-alternatives><mixed-citation xml:lang="ru">Cacoub P, Vautier M, Desbois AC, et al. Effectiveness and cost of hepatitis C virus cryoglobulinaemia vasculitis treatment: From interferon-based to direct-acting antivirals era. Liver Int. 2017;37:1805-1813.</mixed-citation><mixed-citation xml:lang="en">Cacoub P, Vautier M, Desbois AC, et al. Effectiveness and cost of hepatitis C virus cryoglobulinaemia vasculitis treatment: From interferon-based to direct-acting antivirals era. Liver Int. 2017;37:1805-1813.</mixed-citation></citation-alternatives></ref><ref id="cit268"><label>268</label><citation-alternatives><mixed-citation xml:lang="ru">Emery JS, Kuczynski M, La D, et al. Efficacy and safety of direct acting antivirals for the treatment of mixed cryoglobulinemia. Am J Gastroenterol. 2017;112:1298-1308.</mixed-citation><mixed-citation xml:lang="en">Emery JS, Kuczynski M, La D, et al. Efficacy and safety of direct acting antivirals for the treatment of mixed cryoglobulinemia. Am J Gastroenterol. 2017;112:1298-1308.</mixed-citation></citation-alternatives></ref><ref id="cit269"><label>269</label><citation-alternatives><mixed-citation xml:lang="ru">Lauletta G, Russi S, Pavone F, et al. Direct-acting antiviral agents in the therapy of hepatitis C virus-related mixed cryoglobulinaemia: a singlecentre experience. Arthritis Res Ther. 2017;19:74.</mixed-citation><mixed-citation xml:lang="en">Lauletta G, Russi S, Pavone F, et al. Direct-acting antiviral agents in the therapy of hepatitis C virus-related mixed cryoglobulinaemia: a singlecentre experience. Arthritis Res Ther. 2017;19:74.</mixed-citation></citation-alternatives></ref><ref id="cit270"><label>270</label><citation-alternatives><mixed-citation xml:lang="ru">Mazzaro C, Dal Maso L, Quartuccio L, et al. Long-term effects of the new direct antiviral agents (DAAs) therapy for HCV-related mixed cryoglobulinaemia without renal involvement: a multicentre open-label study. Clin Exp Rheumatol. 2018;36 Suppl 111:107-114.</mixed-citation><mixed-citation xml:lang="en">Mazzaro C, Dal Maso L, Quartuccio L, et al. Long-term effects of the new direct antiviral agents (DAAs) therapy for HCV-related mixed cryoglobulinaemia without renal involvement: a multicentre open-label study. Clin Exp Rheumatol. 2018;36 Suppl 111:107-114.</mixed-citation></citation-alternatives></ref><ref id="cit271"><label>271</label><citation-alternatives><mixed-citation xml:lang="ru">Saadoun D, Pol S, Ferfar Y, et al. Efficacy and safety of sofosbuvir plus daclatasvir for treatment of HCV-associated cryoglobulinemia vasculitis. Gastroenterology. 2017;153:49-52.</mixed-citation><mixed-citation xml:lang="en">Saadoun D, Pol S, Ferfar Y, et al. Efficacy and safety of sofosbuvir plus daclatasvir for treatment of HCV-associated cryoglobulinemia vasculitis. Gastroenterology. 2017;153:49-52.</mixed-citation></citation-alternatives></ref><ref id="cit272"><label>272</label><citation-alternatives><mixed-citation xml:lang="ru">Gill K, Ghazinian H, Manch R, et al. Hepatitis C virus as a systemic disease: reaching beyond the liver. Hepatol Int. 2016;10:415-423.</mixed-citation><mixed-citation xml:lang="en">Gill K, Ghazinian H, Manch R, et al. Hepatitis C virus as a systemic disease: reaching beyond the liver. Hepatol Int. 2016;10:415-423.</mixed-citation></citation-alternatives></ref><ref id="cit273"><label>273</label><citation-alternatives><mixed-citation xml:lang="ru">Kasuno K, Ono T, Matsumori A, et al. Hepatitis C virus-associated tubulointerstitial injury. Am J Kidney Dis. 2003;41:767-775.</mixed-citation><mixed-citation xml:lang="en">Kasuno K, Ono T, Matsumori A, et al. Hepatitis C virus-associated tubulointerstitial injury. Am J Kidney Dis. 2003;41:767-775.</mixed-citation></citation-alternatives></ref><ref id="cit274"><label>274</label><citation-alternatives><mixed-citation xml:lang="ru">Agnello V, Chung RT, Kaplan LM. A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med. 1992;327:1490-1495.</mixed-citation><mixed-citation xml:lang="en">Agnello V, Chung RT, Kaplan LM. A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med. 1992;327:1490-1495.</mixed-citation></citation-alternatives></ref><ref id="cit275"><label>275</label><citation-alternatives><mixed-citation xml:lang="ru">Fabrizi F, Colucci P, Ponticelli C, et al. Kidney and liver involvement in cryoglobulinemia. Semin Nephrol. 2002;22:309-318.</mixed-citation><mixed-citation xml:lang="en">Fabrizi F, Colucci P, Ponticelli C, et al. Kidney and liver involvement in cryoglobulinemia. Semin Nephrol. 2002;22:309-318.</mixed-citation></citation-alternatives></ref><ref id="cit276"><label>276</label><citation-alternatives><mixed-citation xml:lang="ru">Fabrizi F, Plaisier E, Saadoun D, et al. Hepatitis C virus infection, mixed cryoglobulinemia, and kidney disease. Am J Kidney Dis. 2013;61:623-637.</mixed-citation><mixed-citation xml:lang="en">Fabrizi F, Plaisier E, Saadoun D, et al. Hepatitis C virus infection, mixed cryoglobulinemia, and kidney disease. Am J Kidney Dis. 2013;61:623-637.</mixed-citation></citation-alternatives></ref><ref id="cit277"><label>277</label><citation-alternatives><mixed-citation xml:lang="ru">Ferri C, Greco F, Longombardo G, et al. Antibodies to hepatitis C virus in patients with mixed cryoglobulinemia. Arthritis Rheum. 1991;34:1606-1610.</mixed-citation><mixed-citation xml:lang="en">Ferri C, Greco F, Longombardo G, et al. Antibodies to hepatitis C virus in patients with mixed cryoglobulinemia. Arthritis Rheum. 1991;34:1606-1610.</mixed-citation></citation-alternatives></ref><ref id="cit278"><label>278</label><citation-alternatives><mixed-citation xml:lang="ru">Zignego AL, Craxi A. Extrahepatic manifestations of hepatitis C virus infection. Clin Liver Dis. 2008;12:611-636.</mixed-citation><mixed-citation xml:lang="en">Zignego AL, Craxi A. Extrahepatic manifestations of hepatitis C virus infection. Clin Liver Dis. 2008;12:611-636.</mixed-citation></citation-alternatives></ref><ref id="cit279"><label>279</label><citation-alternatives><mixed-citation xml:lang="ru">Arase Y, Ikeda K, Murashima N, et al. Glomerulonephritis in autopsy cases with hepatitis C virus infection. Intern Med. 1998;37:836-840.</mixed-citation><mixed-citation xml:lang="en">Arase Y, Ikeda K, Murashima N, et al. Glomerulonephritis in autopsy cases with hepatitis C virus infection. Intern Med. 1998;37:836-840.</mixed-citation></citation-alternatives></ref><ref id="cit280"><label>280</label><citation-alternatives><mixed-citation xml:lang="ru">El-Serag HB, Hampel H, Yeh C, et al. Extrahepatic manifestations of hepatitis C among United States male veterans. Hepatology. 2002;36:1439-1445.</mixed-citation><mixed-citation xml:lang="en">El-Serag HB, Hampel H, Yeh C, et al. Extrahepatic manifestations of hepatitis C among United States male veterans. Hepatology. 2002;36:1439-1445.</mixed-citation></citation-alternatives></ref><ref id="cit281"><label>281</label><citation-alternatives><mixed-citation xml:lang="ru">Kristiansen MG, Gutteberg TJ, Mortensen L, et al. Clinical outcomes in a prospective study of community-acquired hepatitis C virus infection in Northern Norway. Scand J Gastroenterol. 2010;45:746-751.</mixed-citation><mixed-citation xml:lang="en">Kristiansen MG, Gutteberg TJ, Mortensen L, et al. Clinical outcomes in a prospective study of community-acquired hepatitis C virus infection in Northern Norway. Scand J Gastroenterol. 2010;45:746-751.</mixed-citation></citation-alternatives></ref><ref id="cit282"><label>282</label><citation-alternatives><mixed-citation xml:lang="ru">Fabrizi F, Pozzi C, Farina M, et al. Hepatitis C virus infection and acute or chronic glomerulonephritis: an epidemiological and clinical appraisal. Nephrol Dial Transplant. 1998;13:1991-1997.</mixed-citation><mixed-citation xml:lang="en">Fabrizi F, Pozzi C, Farina M, et al. Hepatitis C virus infection and acute or chronic glomerulonephritis: an epidemiological and clinical appraisal. Nephrol Dial Transplant. 1998;13:1991-1997.</mixed-citation></citation-alternatives></ref><ref id="cit283"><label>283</label><citation-alternatives><mixed-citation xml:lang="ru">Huang JF, Chuang WL, Dai CY, et al. Viral hepatitis and proteinuria in an area endemic for hepatitis B and C infections: another chain of link? J Intern Med. 2006;260:255-262.</mixed-citation><mixed-citation xml:lang="en">Huang JF, Chuang WL, Dai CY, et al. Viral hepatitis and proteinuria in an area endemic for hepatitis B and C infections: another chain of link? J Intern Med. 2006;260:255-262.</mixed-citation></citation-alternatives></ref><ref id="cit284"><label>284</label><citation-alternatives><mixed-citation xml:lang="ru">Ishizaka N, Ishizaka Y, Seki G, et al. Association between hepatitis B/C viral infection, chronic kidney disease and insulin resistance in individuals undergoing general health screening. Hepatol Res. 2008;38:775-783.</mixed-citation><mixed-citation xml:lang="en">Ishizaka N, Ishizaka Y, Seki G, et al. Association between hepatitis B/C viral infection, chronic kidney disease and insulin resistance in individuals undergoing general health screening. Hepatol Res. 2008;38:775-783.</mixed-citation></citation-alternatives></ref><ref id="cit285"><label>285</label><citation-alternatives><mixed-citation xml:lang="ru">Lee JJ, Lin MY, Yang YH, et al. Association of hepatitis C and B virus infection with CKD in an endemic area in Taiwan: a cross-sectional study. Am J Kidney Dis. 2010;56:23-31.</mixed-citation><mixed-citation xml:lang="en">Lee JJ, Lin MY, Yang YH, et al. Association of hepatitis C and B virus infection with CKD in an endemic area in Taiwan: a cross-sectional study. Am J Kidney Dis. 2010;56:23-31.</mixed-citation></citation-alternatives></ref><ref id="cit286"><label>286</label><citation-alternatives><mixed-citation xml:lang="ru">Yanik EL, Lucas GM, Vlahov D, et al. HIV and proteinuria in an injection drug user population. Clin J Am Soc Nephrol. 2010;5:1836-1843.</mixed-citation><mixed-citation xml:lang="en">Yanik EL, Lucas GM, Vlahov D, et al. HIV and proteinuria in an injection drug user population. Clin J Am Soc Nephrol. 2010;5:1836-1843.</mixed-citation></citation-alternatives></ref><ref id="cit287"><label>287</label><citation-alternatives><mixed-citation xml:lang="ru">Ando M, Yanagisawa N, Ajisawa A, et al. Urinary albumin excretion within the normal range is an independent risk for near-term development of kidney disease in HIV-infected patients. Nephrol Dial Transplant. 2011;26:3923-3929.</mixed-citation><mixed-citation xml:lang="en">Ando M, Yanagisawa N, Ajisawa A, et al. Urinary albumin excretion within the normal range is an independent risk for near-term development of kidney disease in HIV-infected patients. Nephrol Dial Transplant. 2011;26:3923-3929.</mixed-citation></citation-alternatives></ref><ref id="cit288"><label>288</label><citation-alternatives><mixed-citation xml:lang="ru">Banerjee T, Scherzer R, Powe NR, et al. Race and other risk factors for incident proteinuria in a national cohort of HIV-infected veterans. J Acquir Immune Defic Syndr. 2014;67:145-152.</mixed-citation><mixed-citation xml:lang="en">Banerjee T, Scherzer R, Powe NR, et al. Race and other risk factors for incident proteinuria in a national cohort of HIV-infected veterans. J Acquir Immune Defic Syndr. 2014;67:145-152.</mixed-citation></citation-alternatives></ref><ref id="cit289"><label>289</label><citation-alternatives><mixed-citation xml:lang="ru">Estrella MM, Wyatt CM, Pearce CL, et al. Host APOL1 genotype is independently associated with proteinuria in HIV infection. Kidney Int. 2013;84:834-840.</mixed-citation><mixed-citation xml:lang="en">Estrella MM, Wyatt CM, Pearce CL, et al. Host APOL1 genotype is independently associated with proteinuria in HIV infection. Kidney Int. 2013;84:834-840.</mixed-citation></citation-alternatives></ref><ref id="cit290"><label>290</label><citation-alternatives><mixed-citation xml:lang="ru">Reynes J, Cournil A, Peyriere H, et al. Tubular and glomerular proteinuria in HIV-infected adults with estimated glomerular filtration rate &gt;/¼ 60 ml/ min per 1.73 m2. AIDS. 2013;27:1295-1302.</mixed-citation><mixed-citation xml:lang="en">Reynes J, Cournil A, Peyriere H, et al. Tubular and glomerular proteinuria in HIV-infected adults with estimated glomerular filtration rate &gt;/¼ 60 ml/ min per 1.73 m2. AIDS. 2013;27:1295-1302.</mixed-citation></citation-alternatives></ref><ref id="cit291"><label>291</label><citation-alternatives><mixed-citation xml:lang="ru">Szczech LA, Gange SJ, van der Horst C, et al. Predictors of proteinuria and renal failure among women with HIV infection. Kidney Int. 2002;61:195- 202.</mixed-citation><mixed-citation xml:lang="en">Szczech LA, Gange SJ, van der Horst C, et al. Predictors of proteinuria and renal failure among women with HIV infection. Kidney Int. 2002;61:195- 202.</mixed-citation></citation-alternatives></ref><ref id="cit292"><label>292</label><citation-alternatives><mixed-citation xml:lang="ru">Yanagisawa N, Ando M, Ajisawa A, et al. Clinical characteristics of kidney disease in Japanese HIV-infected patients. Nephron Clin Pract. 2011;118: c285-c291.</mixed-citation><mixed-citation xml:lang="en">Yanagisawa N, Ando M, Ajisawa A, et al. Clinical characteristics of kidney disease in Japanese HIV-infected patients. Nephron Clin Pract. 2011;118: c285-c291.</mixed-citation></citation-alternatives></ref><ref id="cit293"><label>293</label><citation-alternatives><mixed-citation xml:lang="ru">Morales JM, Morales E, Andres A, et al. Glomerulonephritis associated with hepatitis C virus infection. Curr Opin Nephrol Hypertens. 1999;8:205-211.</mixed-citation><mixed-citation xml:lang="en">Morales JM, Morales E, Andres A, et al. Glomerulonephritis associated with hepatitis C virus infection. Curr Opin Nephrol Hypertens. 1999;8:205-211.</mixed-citation></citation-alternatives></ref><ref id="cit294"><label>294</label><citation-alternatives><mixed-citation xml:lang="ru">Meyers CM, Seeff LB, Stehman-Breen CO, et al. Hepatitis C and renal disease: an update. Am J Kidney Dis. 2003;42:631-657.</mixed-citation><mixed-citation xml:lang="en">Meyers CM, Seeff LB, Stehman-Breen CO, et al. Hepatitis C and renal disease: an update. Am J Kidney Dis. 2003;42:631-657.</mixed-citation></citation-alternatives></ref><ref id="cit295"><label>295</label><citation-alternatives><mixed-citation xml:lang="ru">Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int Suppl. 2012;2:139-274.</mixed-citation><mixed-citation xml:lang="en">Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int Suppl. 2012;2:139-274.</mixed-citation></citation-alternatives></ref><ref id="cit296"><label>296</label><citation-alternatives><mixed-citation xml:lang="ru">Kupin WL. Viral-Associated GN: Hepatitis C and HIV. Clin J Am Soc Nephrol. 2017;12:1337-1342.</mixed-citation><mixed-citation xml:lang="en">Kupin WL. Viral-Associated GN: Hepatitis C and HIV. Clin J Am Soc Nephrol. 2017;12:1337-1342.</mixed-citation></citation-alternatives></ref><ref id="cit297"><label>297</label><citation-alternatives><mixed-citation xml:lang="ru">D’Amico G. Renal involvement in hepatitis C infection: cryoglobulinemic glomerulonephritis. Kidney Int. 1998;54:650-671.</mixed-citation><mixed-citation xml:lang="en">D’Amico G. Renal involvement in hepatitis C infection: cryoglobulinemic glomerulonephritis. Kidney Int. 1998;54:650-671.</mixed-citation></citation-alternatives></ref><ref id="cit298"><label>298</label><citation-alternatives><mixed-citation xml:lang="ru">Stehman-Breen C, Alpers CE, Fleet WP, et al. Focal segmental glomerular sclerosis among patients infected with hepatitis C virus. Nephron. 1999;81:37-40.</mixed-citation><mixed-citation xml:lang="en">Stehman-Breen C, Alpers CE, Fleet WP, et al. Focal segmental glomerular sclerosis among patients infected with hepatitis C virus. Nephron. 1999;81:37-40.</mixed-citation></citation-alternatives></ref><ref id="cit299"><label>299</label><citation-alternatives><mixed-citation xml:lang="ru">Dey AK, Bhattacharya A, Majumdar A. Hepatitis C as a potential cause of IgA nephropathy. Indian J Nephrol. 2013;23:143-145.</mixed-citation><mixed-citation xml:lang="en">Dey AK, Bhattacharya A, Majumdar A. Hepatitis C as a potential cause of IgA nephropathy. Indian J Nephrol. 2013;23:143-145.</mixed-citation></citation-alternatives></ref><ref id="cit300"><label>300</label><citation-alternatives><mixed-citation xml:lang="ru">Usalan C, Erdem Y, Altun B, et al. Rapidly progressive glomerulonephritis associated with hepatitis C virus infection. Clin Nephrol. 1998;49:129-131.</mixed-citation><mixed-citation xml:lang="en">Usalan C, Erdem Y, Altun B, et al. Rapidly progressive glomerulonephritis associated with hepatitis C virus infection. Clin Nephrol. 1998;49:129-131.</mixed-citation></citation-alternatives></ref><ref id="cit301"><label>301</label><citation-alternatives><mixed-citation xml:lang="ru">Markowitz GS, Cheng JT, Colvin RB, et al. Hepatitis C viral infection is associated with fibrillary glomerulonephritis and immunotactoid glomerulopathy. J Am Soc Nephrol. 1998;9:2244-2252.</mixed-citation><mixed-citation xml:lang="en">Markowitz GS, Cheng JT, Colvin RB, et al. Hepatitis C viral infection is associated with fibrillary glomerulonephritis and immunotactoid glomerulopathy. J Am Soc Nephrol. 1998;9:2244-2252.</mixed-citation></citation-alternatives></ref><ref id="cit302"><label>302</label><citation-alternatives><mixed-citation xml:lang="ru">Barsoum RS. Hepatitis C virus: from entry to renal injury-facts and potentials. Nephrol Dial Transplant. 2007;22:1840-1848.</mixed-citation><mixed-citation xml:lang="en">Barsoum RS. Hepatitis C virus: from entry to renal injury-facts and potentials. Nephrol Dial Transplant. 2007;22:1840-1848.</mixed-citation></citation-alternatives></ref><ref id="cit303"><label>303</label><citation-alternatives><mixed-citation xml:lang="ru">Wornle M, Schmid H, Banas B, et al. Novel role of toll-like receptor 3 in hepatitis C-associated glomerulonephritis. Am J Pathol. 2006;168:370-385.</mixed-citation><mixed-citation xml:lang="en">Wornle M, Schmid H, Banas B, et al. Novel role of toll-like receptor 3 in hepatitis C-associated glomerulonephritis. Am J Pathol. 2006;168:370-385.</mixed-citation></citation-alternatives></ref><ref id="cit304"><label>304</label><citation-alternatives><mixed-citation xml:lang="ru">Sansonno D, Gesualdo L, Manno C, et al. Hepatitis C virus-related proteins in kidney tissue from hepatitis C virus-infected patients with cryoglobulinemic membranoproliferative glomerulonephritis. Hepatology. 1997;25:1237-1244.</mixed-citation><mixed-citation xml:lang="en">Sansonno D, Gesualdo L, Manno C, et al. Hepatitis C virus-related proteins in kidney tissue from hepatitis C virus-infected patients with cryoglobulinemic membranoproliferative glomerulonephritis. Hepatology. 1997;25:1237-1244.</mixed-citation></citation-alternatives></ref><ref id="cit305"><label>305</label><citation-alternatives><mixed-citation xml:lang="ru">Sansonno D, Lauletta G, Montrone M, et al. Hepatitis C virus RNA and core protein in kidney glomerular and tubular structures isolated with laser capture microdissection. Clin Exp Immunol. 2005;140:498-506.</mixed-citation><mixed-citation xml:lang="en">Sansonno D, Lauletta G, Montrone M, et al. Hepatitis C virus RNA and core protein in kidney glomerular and tubular structures isolated with laser capture microdissection. Clin Exp Immunol. 2005;140:498-506.</mixed-citation></citation-alternatives></ref><ref id="cit306"><label>306</label><citation-alternatives><mixed-citation xml:lang="ru">Johnson RJ, Gretch DR, Couser WG, et al. Hepatitis C virus-associated glomerulonephritis. Effect of alpha-interferon therapy. Kidney Int. 1994;46:1700-1704.</mixed-citation><mixed-citation xml:lang="en">Johnson RJ, Gretch DR, Couser WG, et al. Hepatitis C virus-associated glomerulonephritis. Effect of alpha-interferon therapy. Kidney Int. 1994;46:1700-1704.</mixed-citation></citation-alternatives></ref><ref id="cit307"><label>307</label><citation-alternatives><mixed-citation xml:lang="ru">Mazzaro C, Panarello G, Mauro E, et al. Efficacy and safety of pegylated interferon plus ribavirin for the treatment of hepatitis C virus-positive cryoglobulinemic glomerulonephritis. Dig Liver Dis. 2015;47:613-616.</mixed-citation><mixed-citation xml:lang="en">Mazzaro C, Panarello G, Mauro E, et al. Efficacy and safety of pegylated interferon plus ribavirin for the treatment of hepatitis C virus-positive cryoglobulinemic glomerulonephritis. Dig Liver Dis. 2015;47:613-616.</mixed-citation></citation-alternatives></ref><ref id="cit308"><label>308</label><citation-alternatives><mixed-citation xml:lang="ru">Mazzaro C, Monti G, Saccardo F, et al. Efficacy and safety of peginterferon alfa-2b plus ribavirin for HCV-positive mixed cryoglobulinemia: a multicentre open-label study. Clin Exp Rheumatol. 2011;29:933-941.</mixed-citation><mixed-citation xml:lang="en">Mazzaro C, Monti G, Saccardo F, et al. Efficacy and safety of peginterferon alfa-2b plus ribavirin for HCV-positive mixed cryoglobulinemia: a multicentre open-label study. Clin Exp Rheumatol. 2011;29:933-941.</mixed-citation></citation-alternatives></ref><ref id="cit309"><label>309</label><citation-alternatives><mixed-citation xml:lang="ru">Saadoun D, Resche-Rigon M, Thibault V, et al. Antiviral therapy for hepatitis C virus-associated mixed cryoglobulinemia vasculitis: a longterm followup study. Arthritis Rheum. 2006;54:3696-3706.</mixed-citation><mixed-citation xml:lang="en">Saadoun D, Resche-Rigon M, Thibault V, et al. Antiviral therapy for hepatitis C virus-associated mixed cryoglobulinemia vasculitis: a longterm followup study. Arthritis Rheum. 2006;54:3696-3706.</mixed-citation></citation-alternatives></ref><ref id="cit310"><label>310</label><citation-alternatives><mixed-citation xml:lang="ru">Fabrizi F, Bruchfeld A, Mangano S, et al. Interferon therapy for HCVassociated glomerulonephritis: meta-analysis of controlled trials. Int J Artif Organs. 2007;30:212-219.</mixed-citation><mixed-citation xml:lang="en">Fabrizi F, Bruchfeld A, Mangano S, et al. Interferon therapy for HCVassociated glomerulonephritis: meta-analysis of controlled trials. Int J Artif Organs. 2007;30:212-219.</mixed-citation></citation-alternatives></ref><ref id="cit311"><label>311</label><citation-alternatives><mixed-citation xml:lang="ru">Fabrizi F, Martin P, Cacoub P, et al. Treatment of hepatitis C-related kidney disease. Expert Opin Pharmacother. 2015;16:1815-1827.</mixed-citation><mixed-citation xml:lang="en">Fabrizi F, Martin P, Cacoub P, et al. Treatment of hepatitis C-related kidney disease. Expert Opin Pharmacother. 2015;16:1815-1827.</mixed-citation></citation-alternatives></ref><ref id="cit312"><label>312</label><citation-alternatives><mixed-citation xml:lang="ru">De Nicola S, Aghemo A, Campise MR, et al. Telaprevir in a patient with chronic hepatitis C and cryoglobulinemic glomerulonephritis. Antivir Ther. 2014;19:527-531.</mixed-citation><mixed-citation xml:lang="en">De Nicola S, Aghemo A, Campise MR, et al. Telaprevir in a patient with chronic hepatitis C and cryoglobulinemic glomerulonephritis. Antivir Ther. 2014;19:527-531.</mixed-citation></citation-alternatives></ref><ref id="cit313"><label>313</label><citation-alternatives><mixed-citation xml:lang="ru">Ennaifer R, Sabbah M, Hefaiedh R, et al. Antiviral therapy for hepatitis C virus infection, cryoglobulinemic glomerulonephritis and low-grade malignant lymphoma: A challenge? Tunis Med. 2015;93:203-204.</mixed-citation><mixed-citation xml:lang="en">Ennaifer R, Sabbah M, Hefaiedh R, et al. Antiviral therapy for hepatitis C virus infection, cryoglobulinemic glomerulonephritis and low-grade malignant lymphoma: A challenge? Tunis Med. 2015;93:203-204.</mixed-citation></citation-alternatives></ref><ref id="cit314"><label>314</label><citation-alternatives><mixed-citation xml:lang="ru">Iliescu L, Herlea V, Toma L, et al. Association between chronic HCV hepatitis, membranoproliferative glomerulopathy and cutaneous sarcoidosis. J Gastrointestin Liver Dis. 2015;24:8.</mixed-citation><mixed-citation xml:lang="en">Iliescu L, Herlea V, Toma L, et al. Association between chronic HCV hepatitis, membranoproliferative glomerulopathy and cutaneous sarcoidosis. J Gastrointestin Liver Dis. 2015;24:8.</mixed-citation></citation-alternatives></ref><ref id="cit315"><label>315</label><citation-alternatives><mixed-citation xml:lang="ru">Mauro E, Gattei V, Mazzaro C. Recombinant human erythropoietin (RHuEpo) and granular colony stimulating factor (G-CSF) in hepatitis C virus (HCV) related to mixed cryoglobulinaemia associated to membranoproliferative glomerulonephritis type I: a case report description. Infez Med. 2014;22:337-341.</mixed-citation><mixed-citation xml:lang="en">Mauro E, Gattei V, Mazzaro C. Recombinant human erythropoietin (RHuEpo) and granular colony stimulating factor (G-CSF) in hepatitis C virus (HCV) related to mixed cryoglobulinaemia associated to membranoproliferative glomerulonephritis type I: a case report description. Infez Med. 2014;22:337-341.</mixed-citation></citation-alternatives></ref><ref id="cit316"><label>316</label><citation-alternatives><mixed-citation xml:lang="ru">Otsuka T, Sakai Y, Ohno D, et al. A case of cryoglobulinemic membranoproliferative glomerulonephritis induced by hepatitis C virus. J Nippon Med Sch. 2015;82:193-201.</mixed-citation><mixed-citation xml:lang="en">Otsuka T, Sakai Y, Ohno D, et al. A case of cryoglobulinemic membranoproliferative glomerulonephritis induced by hepatitis C virus. J Nippon Med Sch. 2015;82:193-201.</mixed-citation></citation-alternatives></ref><ref id="cit317"><label>317</label><citation-alternatives><mixed-citation xml:lang="ru">Wu H, Zou HB, Xu Y, et al. Hepatitis C virus-related heat-insoluble cryoglobulinemia and thrombotic microangiopathy. Am J Med Sci. 2013;346:345-348.</mixed-citation><mixed-citation xml:lang="en">Wu H, Zou HB, Xu Y, et al. Hepatitis C virus-related heat-insoluble cryoglobulinemia and thrombotic microangiopathy. Am J Med Sci. 2013;346:345-348.</mixed-citation></citation-alternatives></ref><ref id="cit318"><label>318</label><citation-alternatives><mixed-citation xml:lang="ru">Zhao LJ, Chen F, Li JG, et al. Hepatitis C virus-related mixed cryoglobulinemic endocapillary proliferative glomerulonephritis and B-cell non-Hodgkin lymphoma: a case report and literature review. Eur Rev Med Pharmacol Sci. 2015;19:3050-3055.</mixed-citation><mixed-citation xml:lang="en">Zhao LJ, Chen F, Li JG, et al. Hepatitis C virus-related mixed cryoglobulinemic endocapillary proliferative glomerulonephritis and B-cell non-Hodgkin lymphoma: a case report and literature review. Eur Rev Med Pharmacol Sci. 2015;19:3050-3055.</mixed-citation></citation-alternatives></ref><ref id="cit319"><label>319</label><citation-alternatives><mixed-citation xml:lang="ru">Dussol B, Moal V, Daniel L, et al. Spontaneous remission of HCV-induced cryoglobulinaemic glomerulonephritis. Nephrol Dial Transplant. 2001;16:156-159.</mixed-citation><mixed-citation xml:lang="en">Dussol B, Moal V, Daniel L, et al. Spontaneous remission of HCV-induced cryoglobulinaemic glomerulonephritis. Nephrol Dial Transplant. 2001;16:156-159.</mixed-citation></citation-alternatives></ref><ref id="cit320"><label>320</label><citation-alternatives><mixed-citation xml:lang="ru">Davis CL, Gretch DR, Perkins JD, et al. Hepatitis C-associated glomerular disease in liver transplant recipients. Liver Transpl Surg. 1995;1:166-175.</mixed-citation><mixed-citation xml:lang="en">Davis CL, Gretch DR, Perkins JD, et al. Hepatitis C-associated glomerular disease in liver transplant recipients. Liver Transpl Surg. 1995;1:166-175.</mixed-citation></citation-alternatives></ref><ref id="cit321"><label>321</label><citation-alternatives><mixed-citation xml:lang="ru">Donato MF, Fabrizi F, Fogazzi GB, et al. Remission of HCV-associated glomerulonephritis with pegylated ifn and ribavirin therapy after liver transplantation: case report and literature review. Int J Artif Organs. 2013;36:63-68.</mixed-citation><mixed-citation xml:lang="en">Donato MF, Fabrizi F, Fogazzi GB, et al. Remission of HCV-associated glomerulonephritis with pegylated ifn and ribavirin therapy after liver transplantation: case report and literature review. Int J Artif Organs. 2013;36:63-68.</mixed-citation></citation-alternatives></ref><ref id="cit322"><label>322</label><citation-alternatives><mixed-citation xml:lang="ru">Francesca Donato M, Banfi G, Cresseri D, et al. Antiviral therapy of symptomatic HCV-mixed cryoglobulinemia after liver transplant: case report and literature review. Int J Artif Organs. 2013;36:367-372.</mixed-citation><mixed-citation xml:lang="en">Francesca Donato M, Banfi G, Cresseri D, et al. Antiviral therapy of symptomatic HCV-mixed cryoglobulinemia after liver transplant: case report and literature review. Int J Artif Organs. 2013;36:367-372.</mixed-citation></citation-alternatives></ref><ref id="cit323"><label>323</label><citation-alternatives><mixed-citation xml:lang="ru">Montalbano M, Pasulo L, Sonzogni A, et al. Treatment with pegylated interferon and ribavirin for hepatitis C virus-associated severe cryoglobulinemia in a liver/kidney transplant recipient. J Clin Gastroenterol. 2007;41:216-220.</mixed-citation><mixed-citation xml:lang="en">Montalbano M, Pasulo L, Sonzogni A, et al. Treatment with pegylated interferon and ribavirin for hepatitis C virus-associated severe cryoglobulinemia in a liver/kidney transplant recipient. J Clin Gastroenterol. 2007;41:216-220.</mixed-citation></citation-alternatives></ref><ref id="cit324"><label>324</label><citation-alternatives><mixed-citation xml:lang="ru">Fabrizi F, Aghemo A, Fogazzi GB, et al. Acute tubular necrosis following interferon-based therapy for hepatitis C: case study with literature review. Kidney Blood Press Res. 2013;38:52-60.</mixed-citation><mixed-citation xml:lang="en">Fabrizi F, Aghemo A, Fogazzi GB, et al. Acute tubular necrosis following interferon-based therapy for hepatitis C: case study with literature review. Kidney Blood Press Res. 2013;38:52-60.</mixed-citation></citation-alternatives></ref><ref id="cit325"><label>325</label><citation-alternatives><mixed-citation xml:lang="ru">Artemova M, Abdurakhmanov D, Ignatova T, et al. Persistent hepatitis C virus-associated cryoglobulinemic vasculitis following virus eradication after direct-acting antiviral therapy. Hepatology. 2017;65:1770-1771.</mixed-citation><mixed-citation xml:lang="en">Artemova M, Abdurakhmanov D, Ignatova T, et al. Persistent hepatitis C virus-associated cryoglobulinemic vasculitis following virus eradication after direct-acting antiviral therapy. Hepatology. 2017;65:1770-1771.</mixed-citation></citation-alternatives></ref><ref id="cit326"><label>326</label><citation-alternatives><mixed-citation xml:lang="ru">Cornella SL, Stine JG, Kelly V, et al. Persistence of mixed cryoglobulinemia despite cure of hepatitis C with new oral antiviral therapy including directacting antiviral sofosbuvir: A case series. Postgrad Med. 2015;127:413-417.</mixed-citation><mixed-citation xml:lang="en">Cornella SL, Stine JG, Kelly V, et al. Persistence of mixed cryoglobulinemia despite cure of hepatitis C with new oral antiviral therapy including directacting antiviral sofosbuvir: A case series. Postgrad Med. 2015;127:413-417.</mixed-citation></citation-alternatives></ref><ref id="cit327"><label>327</label><citation-alternatives><mixed-citation xml:lang="ru">Sollima S, Milazzo L, Peri AM, et al. Persistent mixed cryoglobulinaemia vasculitis despite hepatitis C virus eradication after interferon-free antiviral therapy. Rheumatology (Oxford). 2016;55:2084-2085.</mixed-citation><mixed-citation xml:lang="en">Sollima S, Milazzo L, Peri AM, et al. Persistent mixed cryoglobulinaemia vasculitis despite hepatitis C virus eradication after interferon-free antiviral therapy. Rheumatology (Oxford). 2016;55:2084-2085.</mixed-citation></citation-alternatives></ref><ref id="cit328"><label>328</label><citation-alternatives><mixed-citation xml:lang="ru">Cacoub P, Si Ahmed SN, Ferfar Y, et al. Long-term efficacy of interferon-free antiviral treatment regimens in patients with hepatitis C virus-associated cryoglobulinemia vasculitis [e-pub ahead of print]. Clin Gastroenterol Hepatol. https://doi.org/10.1016/j.cgh.2018.05.021.</mixed-citation><mixed-citation xml:lang="en">Cacoub P, Si Ahmed SN, Ferfar Y, et al. Long-term efficacy of interferon-free antiviral treatment regimens in patients with hepatitis C virus-associated cryoglobulinemia vasculitis [e-pub ahead of print]. Clin Gastroenterol Hepatol. https://doi.org/10.1016/j.cgh.2018.05.021.</mixed-citation></citation-alternatives></ref><ref id="cit329"><label>329</label><citation-alternatives><mixed-citation xml:lang="ru">Bonacci M, Lens S, Marino Z, et al. Long-term outcomes of patients with HCV-associated cryoglobulinemic vasculitis after virologic cure [e-pub ahead of print]. Gastroenterology. 2018;155:311-315.</mixed-citation><mixed-citation xml:lang="en">Bonacci M, Lens S, Marino Z, et al. Long-term outcomes of patients with HCV-associated cryoglobulinemic vasculitis after virologic cure [e-pub ahead of print]. Gastroenterology. 2018;155:311-315.</mixed-citation></citation-alternatives></ref><ref id="cit330"><label>330</label><citation-alternatives><mixed-citation xml:lang="ru">Ferri C, Sebastiani M, Giuggioli D, et al. Mixed cryoglobulinemia: demographic, clinical, and serologic features and survival in 231 patients. Semin Arthritis Rheum. 2004;33:355-374.</mixed-citation><mixed-citation xml:lang="en">Ferri C, Sebastiani M, Giuggioli D, et al. Mixed cryoglobulinemia: demographic, clinical, and serologic features and survival in 231 patients. Semin Arthritis Rheum. 2004;33:355-374.</mixed-citation></citation-alternatives></ref><ref id="cit331"><label>331</label><citation-alternatives><mixed-citation xml:lang="ru">Tarantino A, Campise M, Banfi G, et al. Long-term predictors of survival in essential mixed cryoglobulinemic glomerulonephritis. Kidney Int. 1995;47:618-623.</mixed-citation><mixed-citation xml:lang="en">Tarantino A, Campise M, Banfi G, et al. Long-term predictors of survival in essential mixed cryoglobulinemic glomerulonephritis. Kidney Int. 1995;47:618-623.</mixed-citation></citation-alternatives></ref><ref id="cit332"><label>332</label><citation-alternatives><mixed-citation xml:lang="ru">Tarantino A, De Vecchi A, Montagnino G, et al. Renal disease in essential mixed cryoglobulinaemia. Long-term follow-up of 44 patients. Q J Med. 1981;50:1-30.</mixed-citation><mixed-citation xml:lang="en">Tarantino A, De Vecchi A, Montagnino G, et al. Renal disease in essential mixed cryoglobulinaemia. Long-term follow-up of 44 patients. Q J Med. 1981;50:1-30.</mixed-citation></citation-alternatives></ref><ref id="cit333"><label>333</label><citation-alternatives><mixed-citation xml:lang="ru">Ferri C. Mixed cryoglobulinemia. Orphanet J Rare Dis. 2008;3:25.</mixed-citation><mixed-citation xml:lang="en">Ferri C. Mixed cryoglobulinemia. Orphanet J Rare Dis. 2008;3:25.</mixed-citation></citation-alternatives></ref><ref id="cit334"><label>334</label><citation-alternatives><mixed-citation xml:lang="ru">Ahmed MS, Wong CF, Shawki H, et al. Rapidly deteriorating renal function with membranoproliferative glomerulonephritis Type 1 associated with hepatitis C treated successfully with steroids and antiviral therapy: a case report and review of literature. Clin Nephrol. 2008;69:298-301.</mixed-citation><mixed-citation xml:lang="en">Ahmed MS, Wong CF, Shawki H, et al. Rapidly deteriorating renal function with membranoproliferative glomerulonephritis Type 1 associated with hepatitis C treated successfully with steroids and antiviral therapy: a case report and review of literature. Clin Nephrol. 2008;69:298-301.</mixed-citation></citation-alternatives></ref><ref id="cit335"><label>335</label><citation-alternatives><mixed-citation xml:lang="ru">Palombo SB, Wendel EC, Kidd LR, et al. MPGN and mixed cryoglobulinemia in a patient with hepatitis C - new treatment implications and renal outcomes. Clin Nephrol Case Stud. 2017;5:66-69.</mixed-citation><mixed-citation xml:lang="en">Palombo SB, Wendel EC, Kidd LR, et al. MPGN and mixed cryoglobulinemia in a patient with hepatitis C - new treatment implications and renal outcomes. Clin Nephrol Case Stud. 2017;5:66-69.</mixed-citation></citation-alternatives></ref><ref id="cit336"><label>336</label><citation-alternatives><mixed-citation xml:lang="ru">Humphries K, Darling JM, Barritt ASt. Membranoproliferative glomerulonephritis, type II cryoglobulinemia and triple therapy for hepatitis C: a case series and review of the literature. Dig Dis Sci. 2014;59:2007-2012.</mixed-citation><mixed-citation xml:lang="en">Humphries K, Darling JM, Barritt ASt. Membranoproliferative glomerulonephritis, type II cryoglobulinemia and triple therapy for hepatitis C: a case series and review of the literature. Dig Dis Sci. 2014;59:2007-2012.</mixed-citation></citation-alternatives></ref><ref id="cit337"><label>337</label><citation-alternatives><mixed-citation xml:lang="ru">Roccatello D, Baldovino S, Rossi D, et al. Rituximab as a therapeutic tool in severe mixed cryoglobulinemia. Clin Rev Allergy Immunol. 2008;34:111-117.</mixed-citation><mixed-citation xml:lang="en">Roccatello D, Baldovino S, Rossi D, et al. Rituximab as a therapeutic tool in severe mixed cryoglobulinemia. Clin Rev Allergy Immunol. 2008;34:111-117.</mixed-citation></citation-alternatives></ref><ref id="cit338"><label>338</label><citation-alternatives><mixed-citation xml:lang="ru">Roccatello D, Sciascia S, Baldovino S, et al. Improved (4 plus 2) rituximab protocol for severe cases of mixed cryoglobulinemia: a 6-year observational study. Am J Nephrol. 2016;43:251-260.</mixed-citation><mixed-citation xml:lang="en">Roccatello D, Sciascia S, Baldovino S, et al. Improved (4 plus 2) rituximab protocol for severe cases of mixed cryoglobulinemia: a 6-year observational study. Am J Nephrol. 2016;43:251-260.</mixed-citation></citation-alternatives></ref><ref id="cit339"><label>339</label><citation-alternatives><mixed-citation xml:lang="ru">Saadoun D, Resche Rigon M, Sene D, et al. Rituximab plus Peg-interferonalpha/ ribavirin compared with Peg-interferon-alpha/ribavirin in hepatitis C-related mixed cryoglobulinemia. Blood. 2010;116:326-334.</mixed-citation><mixed-citation xml:lang="en">Saadoun D, Resche Rigon M, Sene D, et al. Rituximab plus Peg-interferonalpha/ ribavirin compared with Peg-interferon-alpha/ribavirin in hepatitis C-related mixed cryoglobulinemia. Blood. 2010;116:326-334.</mixed-citation></citation-alternatives></ref><ref id="cit340"><label>340</label><citation-alternatives><mixed-citation xml:lang="ru">De Vita S, Quartuccio L, Isola M, et al. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum. 2012;64:843-853.</mixed-citation><mixed-citation xml:lang="en">De Vita S, Quartuccio L, Isola M, et al. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum. 2012;64:843-853.</mixed-citation></citation-alternatives></ref><ref id="cit341"><label>341</label><citation-alternatives><mixed-citation xml:lang="ru">Quartuccio L, Zuliani F, Corazza L, et al. Retreatment regimen of rituximab monotherapy given at the relapse of severe HCV-related cryoglobulinemic vasculitis: Long-term follow up data of a randomized controlled multicentre study. J Autoimmun. 2015;63:88-93.</mixed-citation><mixed-citation xml:lang="en">Quartuccio L, Zuliani F, Corazza L, et al. Retreatment regimen of rituximab monotherapy given at the relapse of severe HCV-related cryoglobulinemic vasculitis: Long-term follow up data of a randomized controlled multicentre study. J Autoimmun. 2015;63:88-93.</mixed-citation></citation-alternatives></ref><ref id="cit342"><label>342</label><citation-alternatives><mixed-citation xml:lang="ru">Sneller MC, Hu Z, Langford CA. A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis. Arthritis Rheum. 2012;64:835-842.</mixed-citation><mixed-citation xml:lang="en">Sneller MC, Hu Z, Langford CA. A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis. Arthritis Rheum. 2012;64:835-842.</mixed-citation></citation-alternatives></ref><ref id="cit343"><label>343</label><citation-alternatives><mixed-citation xml:lang="ru">Fabrizi F,Martin P, ElliA, et al.HepatitisCvirus infection and rituximab therapy after renal transplantation. Int J Artif Organs. 2007;30:445-449.</mixed-citation><mixed-citation xml:lang="en">Fabrizi F,Martin P, ElliA, et al.HepatitisCvirus infection and rituximab therapy after renal transplantation. Int J Artif Organs. 2007;30:445-449.</mixed-citation></citation-alternatives></ref><ref id="cit344"><label>344</label><citation-alternatives><mixed-citation xml:lang="ru">US Food and Drug Administration. FDA Drug Safety Communication: Boxed warning and new recommendations to decrease risk of hepatitis B reactivation with the immune-suppressing and anti-cancer drugs Arzerra (ofatumumab) and Rituxan (rituximab). Available at: https://www.fda. gov/drugs/drugsafety/ucm366406.htm. Accessed March 23, 2018.</mixed-citation><mixed-citation xml:lang="en">US Food and Drug Administration. FDA Drug Safety Communication: Boxed warning and new recommendations to decrease risk of hepatitis B reactivation with the immune-suppressing and anti-cancer drugs Arzerra (ofatumumab) and Rituxan (rituximab). Available at: https://www.fda. gov/drugs/drugsafety/ucm366406.htm. Accessed March 23, 2018.</mixed-citation></citation-alternatives></ref><ref id="cit345"><label>345</label><citation-alternatives><mixed-citation xml:lang="ru">Terrier B, Launay D, Kaplanski G, et al. Safety and efficacy of rituximab in nonviral cryoglobulinemia vasculitis: data from the French Autoimmunity and Rituximab registry. Arthritis Care Res (Hoboken). 2010;62:1787-1795.</mixed-citation><mixed-citation xml:lang="en">Terrier B, Launay D, Kaplanski G, et al. Safety and efficacy of rituximab in nonviral cryoglobulinemia vasculitis: data from the French Autoimmunity and Rituximab registry. Arthritis Care Res (Hoboken). 2010;62:1787-1795.</mixed-citation></citation-alternatives></ref><ref id="cit346"><label>346</label><citation-alternatives><mixed-citation xml:lang="ru">Colucci G, Manno C, Grandaliano G, et al. Cryoglobulinemic membranoproliferative glomerulonephritis: beyond conventional therapy. Clin Nephrol. 2011;75:374-379.</mixed-citation><mixed-citation xml:lang="en">Colucci G, Manno C, Grandaliano G, et al. Cryoglobulinemic membranoproliferative glomerulonephritis: beyond conventional therapy. Clin Nephrol. 2011;75:374-379.</mixed-citation></citation-alternatives></ref><ref id="cit347"><label>347</label><citation-alternatives><mixed-citation xml:lang="ru">Reed MJ, Alexander GJ, Thiru S, et al. Hepatitis C-associated glomerulonephritis-a novel therapeutic approach. Nephrol Dial Transplant. 2001;16:869-871.</mixed-citation><mixed-citation xml:lang="en">Reed MJ, Alexander GJ, Thiru S, et al. Hepatitis C-associated glomerulonephritis-a novel therapeutic approach. Nephrol Dial Transplant. 2001;16:869-871.</mixed-citation></citation-alternatives></ref><ref id="cit348"><label>348</label><citation-alternatives><mixed-citation xml:lang="ru">Castillo I, Martinez-Ara J, Olea T, et al. High prevalence of occult hepatitis C virus infection in patients with primary and secondary glomerular nephropathies. Kidney Int. 2014;86:619-624.</mixed-citation><mixed-citation xml:lang="en">Castillo I, Martinez-Ara J, Olea T, et al. High prevalence of occult hepatitis C virus infection in patients with primary and secondary glomerular nephropathies. Kidney Int. 2014;86:619-624.</mixed-citation></citation-alternatives></ref><ref id="cit349"><label>349</label><citation-alternatives><mixed-citation xml:lang="ru">IOM (Institute of Medicine). Clinical Practice Guidelines We Can Trust. Washington, DC: The National Academies Press; 2011.</mixed-citation><mixed-citation xml:lang="en">IOM (Institute of Medicine). Clinical Practice Guidelines We Can Trust. Washington, DC: The National Academies Press; 2011.</mixed-citation></citation-alternatives></ref><ref id="cit350"><label>350</label><citation-alternatives><mixed-citation xml:lang="ru">IOM (Institute of Medicine). Finding What Works in Health Care: Standards for Systematic Reviews. Washington, DC: The National Academies Press; 2011.</mixed-citation><mixed-citation xml:lang="en">IOM (Institute of Medicine). Finding What Works in Health Care: Standards for Systematic Reviews. Washington, DC: The National Academies Press; 2011.</mixed-citation></citation-alternatives></ref><ref id="cit351"><label>351</label><citation-alternatives><mixed-citation xml:lang="ru">Prabhu RA, Nair S, Pai G, et al. Interventions for dialysis patients with hepatitis C virus (HCV) infection. Cochrane Database Syst Rev. 2015: CD007003.</mixed-citation><mixed-citation xml:lang="en">Prabhu RA, Nair S, Pai G, et al. Interventions for dialysis patients with hepatitis C virus (HCV) infection. Cochrane Database Syst Rev. 2015: CD007003.</mixed-citation></citation-alternatives></ref><ref id="cit352"><label>352</label><citation-alternatives><mixed-citation xml:lang="ru">Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.</mixed-citation><mixed-citation xml:lang="en">Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.</mixed-citation></citation-alternatives></ref><ref id="cit353"><label>353</label><citation-alternatives><mixed-citation xml:lang="ru">Wells GA, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available at: http://www.ohri.ca/programs/clinical_epidemiology/oxford. asp. Accessed July 27, 2018.</mixed-citation><mixed-citation xml:lang="en">Wells GA, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available at: http://www.ohri.ca/programs/clinical_epidemiology/oxford. asp. Accessed July 27, 2018.</mixed-citation></citation-alternatives></ref><ref id="cit354"><label>354</label><citation-alternatives><mixed-citation xml:lang="ru">Uhlig K, Macleod A, Craig J, et al. Grading evidence and recommendations for clinical practice guidelines in nephrology. A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006;70:2058-2065.</mixed-citation><mixed-citation xml:lang="en">Uhlig K, Macleod A, Craig J, et al. Grading evidence and recommendations for clinical practice guidelines in nephrology. A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006;70:2058-2065.</mixed-citation></citation-alternatives></ref><ref id="cit355"><label>355</label><citation-alternatives><mixed-citation xml:lang="ru">Guyatt GH, Oxman AD, Kunz R, et al. Going from evidence to recommendations. BMJ. 2008;336:1049-1051.</mixed-citation><mixed-citation xml:lang="en">Guyatt GH, Oxman AD, Kunz R, et al. Going from evidence to recommendations. BMJ. 2008;336:1049-1051.</mixed-citation></citation-alternatives></ref><ref id="cit356"><label>356</label><citation-alternatives><mixed-citation xml:lang="ru">Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. BMJ. 2004;328:1490.</mixed-citation><mixed-citation xml:lang="en">Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. BMJ. 2004;328:1490.</mixed-citation></citation-alternatives></ref><ref id="cit357"><label>357</label><citation-alternatives><mixed-citation xml:lang="ru">Shiffman RN, Shekelle P, Overhage JM, et al. Standardized reporting of clinical practice guidelines: a proposal from the Conference on Guideline Standardization. Ann Intern Med. 2003;139:493-498.</mixed-citation><mixed-citation xml:lang="en">Shiffman RN, Shekelle P, Overhage JM, et al. Standardized reporting of clinical practice guidelines: a proposal from the Conference on Guideline Standardization. Ann Intern Med. 2003;139:493-498.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
